αvβ6 INTEGRIN INHIBITION

Novel αvβ6 integrin inhibitor compounds are developed for oral administration, addressing the lack of effective oral integrin inhibitors by ensuring potency and absorption, and are effective in treating conditions like idiopathic pulmonary fibrosis and tumors.

JP2024161471AActive Publication Date: 2024-11-19MORPHIC THERAPEUTIC INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024135240
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-06-10
Filing Date
2024-08-14
Publication Date
2024-11-19
Estimated Expiration
2039-08-29

AI Technical Summary

Technical Problem

There is a need for small molecule αvβ6 integrin inhibitors suitable for oral administration that are potent at their biological target and exhibit effective absorption characteristics, as existing therapeutic responses with orally available integrin inhibitors have been lacking.

Method used

Development of novel αvβ6 integrin inhibitor compounds evaluated for biochemical potency and in vitro permeability, with specific compounds of Formula I or their pharmaceutically acceptable salts being developed for oral administration.

Benefits of technology

The developed compounds effectively inhibit αvβ6 integrin and are suitable for treating conditions such as idiopathic pulmonary fibrosis and various tumors, demonstrating therapeutic potential through oral administration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161471000001_ABST
    Figure 2024161471000001_ABST
Patent Text Reader

Abstract

To provide small molecule inhibitors of αvβ6 integrin suitable for oral administration to treat diseases associated with αvβ6 integrin.SOLUTION: For example, a compound represented by the following formula, or a pharmaceutically acceptable salt thereof, are provided.SELECTED DRAWING: Figure 1-1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related Applications This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 724,423, filed August 29, 2018; and U.S. Provisional Patent Application No. 62 / 859,457, filed June 10, 2019.

[0002] The present disclosure relates to novel compounds and methods useful for inhibiting αvβ6 integrin. [Background technology]

[0003] Receptors of the heterodimeric integrin family respond to exogenous and endogenous cues to regulate cell shape and cell adhesion to the extracellular matrix.

[0004] Integrin signaling regulates cell survival, cell cycle progression, cell differentiation, and cell migration.

[0005] Integrin receptors can exclusively signal cells in both the "inside-out" and "outside-in" directions. Thus, integrin receptors mediate cell migration by transmitting forces from the extracellular matrix to the cytoskeleton and regulate the cytoskeletal machinery to achieve the shape changes required during cell migration. RGD-binding integrins can bind and activate TGF-β, which has recently been implicated in fibrotic diseases.

[0006] Integrins are expressed on the surface of most human cells, and their pathologies contribute to a diverse set of human diseases, including platelet disorders, atherosclerosis, cancer, osteoporosis, fibrosis, renal diabetic neuropathy, macular degeneration, and various autoimmune and chronic inflammatory diseases.

[0007] The role of integrins as drug targets has long been recognized, and a total of six injectable integrin inhibitors have been approved by the Food and Drug Administration for the treatment of various therapeutic indications: inflammatory bowel disease (Entyvio®, Tysabri®), multiple sclerosis (Tysabri®), psoriasis (Raptiva®), and acute coronary syndromes (Reopro®, Aggrastat®, Integrilin®). Of the 24 known integrin heterodimers, at least half are involved in inflammation, fibrosis, tumors, and vascular diseases. Summary of the Invention [Problem to be solved by the invention]

[0008] A new class of integrin inhibitors is needed. There has been a significant lack of therapeutic success with orally available integrin inhibitors. Therefore, there remains a need for small molecule αvβ6 integrin inhibitors suitable for oral administration. The oral administration route is preferred for small molecule delivery because it allows for a wide dose range, allows for convenient patient self-administration, is adaptable to a variety of administration methods, and does not require any specialized equipment. Therefore, it is important to identify αvβ6 integrin inhibitor compounds that are not only potent at their intended biological targets but also exhibit other characteristics related to the compound's ability to be absorbed into the body in a therapeutically effective manner (e.g., after oral administration). For example, αvβ6 integrin inhibitor compounds can be selected based on both potency and performance in an in vitro permeability assay (e.g., assessing the compound's ability to cross a layer of Madin-Darby canine kidney (MDCK) cells from the apical side to the basolateral side (A→B)). [Means for solving the problem]

[0009] The applicants have discovered novel αvβ6 integrin inhibitor compounds and have evaluated the retention, performance and utility of representative examples of such compounds for both biochemical potency (e.g., evaluating the compounds for αvβ6 binding using a fluorescence polarization assay, e.g., using the assay of Example 35) and in vitro permeability properties (e.g., evaluating MDCK permeability using the assay of Example 36).

[0010] In certain embodiments, the present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof:

[0011] [ka] During the ceremony, A is

[0012] [ka] and; B is alkylene, -alkylene-(heterocyclyl)-alkylene-, -(heterocyclyl)-alkylene-, -cycloalkylene, -alkylene-O-, -cycloalkylene-O-, or -alkylene-O-alkylene-; C is

[0013] [ka] and; R1 is independently H, alkyl, halide, alkoxy, CF3, OH, alkylene-OH, NO2, -N(H)R, or NH2; R2 is

[0014] [ka] TIFF2024161471000006.tif19166; R3 and R5 are independently selected from H, CN, halide, CF3, C(H)F2, C(F)H2, alkyl, cycloalkyl, -alkylene-alkoxy, aryl, hydroxyl, and alkoxy; R4 is independently selected from alkyl, -C(F2)CH3, cycloalkyl, heterocycloalkyl, -alkylene-cycloalkyl, -O-alkylene-cycloalkyl; -O-cycloalkyl, -O-alkyl, -alkylene-O-alkyl, -alkylene-O-cycloalkyl, and -alkylene-O-alkylene-cycloalkyl; R a is H, (C1-C6)alkyl, —(C1-C6)alkylene-O—(C1-C6)alkyl, or —(C1-C6)alkylene-OC(O)O(C1-C6)alkyl; n is independently 0, 1, 2, 3, or 4; m is 0, 1, 2, or 3; The absolute configuration of any stereocenter is R, S or a mixture thereof.

[0015] In certain embodiments, the present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof:

[0016] [ka] During the ceremony, A is,

[0017] [ka] and; B is

[0018] [ka] selected from the group consisting of: q is 0, 1, 2, or 3; p is 0, 1, or 2; C is

[0019] [ka] and; In each case, R1 is H; R2 is

[0020] [ka] and; R3 is H, halide, Me, OMe, or Ph; R4 is independently selected from alkyl, -C(F2)CH3, cycloalkyl, heterocycloalkyl, -alkylene-cycloalkyl, -O-alkylene-cycloalkyl; -O-cycloalkyl, -O-alkyl, -alkylene-O-alkyl, -alkylene-O-cycloalkyl, and -alkylene-O-alkylene-cycloalkyl; R5 is F; R a is H; n is independently 0 or 1; m is 0 or 1; The absolute configuration of any stereocenter is R, S or a mixture thereof.

[0021] In certain embodiments, the present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof:

[0022] [ka] During the ceremony, A is,

[0023] [ka] and; B is

[0024] [ka] selected from the group consisting of: q is 0, 1, 2, or 3; p is 0, 1, or 2; C is

[0025] [ka] and; In each case, R1 is H; R2 is

[0026] [ka] and; R3 is H, halide, Me, OMe, or Ph; R4 is independently selected from alkyl, -C(F2)CH3, cycloalkyl, heterocycloalkyl, -alkylene-cycloalkyl, -O-alkylene-cycloalkyl; -O-cycloalkyl, -O-alkyl, -alkylene-O-alkyl, -alkylene-O-cycloalkyl, and -alkylene-O-alkylene-cycloalkyl; R5 is F; R a is H; n is 0 or 1; m is 0 or 1; The absolute configuration of any stereocenter is R, S or a mixture thereof.

[0027] In certain embodiments, the invention relates to a method of treating a disease or condition selected from the group consisting of idiopathic pulmonary fibrosis, diabetic nephropathy, focal segmental glomerulosclerosis, chronic kidney disease, nonalcoholic steatohepatitis, primary biliary cholangitis, primary sclerosing cholangitis, solid tumors, hematological malignancies, organ transplantation, Alport syndrome, interstitial lung disease, radiation-induced fibrosis, bleomycin-induced fibrosis, asbestos-induced fibrosis, influenza-induced fibrosis, coagulation-induced fibrosis, vascular injury-induced fibrosis, aortic stenosis, and cardiac fibrosis, comprising administering to a subject in need thereof a therapeutically effective amount of any one of the compounds described herein. [Brief explanation of the drawings]

[0028] [Figure 1-1] 1 is a table summarizing the inhibition of αvβ6 integrin by exemplary compounds as measured by a fluorescence polarization assay. [Figure 1-2] 1 is a table summarizing the inhibition of αvβ6 integrin by exemplary compounds as measured by a fluorescence polarization assay. [Figure 2] 1 is a table summarizing the inhibition of αvβ6 integrin by exemplary compounds as measured by a fluorescence polarization assay. [Figure 3-1] 1-1 and 1-2 as measured in the MDCK in vitro assay of Example 36. [Figure 3-2] 1-1 and 1-2 as measured in the MDCK in vitro assay of Example 36. [Figure 4] 3 is a table summarizing the permeability properties of exemplary compounds from FIG. 2 as measured in the MDCK in vitro assay of Example 36. DETAILED DESCRIPTION OF THE INVENTION

[0029] In certain embodiments, the present invention relates to compounds that inhibit αvβ6 integrin. In certain embodiments, the compounds are selective for αvβ6 integrin.

[0030] The compounds are useful for the treatment of idiopathic pulmonary fibrosis, diabetic nephropathy, focal segmental glomerulosclerosis, chronic kidney disease, nonalcoholic steatohepatitis, primary biliary cholangitis, primary sclerosing cholangitis, solid tumors, hematological tumors, organ transplantation, Alport syndrome, interstitial lung disease, radiation-induced fibrosis, bleomycin-induced fibrosis, asbestos-induced fibrosis, influenza-induced fibrosis, coagulation-induced fibrosis, vascular injury-induced fibrosis, aortic stenosis, or cardiac fibrosis.

[0031] <Definition> For convenience, before further description of the present invention, certain terms employed in the specification, examples, and appended claims are collected here. These definitions should be read in light of the remainder of the disclosure and understood by one of ordinary skill in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.

[0032] In order that the present invention may be more readily understood, certain terms and phrases are defined below and throughout the specification.

[0033] The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

[0034] The phrase "and / or," as used herein in the specification and claims, should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are sometimes present in conjunction and other times present without conjunction. Multiple elements listed with "and / or" should be construed as the same type, i.e., "one or more" of the elements so conjoined. Other elements may be present other than the elements specifically identified by the "and / or" clause, whether related or not to the elements specifically identified. Thus, as a non-limiting example, "A and / or B," when used in conjunction with open-ended language such as "comprising," in one embodiment may refer to A only (optionally including elements other than B); in another embodiment, may refer to B only (optionally including elements other than A); in yet another embodiment, may refer to both A and B (optionally including other elements), etc.

[0035] As used herein in the specification and claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" shall be interpreted as inclusive, i.e., including at least one of, and including more than one of, several elements or a list of elements, and optionally including additional unlisted items. Only terms expressly specified to the contrary, such as "only one of" or "exactly one of," or, when used in the claims, "consisting of," shall refer to the inclusion of exactly one element of several elements or a list of elements. In general, the term "or," as used herein, shall be interpreted to indicate exclusive alternatives (i.e., "either / or, but not both") only when preceded by terms of exclusivity, e.g., "any of," "one of," "only one of," "exactly one of," "consisting essentially of," and, when used in the claims, shall have its ordinary meaning as used in the field of patent law.

[0036] As used herein in the specification and claims, the phrase "at least one" in connection with a list of one or more elements should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed in the list of elements, nor excluding any combination of elements in the list of elements. This definition also allows for the optional presence of elements other than those specifically identified in the list of elements to which the phrase "at least one" refers, whether related or not to those specifically identified elements. Thus, as a non-limiting example, "at least one of A and B" (or, equivalently, "at least one of A or B" or, equivalently, "at least one of A and / or B") can refer, in one embodiment, to at least one A, optionally including multiple, and no B (and optionally including elements other than B); in another embodiment, to B, optionally including multiple, and no A (and optionally including elements other than A); in yet another embodiment, to at least one A, optionally including multiple, and at least one B (and optionally including other elements), etc.

[0037] It is to be understood that, unless expressly specified to the contrary, in any method claimed herein that includes multiple steps or actions, the order of the method steps or actions is not necessarily limited to the order in which the method steps or actions are recited.

[0038] In the claims, as well as in the above specification, all transitional phrases, such as "comprising," "including," "carrying," "having," "containing," "involving," "holding," "composed of," and the like, are to be understood to be open-ended, i.e., to mean inclusive, but not limited to. Only the transitional phrases "consisting of" and "consisting essentially of" are closed or semi-closed transitional phrases, respectively, as set forth in Section 2111.03 of the United States Patent Office Manual of Patent Examining Procedures.

[0039] Certain compounds contained in the compositions of the present invention may exist in particular geometric or stereoisomeric forms. In addition, the polymers of the present invention may also be optically active. The present invention contemplates all such compounds, including cis and trans isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures thereof, and other mixtures thereof, as being within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers, as well as mixtures thereof, are intended to be encompassed by the present invention.

[0040] For example, if a specific enantiomer of a compound of the invention is desired, it may be prepared by asymmetric synthesis, or by derivatization with a chiral auxiliary, in which case the resulting diastereomeric mixture is separated and the auxiliary cleaved to yield the pure desired enantiomer. Alternatively, if the molecule contains a basic functional group such as amino, or an acidic functional group such as carboxyl, diastereomeric salts may be formed with an appropriate optically active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, followed by recovery of the pure enantiomers.

[0041] Structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, the replacement of a hydrogen by deuterium or tritium, or the replacement of a carbon by 13 C or 14 Compounds produced by substituting C-enriched carbon are within the scope of the present invention.

[0042] The term "prodrug," as used herein, encompasses compounds that are converted under physiological conditions into therapeutically active agents. A common method for making a prodrug is to include certain moieties that are hydrolyzed under physiological conditions to yield the desired molecule. In other embodiments, the prodrug is converted by enzymatic activity in the host animal.

[0043] As used herein, the phrase "pharmaceutically acceptable excipient" or "pharmaceutically acceptable carrier" means a pharmaceutically acceptable substance, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating substance, that is involved in the delivery or transport of a chemical substance of interest from one organ or part of the body to another organ or part of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation, not injurious to the patient, and substantially non-pyrogenic. Some examples of substances that can function as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository wax; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil, etc.; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer; and (21) other non-toxic, compatible substances used in pharmaceutical formulations. In certain embodiments, the pharmaceutical compositions of the present invention are non-pyrogenic, i.e., they induce little or no increase in body temperature when administered to a patient.

[0044] The term "pharmaceutically acceptable salts" refers to relatively non-toxic, inorganic and organic acid addition salts of compounds. These salts can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulfonate salts (see, e.g., Berge et al. (1977) "Pharmaceutical Salts," J. Pharm. Sci. 66:1-19).

[0045] In other cases, compounds useful in the methods of the present invention may contain one or more acidic functional groups, thereby capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases. In these cases, the term "pharmaceutically acceptable salts" refers to the relatively non-toxic, inorganic and organic base addition salts of the compounds. These salts can also be prepared in situ during the final isolation and purification of the compounds, or can be prepared by separately reacting the purified compound in its free acid form with a suitable base, such as a hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal cation, ammonia, or a pharmaceutically acceptable organic primary, secondary, or tertiary amine. Representative alkali or alkaline earth salts include lithium, sodium, potassium, calcium, magnesium, and aluminum salts. Representative organic amines useful for forming base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like (see, e.g., Berge et al., supra).

[0046] With respect to use in treatment, a "therapeutically effective amount" (or "effective amount") of a compound refers to the amount of compound in a preparation that, when administered (to a mammal, preferably a human) as part of a desired regimen, alleviates symptoms, reverses the condition, or delays the onset of a disease state according to clinically accepted criteria for the disorder or condition being treated, or for cosmetic purposes, e.g., at a reasonable benefit / risk ratio applicable to any medical treatment.

[0047] The term "prophylactic or therapeutic" treatment is art-recognized and includes administration of one or more of the subject compositions to a host. If administered prior to the clinical manifestation of an undesirable condition (e.g., a disease or other undesirable condition in the host animal), the treatment is prophylactic (i.e., it protects the host from developing the undesirable condition), whereas if administered after the manifestation of the undesirable condition, the treatment is therapeutic (i.e., it is intended to reduce, ameliorate, or stabilize an existing undesirable condition or its side effects).

[0048] The term "patient" refers to a mammal in need of a particular treatment. In certain embodiments, the patient is a primate, dog, cat, or horse. In certain embodiments, the patient is human.

[0049] Aliphatic chains include alkyl, alkenyl, and alkynyl groups as defined below. A straight aliphatic chain is limited to an unbranched carbon chain portion. As used herein, the term "aliphatic group" refers to a straight, branched, or cyclic aliphatic hydrocarbon group, including saturated and unsaturated aliphatic groups, such as alkyl, alkenyl, or alkynyl groups.

[0050] "Alkyl," unless otherwise specified, refers to a fully saturated, cyclic or acyclic, branched or unbranched carbon chain moiety having the specified number of carbon atoms, or up to 30 carbon atoms. For example, alkyl of 1 to 8 carbon atoms refers to moieties such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl, as well as moieties that are positional isomers of these moieties. Alkyl of 10 to 30 carbon atoms includes decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosyl, heneicosyl, docosyl, tricosyl, and tetracosyl. In certain embodiments, a straight or branched chain alkyl has 30 or fewer carbon atoms (e.g., C1-C for straight chain). 30 , C3 to C for branched chains 30 ), and more preferably has 20 or fewer carbon atoms in its backbone. Alkyl groups can be substituted or unsubstituted.

[0051] As used herein, the term "alkylene" refers to an alkyl group having a specified number of carbons, e.g., 2 to 12 carbon atoms, on its longest carbon chain, including two points of attachment to the remainder of the compound. Non-limiting examples of alkylene groups include methylene-(CH2)-, ethylene-(CH2CH2)-, n-propylene-(CH2CH2CH2)-, isopropylene-(CH2CH(CH3))-, and the like. Alkylene groups can be cyclic or acyclic, branched or unbranched carbon chain moieties, and may be substituted with one or more substituents.

[0052] "Cycloalkyl" means monocyclic, bicyclic, bridged, spirocyclic, or polycyclic saturated carbocyclic rings, each of which having from 3 to 12 carbon atoms. Likewise, preferred cycloalkyls have from 3 to 10 carbon atoms in their ring structure, and more preferably have 3-6 carbons in the ring structure. Cycloalkyl groups can be substituted or unsubstituted.

[0053] Unless the number of carbons is otherwise specified, "lower alkyl," as used herein, refers to an alkyl group, as defined above, but having from 1 to 10 carbons in its backbone structure, more preferably from 1 to 6 carbon atoms, e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl. Similarly, "lower alkenyl" and "lower alkynyl" have similar chain lengths. Throughout this application, preferred alkyl groups are lower alkyls. In certain embodiments, a substituent designated herein as alkyl is a lower alkyl.

[0054] "Alkenyl" refers to any cyclic or acyclic, branched or unbranched, unsaturated carbon chain moiety having a specified number of carbon atoms, or up to 26 carbon atoms if no limit on the number of carbon atoms is specified, and having one or more double bonds within the moiety. Examples of alkenyls of 6 to 26 carbon atoms include hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodenyl, tridecenyl, tetradecenyl, pentadecenyl, hexadecenyl, heptadecenyl, octadecenyl, nonadecenyl, eicosenyl, heneicosoenyl, docosenyl, tricosenyl, and tetracosenyl in their various isomeric forms, where the unsaturated bond can be located anywhere within the moiety and can have either the (Z) or (E) configuration around the double bond.

[0055] "Alkynyl" refers to a hydrocarbyl moiety within the scope of alkenyl, but containing one or more triple bonds within the moiety.

[0056] The term "alkylthio" refers to an alkyl group, as defined above, having a sulfur moiety attached thereto. In certain embodiments, the "alkylthio" moiety includes -(S)-alkyl, -(S)-alkenyl, -(S)-alkynyl, and -(S)-(CH) m -R 1 and m and R 1is defined below. Representative alkylthio groups include methylthio, ethylthio, and the like. The term "alkoxyl" or "alkoxy," as used herein, refers to an alkyl group, as defined below, having an oxygen moiety attached thereto. Representative alkoxyl groups include methoxy, ethoxy, propoxy, tert-butoxy, and the like. An "ether" is two hydrocarbons covalently linked by an oxygen. Thus, the substituent of an alkyl that makes it an ether is an alkoxyl or an alkoxyl-like group, such as, for example, -O-alkyl, -O-alkenyl, -O-alkynyl, -O-(CH2) m -R 10 can be expressed by one of m and R 10 is described below.

[0057] The terms "amine" and "amino" are art-recognized and refer to both unsubstituted and substituted amines, for example, a moiety that can be represented by the formula:

[0058] [ka] In the formula, R 11 , R 12 and R 13 are each independently hydrogen, alkyl, alkenyl, -(CH2) m -R 10 or R 11 and R 12 together with the N atom to which they are attached complete a heterocycle having 4 to 8 atoms in the ring structure, and R 10 represents alkenyl, aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl, and m is zero or an integer ranging from 1 to 8. In certain embodiments, R 11 or R 12 Only one of the groups may be a carbonyl, e.g., R 11 , R 12 and the nitrogen together do not form an imide. In certain further embodiments, R 11 and R12 (and optionally R 13 ) are each independently hydrogen, alkyl, alkenyl, or -(CH) m -R 10 Thus, the term "alkylamine" as used herein refers to an amine having a substituted or unsubstituted alkyl attached thereto, i.e., R 11 and R 12 and n is an alkyl group. In certain embodiments, the amino group or alkylamine is basic, which means that the group has a pK a >7.00, i.e., the protonated form of these functional groups has a pK relative to water above about 7.00. a It means having.

[0059] The term "amide" as used herein refers to the following group:

[0060] [ka] In the formula, each R 14 independently represent hydrogen or a hydrocarbyl group, or two R 14 However, together with the N atom to which they are attached, they complete a heterocycle with 4 to 8 atoms in the ring structure.

[0061] As used herein, the term "aryl" includes 3- to 12-membered, substituted or unsubstituted, monocyclic aromatic groups in which each atom of the ring is carbon (i.e., carbocyclic aryl) or one or more atoms is a heteroatom (i.e., heteroaryl). Preferably, aryl groups include 5- to 12-membered rings, more preferably 6- to 10-membered rings. The term "aryl" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjacent rings, at least one of which is aromatic; for example, the other cyclic rings may be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and / or heterocyclyl. Carbocyclic aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like. Heteroaryl groups include substituted or unsubstituted aromatic 3- to 12-membered ring structures, more preferably 5- to 12-membered rings, more preferably 5- to 10-membered rings, whose ring structures contain one to four heteroatoms. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine. Aryl and heteroaryl can be monocyclic, bicyclic, or polycyclic. Each instance of an aryl group can be independently substituted, i.e., unsubstituted ("unsubstituted aryl") or substituted with one or more substituents, for example, 1 to 5 substituents, 1 to 4 substituents, 1 to 3 substituents, 1 to 2 substituents, or exactly 1 substituent ("substituted aryl"). The aromatic ring may be optionally substituted at one or more ring positions with one or more substituents, such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamide, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moiety, fluoroalkyl (e.g., trifluoromethyl), cyano, etc. For example, in certain embodiments, the aryl group may be an unsubstituted C5-C612 In certain embodiments, the aryl group is a substituted C-C 10 It can be aryl.

[0062] The terms "halo," "halide," or "halogen," as used herein, mean halogens, such as, but not limited to, fluoro, chloro, bromo, iodo, and the like, in both radioactive and non-radioactive forms. In preferred embodiments, halo is selected from the group consisting of fluoro, chloro, and bromo.

[0063] The terms "heterocyclyl" or "heterocyclic group" refer to 3- to 12-membered ring structures, more preferably 5- to 12-membered rings, and more preferably 5- to 10-membered rings, whose ring structures include one to four heteroatoms. The heterocycle can be monocyclic, bicyclic, spirocyclic, or polycyclic. Heterocyclyl groups include, for example, thiophene, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxathiin, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, pyrimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, pyrrolidine, oxolane, thiolane, oxazole, piperidine, piperazine, morpholine, lactones, lactams such as azetidinones and pyrrolidinones, sultams, sultones, and the like. The heterocyclic ring may be optionally substituted at one or more positions with substituents as described above, such as, for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphate, phosphonate, phosphinate, carbonyl, carboxyl, silyl, sulfamoyl, sulfinyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moiety, -CF, -CN, and the like.

[0064] The term "carbonyl" is art-recognized and includes moieties represented by the formula:

[0065] [ka] wherein X′ is a bond or represents oxygen or sulfur; R 15 is hydrogen, alkyl, alkenyl, -(CH2) m -R 10or a pharmaceutically acceptable salt thereof, R 16 is hydrogen, alkyl, alkenyl or -(CH2) m -R 10 where m and R 10 is as defined above. X' is oxygen and R 15 or R 16 Where X' is oxygen and R 15 is as defined above, the moiety is referred to herein as a carboxyl group, and in particular R 15 Where X' is hydrogen, the formula represents a "carboxylic acid". 16 is hydrogen, the formula represents a "formate." In general, where the oxygen atom of the above formula is replaced by a sulfur, the formula represents a "thiocarbonyl" group. 15 or R 16 Where X' is not hydrogen, the formula represents a "thioester" group. 15 Where X' is a sulfur and R 16 is hydrogen, the formula represents a "thioformate" group. On the other hand, if X' is a bond, and R 15 Where X' is a bond and R is not hydrogen, the above formula represents a "ketone" group. 15 Where is hydrogen, the above formula represents an "aldehyde" group.

[0066] As used herein, the term "substituted" is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, those described herein above. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this invention, heteroatoms such as nitrogen can have hydrogen substituents and / or any permissible substituents of organic compounds described herein that satisfy the valences of the heteroatoms. This invention is not intended to be limited in any manner by the permissible substituents of organic compounds. It should be apparent that "substituted" or "substituted with" includes the implicit proviso that such substitution is consistent with the permissible valences of the substituted atom and substituent, and that the substitution results in a stable compound, e.g., a compound that does not spontaneously undergo transformation by rearrangement, cyclization, elimination, and the like.

[0067] As used herein, the term "nitro" means -NO2, the term "halogen" means -F, -Cl, -Br, or -I, the term "sulfhydryl" means -SH, the term "hydroxyl" means -OH, the term "sulfonyl" means -SO2-, the term "azido" means -N3, the term "cyano" means -CN, the term "isocyanato" means -NCO, the term "thiocyanato" means -SCN, the term "isothiocyanato" means -NCS, and the term "cyanato" means -OCN.

[0068] The term "sulfamoyl" is art-recognized and includes a moiety that can be represented by the formula:

[0069] [ka] In the formula, R 11 and R 12 is as defined above.

[0070] The term "sulfate" is art-recognized and includes a moiety that can be represented by the formula:

[0071] [ka] In the formula, R 15 is as defined above.

[0072] The term "sulfonamide" is art-recognized and includes a moiety that can be represented by the formula:

[0073] [ka] In the formula, R 11 and R 16 is as defined above.

[0074] The term "sulfonate" is art-recognized and includes a moiety that can be represented by the formula:

[0075] [ka] In the formula, R 54 is an electron pair, hydrogen, alkyl, cycloalkyl, or aryl.

[0076] As used herein, the term "sulfoxide" or "sulfinyl" refers to a moiety that can be represented by the formula:

[0077] [ka] In the formula, R 17 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aralkyl, or aryl.

[0078] The term "urea" is art-recognized and may be represented by the general formula:

[0079] [ka] In the formula, each R 18 independently represent hydrogen or hydrocarbyl, e.g., alkyl, or R 18 together with other atoms and intervening atoms complete a heterocycle having from 4 to 8 atoms in the ring structure.

[0080] As used herein, the definition of each expression, e.g., alkyl, m, n, etc., when it occurs more than once in any structure, is independent of its definition elsewhere in the same structure.

[0081] The term "substituted" refers to moieties having substituents replacing a hydrogen on one or more carbon atoms of the backbone. It should be clear that "substituted" or "substituted with" includes the implicit proviso that such substitution is consistent with the allowed valencies of the substituted atom and substituent, and that the substitution results in a stable compound, e.g., a compound that does not spontaneously undergo transformation by rearrangement, cyclization, elimination, and the like. As used herein, the term "substituted" is intended to include all permissible substituents of organic compounds. In a broad aspect, permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different, for appropriate organic compounds. For purposes of this invention, heteroatoms, such as nitrogen, can have any permissible substituents of organic compounds described herein that satisfy the hydrogen substituents and / or valencies of the heteroatoms. Substituents can include any substituent described herein, such as halogen, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, araalkyl, or aromatic or heteroaromatic moiety. In preferred embodiments, the substituent on a substituted alkyl is C 1-6 Alkyl, C 3-6In a more preferred embodiment, the substituent on the substituted alkyl is selected from fluoro, carbonyl, cyano, or hydroxyl. It will be apparent to those skilled in the art that the substituent itself can be substituted, where appropriate. Unless specifically stated as "unsubstituted," reference to a chemical moiety herein is understood to include substituted ones. For example, when referring to an "aryl" group or moiety, it is intended to include both substituted and unsubstituted ones.

[0082] For purposes of this invention, chemical elements are identified according to the Periodic Table of the Elements, CAS version, inside cover of the Handbook of Chemistry and Physics, 67th Ed., 1986-87.

[0083] <Exemplary Compounds of the Present Invention> In certain embodiments, the present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof:

[0084] [ka] During the ceremony, A is

[0085] [ka] and; B is alkylene, -alkylene-(heterocyclyl)-alkylene-, -(heterocyclyl)-alkylene-, -cycloalkylene, -alkylene-O-, -cycloalkylene-O-, or -alkylene-O-alkylene-; C is

[0086] [ka] and; R1 is independently H, alkyl, halide, alkoxy, CF3, OH, alkylene-OH, NO2, -N(H)R, or NH2; R2 is

[0087] [ka] TIFF2024161471000030.tif20166; R3 and R5 are independently selected from H, halide, CF3, C(H)F2, C(F)H2, alkyl, cycloalkyl, -alkylene-alkoxy, aryl, hydroxyl, and alkoxy; R4 is independently selected from alkyl, -C(F2)CH3, cycloalkyl, heterocycloalkyl, -alkylene-cycloalkyl, -O-alkylene-cycloalkyl; -O-cycloalkyl, -O-alkyl, -alkylene-O-alkyl, -alkylene-O-cycloalkyl, and -alkylene-O-alkylene-cycloalkyl; R a is H, (C1-C6)alkyl, —(C1-C6)alkylene-O—(C1-C6)alkyl, or —(C1-C6)alkylene-OC(O)O(C1-C6)alkyl; n is independently 0, 1, 2, 3, or 4; m is 0, 1, 2, or 3; The absolute configuration of any stereocenter is R, S or a mixture thereof.

[0088] In certain embodiments, the present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof:

[0089] [ka] During the ceremony, A is,

[0090] [ka] and; B is alkylene, -alkylene-(heterocyclyl)-alkylene-, -(heterocyclyl)-alkylene-, -cycloalkylene, -alkylene-O-, -cycloalkylene-O-, or -alkylene-O-alkylene-; C is

[0091] [ka] and; R1 is H or alkoxy; R2 is

[0092] [ka] TIFF2024161471000035.tif20166; R3 and R5 are independently selected from H, halide, CF3, C(H)F2, C(F)H2, alkyl, cycloalkyl, -alkylene-alkoxy, aryl, hydroxyl, and alkoxy; R4 is independently selected from alkyl, -C(F2)CH3, cycloalkyl, heterocycloalkyl, -alkylene-cycloalkyl, -O-alkylene-cycloalkyl; -O-cycloalkyl, -O-alkyl, -alkylene-O-alkyl, -alkylene-O-cycloalkyl, and -alkylene-O-alkylene-cycloalkyl; R a is H, (C1-C6)alkyl, —(C1-C6)alkylene-O—(C1-C6)alkyl, or —(C1-C6)alkylene-OC(O)O(C1-C6)alkyl; n is independently 0, 1, 2, 3, or 4; m is 0, 1, 2, or 3; The absolute configuration of any stereocenter is R, S or a mixture thereof.

[0093] In certain embodiments, the present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof:

[0094] [ka] During the ceremony, A is,

[0095] [ka] and; B is alkylene, -alkylene-O-, or -alkylene-O-alkylene-; C is

[0096] [ka] and; R1 is H; R2 is

[0097] [ka] TIFF2024161471000040.tif21166; R3 and R5 are independently selected from H, halide, CF3, C(H)F2, C(F)H2, alkyl, cycloalkyl, -alkylene-alkoxy, aryl, hydroxyl, and alkoxy; R4 is independently selected from alkyl, -C(F2)CH3, cycloalkyl, heterocycloalkyl, -alkylene-cycloalkyl, -O-alkylene-cycloalkyl; -O-cycloalkyl, -O-alkyl, -alkylene-O-alkyl, -alkylene-O-cycloalkyl, and -alkylene-O-alkylene-cycloalkyl; R a is H, (C1-C6)alkyl, —(C1-C6)alkylene-O—(C1-C6)alkyl, or —(C1-C6)alkylene-OC(O)O(C1-C6)alkyl; n is independently 0, 1, 2, 3, or 4; m is 0, 1, 2, or 3; The absolute configuration of any stereocenter is R, S or a mixture thereof.

[0098] In certain embodiments, the present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof:

[0099] [ka] During the ceremony, A is,

[0100] [ka] and; B is alkylene or -alkylene-O-; C is

[0101] [ka] and; R1 is H; R2 is

[0102] [ka] TIFF2024161471000045.tif21166; R5 is independently selected from H, halide, CF3, C(H)F2, C(F)H2, alkyl, cycloalkyl, -alkylene-alkoxy, aryl, hydroxyl, and alkoxy; R4 is independently selected from alkyl, -C(F2)CH3, cycloalkyl, heterocycloalkyl, -alkylene-cycloalkyl, -O-alkylene-cycloalkyl; -O-cycloalkyl, -O-alkyl, -alkylene-O-alkyl, -alkylene-O-cycloalkyl, and -alkylene-O-alkylene-cycloalkyl; R a is H; n is 0; m is 0, 1, 2, or 3; The absolute configuration of any stereocenter is R, S or a mixture thereof.

[0103] In certain embodiments, the present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof:

[0104] [ka] During the ceremony, A is,

[0105] [ka] and; B is

[0106] [ka] and; q is 0, 1, 2, or 3; C is

[0107] [ka] and; R1 is independently H, alkyl, halide, alkoxy, CF3, OH, alkylene-OH, NO2, -N(H)R, or NH2; R2 is

[0108] [ka] TIFF2024161471000051.tif19166; R5 is independently selected from H, halide, CF3, C(H)F2, C(F)H2, alkyl, cycloalkyl, -alkylene-alkoxy, aryl, hydroxyl, and alkoxy; R4 is independently selected from alkyl, -C(F2)CH3, cycloalkyl, heterocycloalkyl, -alkylene-cycloalkyl, -O-alkylene-cycloalkyl; -O-cycloalkyl, -O-alkyl, -alkylene-O-alkyl, -alkylene-O-cycloalkyl, and -alkylene-O-alkylene-cycloalkyl; R a is H, (C1-C6)alkyl, —(C1-C6)alkylene-O—(C1-C6)alkyl, or —(C1-C6)alkylene-OC(O)O(C1-C6)alkyl; n is 0; m is 0, 1, 2, or 3; The absolute configuration of any stereocenter is R, S or a mixture thereof.

[0109] In certain embodiments, the present invention provides a method for treating a cancer comprising administering to a patient a cancer-related disorder, ... wherein A is

[0110] [ka] In certain embodiments, the present invention relates to any one of the aforementioned compounds, wherein A is

[0111] [ka] The present invention relates to any one of the above compounds wherein

[0112] In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein B is alkylene. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein B is -alkylene-(heterocyclyl)-alkylene-. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein B is -(heterocyclyl)-alkylene-. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein B is -cycloalkylene. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein B is -alkylene-O-. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein B is -cycloalkylene-O-. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein B is -alkylene-O-alkylene-. In some embodiments, -alkylene-O-alkylene- is -methylene-O-propylene, -ethylene-O-ethylene, or -propylene-O-methylene. In certain embodiments, the invention relates to any one of the above compounds.

[0113] [ka] wherein q is 0, 1, 2, or 3; and p is 0, 1, or 2.

[0114] In some embodiments, B is

[0115] [ka] In some embodiments, B is

[0116] [ka] In some embodiments, q is 0. In some embodiments, q is 1. In some embodiments, q is 2. In some embodiments, q is 3. In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2.

[0117] In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R1 is H. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R1 is alkyl. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R1 is methyl. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R1 is halide. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R1 is alkoxy. In some embodiments, alkoxy is methoxy, ethoxy, iso-propyloxy, iso-butyloxy, or tert-butyloxy. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R1 is CF3. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R1 is OH. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R1 is alkylene-OH. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R1 is NO2. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R1 is -N(H)R a In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R is NH. In some embodiments, at least one instance of R is alkyl, halide, OMe, OH, alkylene-OH, or NH. In some embodiments, at least one instance of R is OMe. In some embodiments, both instances of R are H.

[0118] In certain embodiments, the present invention provides a method for treating a cancer, wherein R

[0119] [ka] In certain embodiments, the present invention relates to any one of the aforementioned compounds, wherein R2 is

[0120] [ka] In certain embodiments, the present invention relates to any one of the aforementioned compounds, wherein R2 is

[0121] [ka] In certain embodiments, the present invention relates to any one of the aforementioned compounds, wherein R2 is

[0122] [ka] In certain embodiments, the present invention relates to any one of the aforementioned compounds, wherein R2 is

[0123] [ka] In certain embodiments, the present invention relates to any one of the aforementioned compounds, wherein R2 is

[0124] [ka] In certain embodiments, the present invention relates to any one of the aforementioned compounds, wherein R2 is

[0125] [ka] The present invention relates to any one of the aforementioned compounds, wherein

[0126] In certain embodiments, the invention relates to any one of the above-mentioned compounds, wherein n is 0. In certain embodiments, the invention relates to any one of the above-mentioned compounds, wherein n is 1. In certain embodiments, the invention relates to any one of the above-mentioned compounds, wherein n is 2. In certain embodiments, the invention relates to any one of the above-mentioned compounds, wherein n is 3. In certain embodiments, the invention relates to any one of the above-mentioned compounds, wherein n is 4.

[0127] In certain embodiments, the invention relates to any one of the above-mentioned compounds, wherein m is 0. In certain embodiments, the invention relates to any one of the above-mentioned compounds, wherein m is 1. In certain embodiments, the invention relates to any one of the above-mentioned compounds, wherein m is 2. In certain embodiments, the invention relates to any one of the above-mentioned compounds, wherein m is 3.

[0128] In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R3 is H. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R3 is a halide. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R3 is CN. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R3 is CF. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R3 is C(H)F2. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R3 is C(F)H2. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R3 is alkyl. In some embodiments, alkyl is methyl, ethyl, iso-propyl, or tert-butyl. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R3 is cycloalkyl. In some embodiments, cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R3 is -alkylene-alkoxy. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R3 is aryl. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R3 is hydroxyl. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R3 is alkoxy. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R3 is H, halide, Me, OMe, or Ph.

[0129] In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R4 is alkyl. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R4 is —C(F2)CH3. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R4 is cycloalkyl. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R4 is heterocycloalkyl. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R4 is -alkylene-cycloalkyl. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R4 is —O-alkylene-cycloalkyl. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R4 is —O-cycloalkyl. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R4 is —O-alkyl. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R4 is -alkylene-O-alkyl. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R4 is -alkylene-O-cycloalkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R4 is -alkylene-O-alkylene-cycloalkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R4 is selected from -alkylene-cycloalkyl, -O-alkylene-cycloalkyl; -alkylene-O-alkyl, -alkylene-O-cycloalkyl, and -alkylene-O-alkylene-cycloalkyl. In some embodiments, alkylene R4 is methylene or ethylene.

[0130] In certain embodiments, the present invention provides a method for treating a cancer, wherein R

[0131] [ka] TIFF2024161471000065.tif77166TIFF2024161471000066.tif18166. In certain embodiments, the present invention relates to any one of the above compounds, wherein R4 is selected from

[0132] [ka] TIFF2024161471000068.tif16166. In certain embodiments, the present invention relates to any one of the aforementioned compounds, wherein R4 is selected from

[0133] [ka] In certain embodiments, the present invention relates to any one of the above compounds, wherein R4 is

[0134] [ka] In certain embodiments, the present invention relates to any one of the above compounds, wherein R4 is

[0135] [ka] In certain embodiments, the present invention relates to any one of the above compounds, wherein R4 is

[0136] [ka] In certain embodiments, the present invention relates to any one of the above compounds, wherein R4 is

[0137] [ka] TIFF2024161471000074.tif96166.

[0138] In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R5 is H. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R5 is halide. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R5 is F. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R5 is CN. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R5 is CF3. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R5 is C(H)F2. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R5 is C(F)H2. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R5 is alkyl. In some embodiments, alkyl is methyl, ethyl, iso-propyl, or tert-butyl. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R5 is cycloalkyl. In some embodiments, cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R5 is -alkylene-alkoxy. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R5 is aryl. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R5 is hydroxyl. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R5 is alkoxy. In certain embodiments, the invention relates to any one of the above-mentioned compounds wherein R5 is H, halide, Me, OMe, or Ph.

[0139] In certain embodiments, the present invention provides a compound comprising R a is H. In certain embodiments, the present invention relates to any one of the above compounds, wherein R ais (C1-C6) alkyl. In some embodiments, (C1-C6) alkyl is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, or t-butyl. In certain embodiments, the present invention relates to any one of the above compounds, wherein R a In certain embodiments, the present invention relates to any one of the above compounds, wherein R is -(C1-C6)alkylene-O-(C1-C6)alkyl. a is —(C1-C6)alkylene-OC(O)O(C1-C6)alkyl.

[0140] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein the absolute configuration at any stereocenter is R. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein the absolute configuration at any stereocenter is S. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein the absolute configuration at any stereocenter is a mixture of R and S.

[0141] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein the compound is a pharmaceutically acceptable salt.

[0142] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0143] [ka] TIFF2024161471000076.tif61166TIFF2024161471000077.tif241166TIFF2024161471000078.tif147166.

[0144] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0145] [ka] TIFF2024161471000080.tif66166TIFF2024161471000081.tif234166TIFF2024161471000082.tif113166.

[0146] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0147] [ka] TIFF2024161471000084.tif59166TIFF2024161471000085.tif123166.

[0148] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0149] [ka] TIFF2024161471000087.tif64166.

[0150] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0151] [ka] TIFF2024161471000089.tif22166.

[0152] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0153] [ka] TIFF2024161471000091.tif138166TIFF2024161471000092.tif231166TIFF2024161471000093.tif208166TIFF2024161471000094.tif112166.

[0154] In certain embodiments, the invention relates to compounds of the formula:

[0155] [ka]

[0156] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0157] [ka] TIFF2024161471000097.tif226166TIFF2024161471000098.tif225166TIFF2024161471000099.tif187166.

[0158] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0159] [ka] TIFF2024161471000101.tif226166TIFF2024161471000102.tif162166TIFF2024161471000103.tif95166.

[0160] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0161] [ka] TIFF2024161471000105.tif60166.

[0162] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0163] [ka] TIFF2024161471000107.tif68166.

[0164] In certain embodiments, the invention relates to compounds of the formula:

[0165] [ka]

[0166] In certain embodiments, the invention relates to compounds of the formula:

[0167] [ka]

[0168] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0169] [ka] The present invention relates to a compound selected from the group consisting of:

[0170] In certain embodiments, the invention relates to compounds of the formula:

[0171] [ka]

[0172] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0173] [ka] TIFF2024161471000113.tif50166 TIFF2024161471000114.tif186166 TIFF2024161471000115.tif230166 TIFF2024161471000116.tif245166 TIFF2024161471000117.tif197166 TIFF2024161471000118.tif208166.

[0174] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0175] [ka] TIFF2024161471000120.tif146166TIFF2024161471000121.tif209166.

[0176] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0177] [ka] TIFF2024161471000123.tif159166TIFF2024161471000124.tif244166TIFF2024161471000125.tif223166TIFF2024161471000126.tif224166TIFF2024161471000127.tif190166.

[0178] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0179] [ka] TIFF2024161471000129.tif117166.

[0180] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0181] [ka] TIFF2024161471000131.tif208166TIFF2024161471000132.tif136166.

[0182] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0183] [ka] TIFF2024161471000134.tif59166.

[0184] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0185] [ka] TIFF2024161471000136.tif59166TIFF2024161471000137.tif137166.

[0186] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0187] [ka] TIFF2024161471000139.tif51166.

[0188] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0189] [ka] TIFF2024161471000141.tif122166.

[0190] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0191] [ka] TIFF2024161471000143.tif69166.

[0192] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0193] [ka] TIFF2024161471000145.tif52166.

[0194] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0195] [ka] TIFF2024161471000147.tif40166TIFF2024161471000148.tif75166.

[0196] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0197] [ka] TIFF2024161471000150.tif51166TIFF2024161471000151.tif215166.

[0198] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0199] [ka] TIFF2024161471000153.tif150166.

[0200] In certain embodiments, the present invention provides a method for treating a cancer cell comprising:

[0201] [ka] The present invention relates to a compound selected from the group consisting of:

[0202] In some embodiments, the present invention provides a method for treating a skin condition comprising:

[0203] [ka] TIFF2024161471000156.tif68166.

[0204] Exemplary Pharmaceutical Compositions In certain embodiments, the invention relates to a pharmaceutical composition comprising any one of the above-mentioned compounds and a pharmaceutically acceptable carrier.

[0205] A patient, such as, but not limited to, a human, can be treated by administering to the patient an effective amount of an active compound or a pharmaceutically acceptable prodrug or salt thereof in the presence of a pharmaceutically acceptable carrier or diluent. The active agent can be administered by any suitable route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, in liquid or solid form.

[0206] The concentration of active compound in the drug composition depends on the absorption, inactivation and excretion rate of the drug and other factors known to those skilled in the art.It should be noted that the dosage value also varies depending on the severity of the condition to be improved.It should be further understood that for a particular subject, specific dosage regimens should be adjusted over time according to the individual needs and the professional judgment of the person administering or supervising the administration of the composition, and the concentration ranges described herein are merely exemplary and do not limit the scope or implementation of the claimed compositions.The active ingredient can be administered at a single time or can be divided into several small doses administered at varying time intervals.

[0207] In certain embodiments, the mode of administration of the active compound is oral. Oral compositions generally contain an inert diluent or an edible carrier. These can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binders and / or adjuvant materials can be included as part of the composition.

[0208] Tablets, pills, capsules, troches, etc. may contain any of the following ingredients, or compounds of a similar nature: binders such as microcrystalline cellulose, tragacanth gum, or gelatin; excipients such as starch or lactose; disintegrants such as alginic acid, Primogel, or corn starch; lubricants such as magnesium stearate or sterotes; glidants such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; or flavoring agents such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit is a capsule, it may contain, in addition to the above-mentioned types of materials, a liquid carrier such as fatty oils. In addition, dosage unit can contain various other materials that modify the physical form of the dosage unit, such as sugar coatings, shellac, or other enteric agents.

[0209] The compounds can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum, etc. A syrup may contain, in addition to the active compounds, sucrose or other sweetening agents as a sweetening agent and certain preservatives, dyes and colorings and flavors.

[0210] The compound or its pharmaceutically acceptable prodrug or salt can also be mixed with other active substances that do not interfere with the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, anti-inflammatory agents, or other antivirals, for example, but not limited to, nucleoside compounds. Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can contain the following components: a sterile diluent such as water for injection, saline, fixed oils, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents; an antibacterial agent such as benzyl alcohol or methylparaben; an antioxidant such as ascorbic acid or sodium bisulfite; a chelating agent such as ethylenediaminetetraacetic acid; a buffer such as acetate, citrate, or phosphate, and an agent for adjusting tonicity such as sodium chloride or glucose. Parenteral preparations can be enclosed in ampoules, disposable syringes, or multiple-dose vials made of glass or plastic.

[0211] If administered intravenously, carriers include saline and phosphate buffered saline (PBS).

[0212] In certain embodiments, the active compound is formulated with a carrier that protects the compound from rapid elimination from the body, for example, sustained-release formulations, including, but not limited to, implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid, can be used. For example, enteric coating compounds can be used to protect against cleavage by stomach acid. Methods for preparing such formulations are readily apparent to those skilled in the art. Suitable materials can also be obtained commercially.

[0213] Liposomal suspensions (including, but not limited to, liposomes targeting infected cells bearing monoclonal antibodies against viral antigens) are also preferred as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811 (incorporated by reference). For example, liposomal formulations can be prepared by dissolving a suitable lipid (e.g., stearoylphosphatidylethanolamine, stearoylphosphatidylcholine, arachadoylphosphatidylcholine, and cholesterol) in an inorganic solvent, followed by evaporation of the solvent, leaving a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound is then introduced into the container. The container is then manually swirled to remove lipid material from the sides of the container and disperse lipid aggregates, thereby forming a liposomal suspension.

[0214] Exemplary Methods of the Invention In certain embodiments, the invention relates to a method of treating a disease or condition selected from the group consisting of idiopathic pulmonary fibrosis, diabetic nephropathy, focal segmental glomerulosclerosis, chronic kidney disease, nonalcoholic steatohepatitis, primary biliary cholangitis, primary sclerosing cholangitis, solid tumors, hematological malignancies, organ transplantation, Alport syndrome, interstitial lung disease, radiation-induced fibrosis, bleomycin-induced fibrosis, asbestos-induced fibrosis, influenza-induced fibrosis, coagulation-induced fibrosis, vascular injury-induced fibrosis, aortic stenosis, and cardiac fibrosis, comprising administering to a subject in need thereof a therapeutically effective amount of any one of the above compounds.

[0215] In certain embodiments, the invention relates to any one of the above methods, wherein the disease or condition is a solid tumor (sarcoma, carcinoma, and lymphoma). Exemplary tumors that can be treated according to the invention include, for example, Ewing's sarcoma, rhabdomyosarcoma, osteosarcoma, myeloid sarcoma, chondrosarcoma, liposarcoma, leiomyosarcoma, soft tissue sarcoma, non-small cell lung cancer, small cell lung cancer, bronchial cancer, prostate cancer, breast cancer, pancreatic cancer, gastrointestinal cancer, colon cancer, rectal cancer, colorectal adenoma, thyroid cancer, liver cancer, intrahepatic bile duct cancer, hepatocellular carcinoma, adrenal cancer, gastric cancer, gastric cancer, glioma (e.g., adult, pediatric brainstem, pediatric brain astrocytoma, pediatric visual pathway and hypothalamic), glioblastoma, endometrial cancer, Cancer, melanoma, kidney cancer, renal pelvis cancer, bladder cancer, uterine cancer, cervical cancer of the uterus, vaginal cancer, ovarian cancer, multiple myeloma, esophageal cancer, brain cancer (e.g., brainstem glioma, cerebellar astrocytoma, cerebral astrocytoma / malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumor, optic tract and hypothalamic glioma), lips and oral cavity and pharynx, larynx, small intestine, melanoma, villous colon adenoma, neoplasms, neoplasms of an epithelial nature, lymphomas (e.g., AIDS-associated lymphoma, Burkitt's lymphoma, cutaneous T-cell lymphoma, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, and primary central nervous system lymphoma), cancer of the breast, basal cell carcinoma, squamous cell carcinoma, actinic keratoepitheliosis, neoplastic diseases including solid tumors, tumors of the neck or head, polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid metaplasia, Waldenstrom's macroglobulinemia, adrenocortical carcinoma, AIDS-related cancer, childhood cerebellar astrocytoma, childhood cerebellar astrocytoma, basal cell carcinoma, extrahepatic bile duct cancer, malignant fibrous histiocytoma, bone cancer, bronchial adenoma / carcinoid, carcinoid tumor, gastrointestinal carcinoid tumor, primary central nervous system Nervous system, cerebellar astrocytoma, childhood cancer, ependymoma, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, intraocular melanoma eye cancer, retinoblastoma eye cancer, gallbladder cancer, gastrointestinal carcinoid tumor, germ cell tumor (e.g., extracranial, extragonadal, and ovarian), gestational trophoblastic tumor, hepatocellular carcinoma, hypopharyngeal cancer, hypothalamic and optic tract glioma, islet cell carcinoma (endocrine pancreas), laryngeal cancer, malignant fibrous histiocytoma of bone / osteosarcoma, medulloblastoma, mesothelioma, metastatic squamous cell carcinoma of the neck of unknown primary, prediabetes, multiple myeloma / plasma cell neoplasm, mycosis fungoides,These include nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cavity cancer, oropharyngeal cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, islet cell pancreatic cancer, parathyroid cancer, pheochromocytoma, pineoblastoma, pituitary tumor, pleuropulmonary blastoma, ureteral transitional cell carcinoma, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, Sézary syndrome, non-melanoma skin cancer, Merkel cell carcinoma, squamous cell carcinoma, testicular cancer, thymoma, gestational trophoblastic tumor, and Wilms' tumor.

[0216] In certain embodiments, the invention relates to any one of the aforementioned methods, wherein the disease or condition is a hematological tumor. Exemplary hematological tumors that can be treated according to the invention include, for example, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and multiple myeloma.

[0217] In certain embodiments, the invention relates to any one of the aforementioned methods, wherein the disease or condition is selected from the group consisting of idiopathic pulmonary fibrosis, interstitial lung disease associated with systemic sclerosis, interstitial lung disease associated with myositis, interstitial lung disease associated with systemic lupus erythematosus, rheumatoid arthritis, and related interstitial lung diseases.

[0218] In certain embodiments, the invention relates to any one of the aforementioned methods, wherein the disease or condition is selected from the group consisting of diabetic nephropathy, focal segmental glomerulosclerosis, and chronic kidney disease.

[0219] In certain embodiments, the invention relates to any one of the aforementioned methods, wherein the disease or condition is selected from the group consisting of nonalcoholic steatohepatitis, primary biliary cholangitis, and primary sclerosing cholangitis.

[0220] In certain embodiments, the invention relates to any one of the above methods, wherein the subject is a mammal. In certain embodiments, the invention relates to any one of the above methods, wherein the subject is a human.

[0221] Alternative Numeric Embodiments

[0222] 1. A compound of the following formula (I) or a pharmaceutically acceptable salt of said compound:

[0223] [ka] During the ceremony, A is,

[0224] [ka] and; B is alkylene, -alkylene-(heterocyclyl)-alkylene-, -(heterocyclyl)-alkylene-, -cycloalkylene, -alkylene-O-, -cycloalkylene-O-, or -alkylene-O-alkylene-; C is

[0225] [ka] and; R1 is independently H, alkyl, halide, alkoxy, CF3, OH, alkylene-OH, NO2, or -N(H)R a and; R2 is

[0226] [ka] TIFF2024161471000161.tif20166; R3 and R5 are independently selected from H, -CN, halide, CF3, C(H)F2, C(F)H2, alkyl, cycloalkyl, -alkylene-alkoxy, aryl, hydroxyl, and alkoxy; R4 is independently selected from alkyl, -C(F2)CH3, cycloalkyl, heterocycloalkyl, -alkylene-cycloalkyl, -O-alkylene-cycloalkyl, -O-cycloalkyl, -O-alkyl, -alkylene-O-alkyl, -alkylene-O-cycloalkyl, and -alkylene-O-alkylene-cycloalkyl; Ra is H, (C1-C6)alkyl, —(C1-C6)alkylene-O—(C1-C6)alkyl, or —(C1-C6)alkylene-OC(O)O(C1-C6)alkyl; n is independently 0, 1, 2, 3, or 4; m is 0, 1, 2, or 3; The absolute configuration of any stereocenter is R, S or a mixture thereof.

[0227] 2.B is

[0228] [ka] selected from the group consisting of: q is 0, 1, 2 or 3; The compound of embodiment 1, wherein p is 0, 1, or 2.

[0229] 3. The compound of embodiment 1, wherein B is -alkylene-O-alkylene-.

[0230] 4. The compound of embodiment 3, wherein -alkylene-O-alkylene- is -methylene-O-propylene, -ethylene-O-ethylene, or -propylene-O-methylene.

[0231] 5. The compound of any one of embodiments 1-4, wherein at least one instance of R1 is alkyl, halide, OMe, OH, alkylene-OH, or NH2.

[0232] 6. The compound of embodiment 5, wherein at least one instance of R1 is OMe.

[0233] 7. The compound of any one of embodiments 1-4, wherein each occurrence of R1 is H.

[0234] 8.R2

[0235] [ka] The compound of any one of embodiments 1-7, wherein

[0236] 9. The compound of embodiment 8, wherein n in R2 is 0.

[0237] 10. The compound of embodiment 8, wherein n in R2 is 1.

[0238] 11.R2

[0239] [ka] The compound of any one of embodiments 1-7, wherein

[0240] 12. The compound of embodiment 11, wherein m in R2 is 0.

[0241] 13. The compound of embodiment 11, wherein m in R2 is 1.

[0242] 14. The compound of embodiment 1, 8, 10, 11 or 13, wherein R5 is F.

[0243] 15. The compound of embodiment 1, 8, 10, 11 or 13, wherein R5 is CN.

[0244] 16.R2

[0245] [ka] The compound of any one of embodiments 1-7, wherein

[0246] 17. The compound of any one of embodiments 1-16, wherein cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

[0247] 18. The compound of any one of embodiments 1-16, wherein alkyl is methyl, ethyl, iso-propyl, or tert-butyl.

[0248] 19. The compound of any one of embodiments 1-18, wherein R3 is H, halide, Me, OMe, or Ph.

[0249] 20. The compound of any one of embodiments 1-19, wherein R4 is independently selected from -alkylene-cycloalkyl, -O-alkylene-cycloalkyl; -alkylene-O-alkyl, -alkylene-O-cycloalkyl, and -alkylene-O-alkylene-cycloalkyl.

[0250] 21. A compound of embodiment 20, wherein the alkylene in R4 is methylene or ethylene.

[0251] 22.R4

[0252] [ka] 20. The compound of any one of embodiments 1-19, selected from TIFF2024161471000167.tif112166.

[0253] 23.R4

[0254] [ka] 20. The compound of any one of embodiments 1-19, selected from TIFF2024161471000169.tif98166.

[0255] 24.R a The compound of any one of embodiments 1-23, wherein is H.

[0256] <Example> Having now generally described the invention, the same will be more readily understood by reference to the following examples, which are included solely for the purpose of illustrating certain aspects and embodiments of the invention and are not intended to limit the invention.

[0257] General Schemes and Procedures for the Preparation of Compounds of the Invention The moieties R1 and R2 represent suitable substituents; L represents a suitable linking group, and X represents a suitable halogen, such as Br, Cl, or I, or another leaving group, such as mesylate or tosylate.

[0258] [ka] represents an appropriate optionally substituted pyrrolidine.

[0259] [ka] represents an appropriate optionally substituted tetrahydronaphthyridine.

[0260] [ka] represents a suitable optionally substituted naphthyridine.

[0261] <General scheme for the synthesis of αvβ6 inhibitors>

[0262] [ka]

[0263] <General Procedure> 9-BBN and Suzuki reaction

[0264] [ka]

[0265] The alkene intermediate can be cross-coupled to a 2-halonaphthyridine or tetrahydronaphthyridine by the following procedure. To a solution of the alkene (1 equiv) in dry THF (2–10 mL / mmol) under Ar was added 9-BBN (0.5 M solution in THF, 1–2 equiv). The reaction was stirred at 40–80 °C for 1–4 h and then cooled to room temperature. This solution was added to a mixture of the 2-halonaphthyridine or Boc-protected 2-halotetrahydronaphthyridine (1–1.5 equiv), cesium carbonate (2–5 equiv), and Pd(PPh3)4 or another appropriate Pd / ligand combination (0.05–0.1 equiv) in 1,4-dioxane (2–10 mL / mmol). The reaction was stirred at 80–100 °C for 12–24 h. The solvent was removed under reduced pressure and the residue was purified by silica gel column to give the alkyl-linked naphthyridine product.

[0266] Transannular Reaction

[0267] [ka]

[0268] Naphthyridines can also be prepared from methyl ketones by the following procedure: A mixture of methyl ketone (1 equivalent), 2-aminonicotinaldehyde (1-2 equivalents), and a secondary amine, such as pyrrolidine or L-proline (1-2 equivalents), in DMF or EtOH (1-10 mL / mmol) was stirred at 70-100°C for 2-10 hours. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography to give the desired naphthyridine product.

[0269] Naphthyridine reduction

[0270] [ka]

[0271] Naphthyridines can be reduced to tetrahydronaphthyridines by the following procedure: A mixture of the appropriate naphthyridine (1 equivalent) and Pd / C (5-20 wt% Pd, 0.05-0.2 equivalents) in ethyl acetate or another appropriate solvent (2-10 mL / mmol) was stirred under a H balloon at room temperature to 50°C for 2-20 hours. The reaction was filtered and concentrated under reduced pressure to give the desired tetrahydronaphthyridine product.

[0272] Boc deprotection

[0273] [ka]

[0274] Boc-protected amines (1 equiv.) were treated with HCl (4–100 equiv.) in 1,4-dioxane (1–50 mL / mmol amine) at room temperature–50 °C for 1–4 h. The reactions were concentrated under reduced pressure, and the amine products were used crude or after purification on a silica gel column. The amines could be used crude as the dihydrochloride salt or converted to the free base by dissolving in an appropriate solvent and washing with aqueous NaHCO.

[0275] Amine Alkylation

[0276] [ka]

[0277] A mixture of amine (1 equivalent), alkylating agent (1-1.5 equivalents), and KCO or N,N-diisopropylethylamine (2-10 equivalents) in MeCN or DMF (3-10 mL / mmol amine) was stirred at room temperature to 80°C for 4-16 hours. The reaction was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give the desired aminoacetate ester. The amine used can be the free base or a salt such as the hydrochloride or dihydrochloride. When the reaction is performed using a salt of the amine, an additional equivalent of base may be required.

[0278] Saponification

[0279] [ka]

[0280] In the case of certain esters, such as R = Me or ethyl, the ester can be saponified under basic conditions. The ester (1 equiv.) was treated with LiOH-HO (3-5 equiv.) / MeOH (3-10 mL / mmol ester) and water (3-10 mL / mmol ester) at room temperature to 50 °C for 1-16 h. The reaction was concentrated under reduced pressure, and the residue was purified by preparative HPLC to give the desired carboxylic acid product.

[0281] For certain esters, such as R1 = tert-butyl, the ester can be saponified under acidic conditions. The ester (1 equiv.) was treated with 4N HCl (4-100 equiv.) in 1,4-dioxane (1-25 mL / mmol ester) at room temperature to 50 °C for 1-16 h. The reaction was concentrated under reduced pressure, and the residue was purified by preparative HPLC to give the desired carboxylic acid product.

[0282] Petasis reaction

[0283] [ka]

[0284] As an alternative to the amine alkylation / saponification procedure, the Petasis reaction can be used to prepare certain aryl analogs. A mixture of an amine (1 equiv.), an arylboronic acid or arylboronic ester (1-1.5 equiv.), and 2-oxoacetic acid (1.5-2 equiv.) in MeCN or DMF (2-10 mL / mmol amine) was stirred at 50-80 °C for 2-16 h. The reaction was concentrated under reduced pressure, and the residue was purified by preparative HPLC to give the desired aminoacetic acid.

[0285] <Analysis method> Preparative HPLC method The crude sample was dissolved in MeOH and purified by preparative HPLC using a Gilson 215 instrument with a detection wavelength of 214 nm.

[0286] Preparative HPLC A: Column: XBridge C18, 21.2 × 250 mm, 10 μm; Mobile phase: A water (10 mM ammonium bicarbonate), B CH3CN; Gradient elution as in the text; Flow rate: 20 mL / min.

[0287] Preparative HPLC B: Column: XBridge C18, 21.2 × 250 mm, 10 μm; Mobile phase: A water (10 mM formic acid), B CH3CN; Gradient elution as in the text; Flow rate: 20 mL / min.

[0288] Preparative HPLC C: Column: XBridge OBD C18, 19 x 100 mm, 5 μm; Mobile phase: A water, B CH3CN; Gradient elution as in the text; Flow rate: 20 mL / min.

[0289] Preparative Chiral SFC Method The racemic product was separated into individual enantiomers by chiral preparative SFC using an SFC-80 (Thar, Waters) instrument, detection wavelength 214 nm.

[0290] Preparative chiral SFC A: Column: (R,R)-Whelk-O1, 20 × 250 mm, 5 μm (Decial), Column temperature: 35 °C, Mobile phase: CO2 / methanol (0.2% methanolic ammonia) = 60 / 40, Flow rate: 80 g / min, Back pressure: 100 bar.

[0291] Preparative chiral SFC B: Column: AD 20 x 250 mm, 10 μm (Daicel), column temperature: 35 °C, mobile phase: CO2 / methanol (0.2% m methanolic ammonia) = 60 / 40, flow rate: 80 g / min, back pressure: 100 bar.

[0292] Preparative chiral SFC C: Column: AS 20 × 250 mm, 10 μm (Daicel), column temperature: 35 °C, mobile phase: CO2 / methanol (0.2% methanolic ammonia) = 60 / 40, flow rate: 80 g min, back pressure: 100 bar.

[0293] Preparative chiral SFC D: Column: OD 20 x 250 mm, 10 μm (Daicel), column temperature: 35 °C, mobile phase: CO2 / methanol (0.2% methanolic ammonia) = 60 / 40, flow rate: 80 g / min, back pressure: 100 bar.

[0294] Preparative chiral SFC E: Column: Cellulose-SC 20 × 250 mm, 10 μm (Daicel), column temperature: 35 °C, mobile phase: CO2 / methanol (0.2% methanolic ammonia) = 60 / 40, flow rate: 80 g / min, back pressure: 100 bar.

[0295] Preparative chiral SFC F: Column: OZ20 x 250 mm, 10 μm (Daicel), column temperature: 35 °C, mobile phase: CO2 / methanol (0.2% methanolic ammonia) = 60 / 40, flow rate: 80 g / min, back pressure: 100 bar.

[0296] Preparative chiral SFC G: Column: IC20 x 250 mm, 10 μm (Daicel), column temperature: 35 °C, mobile phase: CO2 / methanol (0.2% methanolic ammonia) = 60 / 40, flow rate: 80 g / min, back pressure: 100 bar.

[0297] Preparative chiral SFC H: Column: (S,S)-Whelk-O1, 20 × 250 mm, 5 μm (Decial), Column temperature: 35 °C, Mobile phase: CO2 / methanol (0.2% methanolic ammonia) = 60 / 40, Flow rate: 80 g / min, Back pressure: 100 bar.

[0298] Analytical Chiral SFC Method The chiral products were analyzed by chiral SFC using an SFC-80 (Thar, Waters) instrument, detection wavelength 214 nm:

[0299] Chiral SFC A: Column: (R,R)-Whelk-O1, 4.6 × 100 mm, 5 μm (Decial), column temperature: 40 °C, mobile phase: CO2 / methanol (0.2% methanolic ammonia), isocratic elution as in the text, flow rate: 4 g / min, back pressure: 120 bar.

[0300] Chiral SFC B: Column: AD 4.6 x 100 mm, 5 μm (Daicel), column temperature: 40 °C, mobile phase: CO2 / methanol (0.2% methanolic ammonia), isocratic elution as in the text, flow rate: 4 g / min, back pressure: 120 bar.

[0301] Chiral SFC C: Column: AS 4.6 × 100 mm, 5 μm (Daicel), column temperature: 40 °C, mobile phase: CO2 / methanol (0.2% methanolic ammonia), isocratic elution as in the text, flow rate: 4 g / min, back pressure: 120 bar.

[0302] Chiral SFC D: Column: OD 4.6 x 100 mm, 5 μm (Daicel), column temperature: 40 °C, mobile phase: CO2 / methanol (0.2% methanolic ammonia), isocratic elution as in the text, flow rate: 4 g / min, back pressure: 120 bar.

[0303] Chiral SFC E: Column: Cellulose-SC 4.6 × 100 mm, 5 μm (Daicel), column temperature: 40 °C, mobile phase: CO2 / methanol (0.2% methanolic ammonia), isocratic elution as in the text, flow rate: 4 g / min, back pressure: 120 bar.

[0304] Chiral SFC F: Column: OZ 4.6 x 100 mm, 5 μm (Daicel), column temperature: 40 °C, mobile phase: CO2 / methanol (0.2% methanolic ammonia), isocratic elution as in the text, flow rate: 4 g / min, back pressure: 120 bar.

[0305] Chiral SFC G: Column: IC 4.6 x 100 mm, 5 μm (Daicel), column temperature: 40 °C, mobile phase: CO2 / methanol (0.2% methanolic ammonia), isocratic elution as in the text, flow rate: 4 g / min, back pressure: 120 bar.

[0306] Chiral SFC H: Column: (S,S)-Whelk-O1, 4.6 × 100 mm, 5 μm (Decial), column temperature: 40 °C, mobile phase: CO2 / methanol (0.2% methanolic ammonia), isocratic elution as in the text, flow rate: 4 g / min, back pressure: 120 bar.

[0307] Chiral SFC I: Column: IC 4.6 × 250 mm, 5 μm (SHIMADZU), column temperature: 40 °C, mobile phase: n-hexane (0.1% DEA): EtOH (0.1% DEA), isocratic elution as described in the text, flow rate: 1 mL / min.

[0308] Chiral SFC J: Column: (S,S)-Whelk-O1 4.6 × 250 mm, 5 μm (SHIMADZU), column temperature: 40 °C, mobile phase: n-hexane (0.1% DEA): EtOH (0.1% DEA), isocratic elution as described in the text, flow rate: 1 mL / min.

[0309] Chiral SFC K: Column: OZ-H 4.6 × 250 mm, 5 μm (SHIMADZU), column temperature: 40 °C, mobile phase: n-hexane (0.1% DEA): EtOH (0.1% DEA), isocratic elution as described in the text, flow rate: 1 mL / min.

[0310] Chiral SFC L: Column: Chiral PAK IG 4.6 × 250 mm, 5 μm (SHIMADZU), column temperature: 35 °C, mobile phase: n-hexane (0.1% DEA): EtOH (0.1% DEA), isocratic elution as described in the text, flow rate: 1 mL / min.

[0311] Chiral SFC M: Column: EnantioPak OJ 4.6 × 250 mm, 5 μm (Decial), Column temperature: 40 °C, Mobile phase: n-hexane (0.1% DEA): EtOH (0.1% DEA), Isocratic elution as in the text, Flow rate: 1 mL / min.

[0312] <Synthesis of intermediates> For use in the synthetic examples, the following intermediates were prepared according to the procedures set out below.

[0313] Preparation of (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride Step 1: tert-butyl (R)-3-(4-(2-methyl-1,3-dioxolan-2-yl)butoxy)pyrrolidine-1-carboxylate

[0314] [ka]

[0315] A mixture of (R)-tert-butyl 3-hydroxypyrrolidine-1-carboxylate (1.09 g, 5.41 mmol), 2-(4-bromobutyl)-2-methyl-1,3-dioxolane (1.2 g, 5.41 mmol), and sodium hydride (260 mg, 10.82 mmol) in DMF (5 mL) was stirred at 100° C. for 6 h. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product (R)-tert-butyl 3-(4-(2-methyl-1,3-dioxolan-2-yl)butoxy)pyrrolidine-1-carboxylate as a colorless oil (380 mg). Yield 21% (ESI 330.2 (M+H) + ).

[0316] Step 2: (R)-tert-butyl 3-(5-oxohexyloxy)pyrrolidine-1-carboxylate

[0317] [ka]

[0318] (R)-tert-Butyl 3-(4-(2-methyl-1,3-dioxolan-2-yl)butoxy)pyrrolidine-1-carboxylate (1.3 g, 3.95 mmol) was treated with a solution of HCl / dioxane (4.0 M, 10 mL) at room temperature for 2 h. The solvent was removed under reduced pressure, and the residue was diluted with acetone (10 mL) and HO (1 mL). Potassium carbonate was added to adjust the pH to 8-9, and then BocO (1.24 g, 5.69 mmol) was added. The reaction was stirred at room temperature for 3 h, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 15:1) to give the desired product (R)-tert-butyl 3-(5-oxohexyloxy)pyrrolidine-1-carboxylate as a colorless oil (820 mg). Yield 73% (ESI 186 (M-100) + , 230(M-56) + ).

[0319] Step 3: (R)-tert-butyl 3-(4-(1,8-naphthyridin-2-yl)butoxy)pyrrolidine-1-carboxylate

[0320] [ka]

[0321] A mixture of (R)-tert-butyl 3-(5-oxohexyloxy)pyrrolidine-1-carboxylate (820 mg, 2.88 mmol), 2-aminonicotinaldehyde (456 mg, 3.77 mmol), and pyrrolidine (265 mg, 3.77 mmol) in DMF (5 mL) was stirred at 85° C. for 4 h. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (DCM:MeOH 15:1) to give the desired product (R)-tert-butyl 3-(4-(1,8-naphthyridin-2-yl)butoxy)pyrrolidine-1-carboxylate as a colorless oil (750 mg). Yield 70% (ESI 372.2 (M+H) + ).

[0322] Step 4: (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride

[0323] [ka]

[0324] A mixture of (R)-tert-butyl 3-(4-(1,8-naphthyridin-2-yl)butoxy)pyrrolidine-1-carboxylate (750 mg, 2.02 mmol), Pd / C (10%, 500 mg) in EtOAc (10 mL) was stirred under hydrogen at 60° C. for 6 hours. The reaction was filtered and concentrated under reduced pressure. The residue was treated with a solution of HCl / dioxane (4.0 M, 4 mL) at room temperature for 2 hours, and the solvent was removed under reduced pressure to give the desired product (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride (600 mg) as a white solid. Yield 96% (ESI 276.2 (M+H) + ).

[0325] Preparation of (R)-5-methoxy-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride Step 1: (R)-tert-butyl 3-(4-bromobutoxy)pyrrolidine-1-carboxylate

[0326] [ka]

[0327] To a solution of tert-butyl (R)-3-hydroxypyrrolidine-1-carboxylate (500 mg, 2.67 mmol) in n-heptane (10 mL) was added 50% aqueous sodium hydroxide (5 mL, 31.2 mmol), tetrabutylammonium bromide (43.0 mg, 0.13 mmol), and 1,4-dibromobutane (1.595 mL, 13.35 mmol). The mixture was stirred at 80 °C for 2 h, then cooled to room temperature, diluted with water (10 mL), and extracted with diethyl ether (3 x 10 mL). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified using a silica gel column (petroleum ether: EtOAc = 4:1) to give the desired product (R)-tert-butyl 3-(4-bromobutoxy)pyrrolidine-1-carboxylate as a colorless oil (686 mg). Yield 80% (ESI 314 (M+H-Boc) + ).

[0328] Step 2: (R)-tert-butyl 3-(but-3-enyloxy)pyrrolidine-1-carboxylate

[0329] [ka]

[0330] To a solution of tert-butyl (R)-3-(4-bromobutoxy)pyrrolidine-1-carboxylate (512 mg, 1.58 mmol) in THF (10 mL) was added t-BuOK (446 mg, 3.97 mmol) at 0 °C. The reaction was stirred at room temperature for 1 hour, diluted with water (20 mL), and extracted with diethyl ether (3 x 20 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the desired product, (R)-tert-butyl 3-(but-3-enyloxy)pyrrolidine-1-carboxylate, as a colorless oil (355 mg). Yield 90% (ESI 186 (M+H-Boc) + ).

[0331] Step 3: (R)-tert-butyl 3-(4-(4-chloro-1,8-naphthyridin-2-yl)butoxy)pyrrolidine-1-carboxylate

[0332] [ka]

[0333] To a solution of tert-butyl (R)-tert-butyl 3-(but-3-enyloxy)pyrrolidine-1-carboxylate (486 mg, 1.8 mmol) in THF (anhydrous, 2 mL) under Ar, 9-BBN (0.5 M solution in THF, 7.2 mL, 3.6 mmol) was added. The reaction was stirred at 50 °C for 2 h and then cooled to room temperature. This solution was added to a mixture of 2,4-dichloro-1,8-naphthyridine (360 mg, 1.8 mmol), cesium carbonate (1730 mg, 5.4 mmol), and Pd(PPh) (208 mg, 0.18 mmol) in 1,4-dioxane (7 mL). The reaction was stirred at 90 °C for 1.5 h. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 1:1 to 1:10) to give the desired product (R)-tert-butyl 3-(4-(4-chloro-1,8-naphthyridin-2-yl)butoxy)pyrrolidine-1-carboxylate as a yellow oil (300 mg). Yield 41% (ESI 406 (M+H) + ).

[0334] Step 4: (R)-tert-butyl 3-(4-(4-methoxy-1,8-naphthyridin-2-yl)butoxy)pyrrolidine-1-carboxylate

[0335] [ka]

[0336] To a solution of (R)-tert-butyl 3-(4-(4-chloro-1,8-naphthyridin-2-yl)butoxy)pyrrolidine-1-carboxylate (76 mg, 0.13 mmol) in MeOH (5 mL) was added NaOMe (45 mg, 0.26 mmol). The reaction was stirred at reflux overnight, concentrated under reduced pressure, diluted with ethyl acetate (30 mL), washed with water (2 x 20 mL), dried over MgSO, filtered, and concentrated under reduced pressure to give the desired product, (R)-tert-butyl 3-(4-(4-methoxy-1,8-naphthyridin-2-yl)butoxy)pyrrolidine-1-carboxylate, as a colorless oil (60 mg). Yield 80% (ESI 402 (M+H) + ).

[0337] Step 5: (R)-5-Methoxy-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride

[0338] [ka]

[0339] A mixture of (R)-tert-butyl 3-(4-(4-methoxy-1,8-naphthyridin-2-yl)butoxy)pyrrolidine-1-carboxylate (60 mg, 0.15 mmol) and Pd / C (10%, 30 mg) in EtOAc (10 mL) was stirred under balloon hydrogen at 30° C. for 17 hours. The mixture was filtered and concentrated under reduced pressure. The residue was treated with 4 M HCl / dioxane (3 mL, 12 mmol) at room temperature for 2 hours. The solvent was removed under reduced pressure to give the desired product, (R)-5-methoxy-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride, as a colorless oil (45 mg). Yield 88% (ESI 306 (M+H) + ).

[0340] Preparation of (R)-7-(5-(pyrrolidin-3-yl)pentyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride Step 1: (R)-tert-butyl 3-(iodomethyl)pyrrolidine-1-carboxylate

[0341] [ka]

[0342] A solution of PPh3 (5.11 g, 19.5 mmol) and 1H-imidazole (1.33 g, 19.5 mmol) in DCM (50 mL) was cooled to 0 °C and slowly treated with I2 (4.95 g, 19.5 mmol). After stirring at 0 °C for 30 min, a solution of (R)-tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate in DCM (10 mL) was added, and the reaction was stirred at room temperature overnight. The reaction was diluted with water (50 mL) and extracted with DCM (3 x 30 mL). The combined organic layers were dried over Na2SO4, filtered, and evaporated under reduced pressure. The residue was purified using a silica gel column (petroleum ether: EtOAc 10:1) to give the desired product, (R)-tert-butyl 3-(iodomethyl)pyrrolidine-1-carboxylate, as a colorless oil (3.7 g). Yield: 80%. (ESI 256(M+H-56) + ).

[0343] Step 2: (R)-((1-(tert-butoxycarbonyl)pyrrolidin-3-yl)methyl)triphenylphosphonium

[0344] [ka]

[0345] A solution of (R)-tert-butyl 3-(iodomethyl)pyrrolidine-1-carboxylate (3.7 g, 12 mmol) and PPh3 (4.1 g, 15.5 mmol) in DMF (50 mL) was stirred at room temperature overnight. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (DCM:MeOH 10:1) to give the crude product. Diethyl ether (30 mL) was added to the crude product, stirred at room temperature for 30 minutes, and filtered. The filter cake was dried under vacuum to give the desired product, (R)-((1-(tert-butoxycarbonyl)pyrrolidin-3-yl)methyl)triphenylphosphonium, as a white solid (5.6 g). Yield: 84%. (ESI N / A).

[0346] Step 3: Ethyl 4-(2-methyl-1,3-dioxolan-2-yl)butanoate

[0347] [ka]

[0348] A solution of ethyl 5-oxohexanoate (2 g, 13.9 mmol), ethylene glycol (2.6 g, 42 mmol), and p-toluenesulfonic acid (478 mg, 2.78 mmol) in toluene (50 mL) was stirred under reflux for 6 h, and water was removed using a Dean-Stark trap. The solvent was removed under reduced pressure, and the residue was purified on a silica gel column (petroleum ether: EtOAc 10:1) to give the desired product, ethyl 4-(2-methyl-1,3-dioxolan-2-yl)butanoate, as a colorless oil (1.4 g, 50% yield). (ESI 203 (M+H) + ).

[0349] Step 4: 4-(2-methyl-1,3-dioxolan-2-yl)butanal

[0350] [ka]

[0351] To a solution of ethyl 4-(2-methyl-1,3-dioxolan-2-yl)butanoate (500 mg, 2.48 mmol) in DCM (10 mL) at −78 °C under Ar, DIBAL-H (1 M, 3.7 mL, 3.7 mmol) was slowly added. The reaction was stirred at −78 °C for 30 min, 20 mL of water was added, warmed to room temperature, and extracted with DCM (3×20 mL). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 2:1) to give the desired product, 4-(2-methyl-1,3-dioxolan-2-yl)butanal (220 mg) as a colorless oil. Yield: 56%. (ESI 159 (M+H) + ).

[0352] Step 5: (S)-tert-butyl 3-(5-(2-methyl-1,3-dioxolan-2-yl)pent-1-enyl)pyrrolidine-1-carboxylate

[0353] [ka]

[0354] To a solution of (R)-((1-(tert-butoxycarbonyl)pyrrolidin-3-yl)methyl)triphenylphosphonium (2.0 g, 3.6 mmol) in DCM (30 mL) under N2 at 0 °C was added LiHMDS (1 M, 5.4 mL, 5.4 mmol). The mixture was stirred at 0 °C for 30 min, and 4-(2-methyl-1,3-dioxolan-2-yl)butanal (565 mg, 3.6 mmol) was added. The reaction was stirred at room temperature for 4 h, and MeOH (20 mL) was added. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 3:1) to give the desired product (S)-tert-butyl 3-(5-(2-methyl-1,3-dioxolan-2-yl)pent-1-enyl)pyrrolidine-1-carboxylate as a yellow oil (500 mg). Yield: 43%. (ESI 226(M+H-100) + ).

[0355] Step 6: (R)-tert-butyl 3-(6-oxoheptyl)pyrrolidine-1-carboxylate

[0356] [ka]

[0357] To a solution of (S)-tert-butyl 3-(5-(2-methyl-1,3-dioxolan-2-yl)pent-1-enyl)pyrrolidine-1-carboxylate (500 mg, 1.54 mmol) in EtOAc (20 mL) was added Pd / C (10%, 50 mg), and the mixture was stirred under H at 40 °C overnight. The reaction was filtered, and the filtrate was concentrated under reduced pressure. The residue was treated with TsOH (264 mg, 1.54 mmol) in acetone (5 mL). The mixture was stirred at room temperature for 6 h, and then EtOAc (20 mL) was added and washed with saturated NaHCO solution (20 mL) and brine. The organic layer was dried over NaSO, filtered, and concentrated under reduced pressure to give the desired product, (R)-tert-butyl 3-(6-oxoheptyl)pyrrolidine-1-carboxylate, as a yellow oil (200 mg). Yield 46% (ESI 184 (M+H-100) + ).

[0358] Step 7: (R)-tert-butyl 3-(5-(1,8-naphthyridin-2-yl)pentyl)pyrrolidine-1-carboxylate

[0359] [ka]

[0360] To a solution of (R)-tert-butyl 3-(6-oxoheptyl)pyrrolidine-1-carboxylate (300 mg, 1.06 mmol) in EtOH (10 mL) was added 2-aminonicotinaldehyde (155 mg, 1.27 mmol) and pyrrolidine (90 mg, 1.27 mmol). The reaction mixture was heated to reflux overnight. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (DCM:MeOH=20:1) to give the desired product (R)-tert-butyl 3-(5-(1,8-naphthyridin-2-yl)pentyl)pyrrolidine-1-carboxylate as a yellow oil (220 mg). Yield: 56%. (ESI 370 (M+H) + ).

[0361] Step 8: (R)-7-(5-(pyrrolidin-3-yl)pentyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride

[0362] [ka]

[0363] To a solution of (R)-tert-butyl 3-(5-(1,8-naphthyridin-2-yl)pentyl)pyrrolidine-1-carboxylate (220 mg, 0.60 mmol) in EtOAc (10 mL) was added Pd / C (10%, 30 mg). The mixture was stirred under H2 at 40°C overnight. The reaction was filtered, and the filtrate was concentrated under reduced pressure. The residue was treated with HCl / dioxane solution (4.0 M, 5 mL) at room temperature for 2 hours, and the solvent was removed under reduced pressure to give the desired product, (R)-7-(5-(pyrrolidin-3-yl)pentyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride, as a yellow oil (160 mg). Yield: 86%. (ESI 274 (M+H) + ).

[0364] Preparation of (R)-7-(3-(pyrrolidin-3-yloxy)propyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride Step 1: 2-(3-bromopropyl)-2-methyl-1,3-dioxolane

[0365] [ka]

[0366] A solution of 5-bromopentan-2-one (2.0 g, 12.12 mmol) in toluene (40 mL) was treated with ethylene glycol (6.93 g, 111.7 mmol) and TsOH (384 mg, 0.22 mmol) in a flame-dried round-bottom flask equipped with a magnetic stir bar and Dean-Stark trap under N2. The reaction mixture was heated to reflux for 1 h, allowed to cool to room temperature, diluted with saturated aqueous NaHCO3 (60 mL), and extracted with ethyl acetate (100 mL). The organic layer was washed with water (2 x 100 mL), dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 4:1) to give the desired product (1.5 g) as a colorless oil. Yield: 59%.

[0367] Step 2: (R)-tert-butyl 3-(3-(2-methyl-1,3-dioxolan-2-yl)propoxy)pyrrolidine-1-carboxylate

[0368] [ka]

[0369] A mixture of (R)-tert-butyl 3-hydroxypyrrolidine-1-carboxylate (894 mg, 4.78 mmol) and NaH (287 mg, 7.18 mmol) in DMF (10 mL) was stirred at 0° C. for 1 h. A solution of 2-(3-bromopropyl)-2-methyl-1,3-dioxolane (1 g, 4.78 mmol) in DMF (5 mL) was added dropwise at 0° C., and the reaction mixture was stirred at 100° C. overnight. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 1:1) to give the desired product as a colorless oil (500 mg). Yield 33% (ESI 216 (M+H-100) + ).

[0370] Step 3: (R)-tert-butyl 3-(4-oxopentyloxy)pyrrolidine-1-carboxylate

[0371] [ka]

[0372] A mixture of (R)-tert-butyl 3-(3-(2-methyl-1,3-dioxolan-2-yl)propoxy)pyrrolidine-1-carboxylate (500 mg, 1.59 mmol) and p-toluenesulfonic acid monohydrate (151 mg, 0.79 mmol) in acetone (10 mL) and HO (5 mL) was stirred at room temperature for 4 hours. The reaction was diluted with HO (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure to give the desired product (380 mg) as a colorless oil. Yield 88% (ESI 172 (M+H-100) + ).

[0373] Step 4: (R)-tert-butyl 3-(3-(1,8-naphthyridin-2-yl)propoxy)pyrrolidine-1-carboxylate

[0374] [ka]

[0375] A mixture of (R)-tert-butyl 3-(4-oxopentyloxy)pyrrolidine-1-carboxylate (380 mg, 1.40 mmol), 2-aminonicotinaldehyde (171 mg, 1.40 mmol), and pyrrolidine (99 mg, 1.40 mmol) in ethanol (8 mL) was refluxed overnight. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (DCM:MeOH 40:1) to give the desired product as a colorless oil (310 mg). Yield 62% (ESI 358 (M+H) + ).

[0376] Step 5: (R)-7-(3-(pyrrolidin-3-yloxy)propyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride

[0377] [ka]

[0378] A mixture of (R)-tert-butyl 3-(3-(1,8-naphthyridin-2-yl)propoxy)pyrrolidine-1-carboxylate (310 mg, 0.87 mmol) and Pd / C (10%, 30 mg) in EtOAc (30 mL) was stirred under a balloon hydrogen atmosphere at room temperature for 16 hours. The mixture was filtered and concentrated under reduced pressure. The residue was treated with HCl / 1,4-dioxane (4 M, 5 mL) at 25° C. for 2 hours. The solvent was removed under reduced pressure to give (R)-7-(3-(pyrrolidin-3-yloxy)propyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride as a colorless oil (240 mg). Yield 83% (ESI 262 (M+H) + ).

[0379] Preparation of (R)-7-(5-(pyrrolidin-3-yloxy)pentyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride Step 1: 2-(5-bromopentyl)-2-methyl-1,3-dioxolane

[0380] [ka]

[0381] To a solution of 7-bromoheptan-2-one (14 g, 73 mmol) in toluene (150 mL) in a three-necked flask equipped with a Dean-Stark trap, ethane-1,2-diol (15 g, 255 mmol) and p-toluenesulfonic acid (251 mg, 1.46 mmol) were added. The reaction mixture was stirred at reflux for 20 h. The reaction mixture was cooled to room temperature and washed with saturated NaHCO3 solution, water, and brine. The organic phase was concentrated, and the residue was separated using a silica gel column (7% EtOAc / petroleum ether) to give 2-(5-bromopentyl)-2-methyl-1,3-dioxolane (16 g, 92%).

[0382] Step 2: (R)-tert-butyl 3-(5-(2-methyl-1,3-dioxolan-2-yl)pentyloxy)pyrrolidine-1-carboxylate

[0383] [ka]

[0384] To a solution of (R)-tert-butyl 3-hydroxypyrrolidine-1-carboxylate (3.5 g, 18.7 mmol) in DMF (25 mL) was added NaH (830 mg, 20.6 mmol) in small portions at 0° C. The reaction mixture was stirred at 0° C. for 1 h. 2-(5-Bromopentyl)-2-methyl-1,3-dioxolane (4.9 g, 20.6 mmol) was added, and the reaction mixture was stirred at 100° C. for 16 h. The reaction mixture was poured into ice water and extracted with EtOAc (3×150 mL). The combined organic phase was washed with brine and dried over Na2SO4. The organic phase was concentrated and the residue was chromatographed on silica gel (20% EtOAc / petroleum ether) to give the product (R)-tert-butyl 3-(5-(2-methyl-1,3-dioxolan-2-yl)pentyloxy)pyrrolidine-1-carboxylate as a yellow oil (3.7 g, 57%); (ESI 344.3 (M+H) + ).

[0385] Step 3: (R)-tert-butyl 3-(6-oxoheptyloxy)pyrrolidine-1-carboxylate

[0386] [ka]

[0387] To a solution of (R)-tert-butyl 3-(5-(2-methyl-1,3-dioxolan-2-yl)pentyloxy)pyrrolidine-1-carboxylate (3.7 g, 10.8 mmol) in acetone (70 mL) and water (7 mL) was added p-toluenesulfonic acid (927 mg, 5.4 mmol). The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was neutralized with saturated aqueous NaHCO3 and concentrated under reduced pressure. The residue was extracted with EtOAc (3 x 100 mL). The combined organic phases were washed with brine, dried over Na2SO4, and concentrated to give the product (R)-tert-butyl 3-(6-oxoheptyloxy)pyrrolidine-1-carboxylate as a yellow oil (2.99 g, 92%); (ESI 300.1 (M+H) + ).

[0388] Step 4: (R)-tert-butyl 3-(5-(1,8-naphthyridin-2-yl)pentyloxy)pyrrolidine-1-carboxylate

[0389] [ka]

[0390] To a solution of (R)-tert-butyl 3-(6-oxoheptyloxy)pyrrolidine-1-carboxylate (2.9 g, 9.7 mmol) in EtOH (40 mL) was added 2-aminonicotinaldehyde (1.2 g, 9.7 mmol) and L-proline (558 mg, 4.8 mmol). The reaction mixture was stirred at reflux for 16 h. The reaction mixture was then concentrated, and the residue was separated by silica gel column (5% MeOH / EtOAc) to give (R)-tert-butyl 3-(5-(1,8-naphthyridin-2-yl)pentyloxy)pyrrolidine-1-carboxylate as a yellow solid (2.4 g, 64%); (purity 95%, UV = 214 nm, ESI 386.0 (M+H) + ).

[0391] Step 5: (R)-tert-butyl 3-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentyloxy)pyrrolidine-1-carboxylate

[0392] [ka]

[0393] To a solution of (R)-tert-butyl 3-(5-(1,8-naphthyridin-2-yl)pentyloxy)pyrrolidine-1-carboxylate (2.4 g, 6.2 mmol) in EtOH (30 mL) was added Pd / C (10%, 300 mg). The reaction mixture was degassed and purged with H 3 times and stirred at 45° C. under H 2 for 20 h. The reaction mixture was filtered, and the filtrate was concentrated to give (R)-tert-butyl 3-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentyloxy)pyrrolidine-1-carboxylate as a yellow oil (2.5 g, 100%); (ESI 390.5 (M+H) + ).

[0394] Step 6: (R)-7-(5-(pyrrolidin-3-yloxy)pentyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride

[0395] [ka]

[0396] To a solution of (R)-tert-butyl 3-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentyloxy)pyrrolidine-1-carboxylate (2.4 g, 6.2 mmol) in DCM (10 mL) was added HCl / 1,4-dioxane (4 mol / L, 30 mL). The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated to give (R)-7-(5-(pyrrolidin-3-yloxy)pentyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride as a yellow oil (2.9 g, 100%); (ESI 290.4 (M-55) + ).

[0397] Preparation of 7-(5-(3-fluoropyrrolidin-3-yl)pentyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride Step 1: tert-butyl 3-(4-(benzyloxy)butyl)-3-hydroxypyrrolidine-1-carboxylate

[0398] [ka]

[0399] To a mixture of ((4-bromobutoxy)methyl)benzene (9.45 g, 38.87 mmol) and Mg (1.89 g, 77.74 mmol) in EtO (20 mL) was added I (202 mg, 1.09 mmol). The reaction mixture was stirred at 40 °C for 1 h. After cooling to room temperature, the mixture was added to a solution of tert-butyl 3-oxopyrrolidine-1-carboxylate (2.4 g, 12.96 mmol) in EtO (30 mL) at 5 °C. The reaction was stirred overnight at room temperature, quenched with aqueous NH Cl (10 mL), and extracted with EtOAc (3 x 30 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 5:1 to 2:1) to give the desired product tert-butyl 3-(4-(benzyloxy)butyl)-3-hydroxypyrrolidine-1-carboxylate as a yellow oil (1.7 g). Yield 38% (ESI 294 (M+H-56) + ).

[0400] Step 2: tert-butyl 3-(4-(benzyloxy)butyl)-3-fluoropyrrolidine-1-carboxylate

[0401] [ka]

[0402] A mixture of tert-butyl 3-(4-(benzyloxy)butyl)-3-hydroxypyrrolidine-1-carboxylate as (1.7 g, 4.86 mmol) and BAST (10.76 g, 48.6 mmol) in DCM (30 mL) was stirred at 40 °C for 24 h. The reaction was diluted with MeOH (2 mL), washed with water (20 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 20:1 to 10:1) to give the desired product, tert-butyl 3-(4-(benzyloxy)butyl)-3-fluoropyrrolidine-1-carboxylate, as a light yellow oil (1.1 g). Yield 64% (ESI 296 (M+H-56) + ).

[0403] Step 3: (tert-butyl 3-fluoro-3-(4-hydroxybutyl)pyrrolidine-1-carboxylate

[0404] [ka]

[0405] A mixture of tert-butyl 3-(4-(benzyloxy)butyl)-3-fluoropyrrolidine-1-carboxylate (1.1 g, 3.13 mmol) and Pd / C (5%, 1.1 g) in EtOAc (100 mL) was stirred under hydrogen at 45° C. overnight. The mixture was filtered and concentrated under reduced pressure to give the desired product, tert-butyl 3-fluoro-3-(4-hydroxybutyl)pyrrolidine-1-carboxylate, as a light yellow oil (780 mg). Yield 95% (ESI 206 (M+H-56) + ).

[0406] Step 4: tert-butyl 3-fluoro-3-(4-iodobutyl)pyrrolidine-1-carboxylate

[0407] [ka]

[0408] To a solution of triphenylphosphine (1.58 g, 6.04 mmol) and imidazole (411 mg, 6.04 mmol) in DCM (40 mL) was added I2 (835 mg, 3.29 mmol) at 5 °C. The reaction mixture was stirred at 5 °C for 15 min, and a solution of tert-butyl 3-fluoro-3-(4-hydroxybutyl)pyrrolidine-1-carboxylate (780 mg, 2.99 mmol) in DCM (15 mL) was added. The reaction mixture was stirred at 5 °C for 1 h, concentrated under reduced pressure at 15 °C, and the residue was purified by silica gel column (petroleum ether: EtOAc 20:1 to 10:1) to give the desired product, tert-butyl 3-fluoro-3-(4-iodobutyl)pyrrolidine-1-carboxylate, as a light yellow oil (700 mg). Yield: 63% (ESI 316 (M+H −56) + ).

[0409] Step 5: tert-butyl 3-(5-(1,8-naphthyridin-2-yl)pentyl)-3-fluoropyrrolidine-1-carboxylate

[0410] [ka]

[0411] To a solution of (R)-tert-butyl 3-(1,1-difluoro-4-iodobutyl)pyrrolidine-1-carboxylate (700 mg, 1.88 mmol) and 2-methyl-1,8-naphthyridine (407 mg, 2.82 mmol) in THF (12 mL) was added LiHMDS (2.82 mL, 1 M, 2.82 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 3 h, quenched with saturated ammonium chloride solution (6 mL), diluted with water (15 mL), and extracted with EtOAc (2 x 30 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by preparative TLC to give the desired product, tert-butyl 3-(5-(1,8-naphthyridin-2-yl)pentyl)-3-fluoropyrrolidine-1-carboxylate (350 mg), as a light yellow solid. Yield 48% (ESI 388 (M+H) + ).

[0412] Step 6: 7-(5-(3-fluoropyrrolidin-3-yl)pentyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride

[0413] [ka]

[0414] A mixture of 3-(5-(1,8-naphthyridin-2-yl)pentyl)-3-fluoropyrrolidine-1-carboxylate (200 mg, 0.516 mmol) and Pd / C (5%, 200 mg) in EtOAc (20 mL) was stirred under hydrogen at 45° C. overnight. The reaction mixture was filtered and concentrated under reduced pressure. To the residue was added 1,4-dioxane (2 mL) and HCl / dioxane (2 mL, 4 M) at room temperature. The reaction mixture was stirred at room temperature for 3 hours and concentrated under reduced pressure to give the desired product, 7-(5-(3-fluoropyrrolidin-3-yl)pentyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride, as a light yellow solid (140 mg). Yield 93% (ESI 292 (M+H) + ).

[0415] Preparation of 2-(4-(((R)-pyrrolidin-3-yl)oxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride Step 1: tert-Butyl (R)-3-(hex-5-en-1-yloxy)pyrrolidine-1-carboxylate

[0416] [ka]

[0417] To a suspension of tert-butyl (R)-3-hydroxypyrrolidine-1-carboxylate (12.8 g, 68.4 mmol), tetrabutylammonium bromide (1.102 g, 3.42 mmol), and 6-bromo-1-hexene (13.71 mL, 103 mmol) in heptane (256 mL) was added sodium hydroxide (128 mL, 68.4 mmol, 50 wt% aqueous solution). The mixture was vigorously stirred at 80 °C for 2 hours, cooled to room temperature, diluted with water, and extracted twice with heptane and diethyl ether / heptane. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. Purification by column chromatography (600 g silica, 5% to 14% ethyl acetate / heptane) afforded the desired product, tert-butyl (R)-3-(hex-5-en-1-yloxy)pyrrolidine-1-carboxylate (14.93 g). Yield: 81%. 1 H NMR (400 MHz, chloroform-d) δ 5.87-5.74 (m, 1H), 5.05-4.91 (m, 2H), 4.04-3.95 (m, 1H), 3.48-3.27 (m, 6H), 2.07 (q, J = 7.2 Hz, 2H), 2.02-1.84 (m, 2H), 1.60-1.51 (m, 2H), 1.51-1.38 (m, 11H).

[0418] Step 2: tert-butyl (R)-3-((5-oxopentyl)oxy)pyrrolidine-1-carboxylate

[0419] [ka]

[0420] To a solution of tert-butyl (R)-3-(hex-5-en-1-yloxy)pyrrolidine-1-carboxylate (14.93 g, 55.4 mmol) in THF (420 mL) and water (140 mL) was added sodium periodate (26.1 g, 122 mmol) and osmium tetroxide (1.5 mL, 0.232 mmol, 4% aqueous solution). After 1 h, additional sodium periodate (5 g, 23.38 mmol) was added. After 30 min, the mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by flash column chromatography (approximately 600 g silica, 20% to 50% ethyl acetate / heptane). This gave the desired product tert-butyl (R)-3-((5-oxopentyl)oxy)pyrrolidine-1-carboxylate (10.97 g), 72% yield. 1 H NMR (400 MHz, chloroform-d) δ 9.77 (s, 1H), 4.03-3.94 (m, 1H), 3.50-3.27 (m, 6H), 2.47 (t, J = 7.2 Hz, 2H), 2.02-1.84 (m, 2H), 1.77-1.65 (m, 2H), 1.65-1.54 (m, 2H), 1.46 (s, 9H).

[0421] Step 3: tert-butyl (3R)-3-((5-hydroxyhept-6-en-1-yl)oxy)pyrrolidine-1-carboxylate

[0422] [ka]

[0423] To a solution of tert-butyl (R)-3-((5-oxopentyl)oxy)pyrrolidine-1-carboxylate (10.97 g, 40.4 mmol) in THF (70 mL) at 0 °C, vinylmagnesium bromide (66.4 mL, 46.5 mmol, 0.7 M solution in THF) was added dropwise. After 16 h, the mixture was quenched with saturated aqueous ammonium chloride and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and concentrated, and the residue was purified by flash column chromatography (20% to 50% EtOAc / heptane) to give the desired product, tert-butyl (3R)-3-((5-hydroxyhept-6-en-1-yl)oxy)pyrrolidine-1-carboxylate (7.68 g). Yield: 63%. 1 H NMR (400 MHz, chloroform-d) δ 5.93-5.80 (m, 1H), 5.28-5.17 (m, 1H), 5.15-5.06 (m, 1H), 4.17-4.05 (m, 1H), 3.99 (s, 1H), 3.52-3.23 (m, 6H), 2.03-1.83 (m, 2H), 1.65-1.50 (m, 5H), 1.50-1.33 (m, 11H).

[0424] Step 4: tert-butyl (R)-3-((7-(2-chloropyridin-3-yl)-5-oxoheptyl)oxy)pyrrolidine-1-carboxylate

[0425] [ka]

[0426] tert-Butyl (3R)-3-((5-hydroxyhept-6-en-1-yl)oxy)pyrrolidine-1-carboxylate (10.48 g, 35.0 mmol), 2-chloro-3-iodopyridine (4.19 g, 17.50 mmol), tetrabutylammonium chloride (0.486 g, 1.750 mmol), and sodium bicarbonate (3.68 g, 43.8 mmol) were dissolved / suspended in DMF (35 mL) under argon, and argon was bubbled through the mixture for 15 min. Palladium(II) acetate (0.393 g, 1.750 mmol) was added, and the mixture was heated to 50°C for 24 h, cooled to room temperature, diluted with water, and extracted three times with ethyl acetate. The combined organic layers were washed three times with brine, dried over sodium sulfate, concentrated, and the residue was purified by column chromatography (silica, 20% to 55% EtOAc / heptane) to give the desired product tert-butyl (R)-3-((7-(2-chloropyridin-3-yl)-5-oxoheptyl)oxy)pyrrolidine-1-carboxylate (3.05 g). Yield: 42%. 1 H NMR (400MHz, chloroform-d) δ8.25 (dd, J=4.7, 1.9Hz, 1H), 7.62 (dd, J=7.5, 1.9Hz, 1H), 7.17 (dd, J=7.5, 4.7Hz, 1H), 4.04-3.93 (m, 1H), 3.5 1-3.25(m, 6H), 2.99(t, J=7.3Hz, 2H), 2.79(t, J=7.3Hz, 2H), 2.43(t, J=7.2Hz, 2H), 2.01-1.83(m, 2H), 1.72-1.48(m, 4H), 1.30(s, 9H).

[0427] Step 5: tert-butyl (R)-3-((5-(((R)-tert-butylsulfinyl)imino)-7-(2-chloropyridin-3-yl)heptyl)oxy)pyrrolidine-1-carboxylate

[0428] [ka]

[0429] To a solution of (R)-(+)-2-methyl-2-propanesulfinamide (1.799 g, 14.84 mmol) and tert-butyl (R)-3-((7-(2-chloropyridin-3-yl)-5-oxoheptyl)oxy)pyrrolidine-1-carboxylate (3.05 g, 7.42 mmol) in THF (30 mL) was added titanium(IV) ethoxide (7.24 mL, 22.27 mmol). The resulting mixture was heated to 50°C for 20 hours, poured into half-saturated aqueous sodium bicarbonate, stirred for 10 minutes, transferred to two centrifuge vials, and centrifuged at 7800 rpm for 5 minutes. The liquid was decanted into a separatory funnel. The vials were then filled with ethyl acetate, vigorously shaken, and centrifuged again at 7800 rpm for 5 minutes. The liquids were combined in the separatory funnel. The layers were separated and the aqueous phase was extracted once more with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, concentrated, and the residue was purified by flash column chromatography (300 g silica, 35% to 65% EtOAc / heptane) to give the desired product, tert-butyl (R)-3-((5-(((R)-tert-butylsulfinyl)imino)-7-(2-chloropyridin-3-yl)heptyl)oxy)pyrrolidine-1-carboxylate (3.15 g). Yield 78% (ESI 514 / 516 (M+H) + ). 1 H NMR (400MHz, chloroform-d) δ8.27(dd, J=4.7, 1.9Hz, 1H), 7.64(dd, J=62.5, 7.4Hz, 1H), 7.19(dd, J=7.5, 4.8Hz, 1H), 3.99(s, 1H), 3.54-3 .24(m, 6H), 3.16-2.87(m, 2H), 2.87-2.60(m, 2H), 2.60-2.35(m, 1H), 1.94(s, 2H), 1.77-1.53(m, 5H), 1.45(s, 9H), 1.35-1.11(m, 9H).

[0430] Step 6: tert-butyl (3R)-3-((5-(((R)-tert-butylsulfinyl)amino)-7-(2-chloropyridin-3-yl)heptyl)oxy)pyrrolidine-1-carboxylate

[0431] [ka]

[0432] To a solution of tert-butyl (R)-3-((5-(((R)-tert-butylsulfinyl)imino)-7-(2-chloropyridin-3-yl)heptyl)oxy)pyrrolidine-1-carboxylate (3.15 g, 6.13 mmol) in methanol (20 mL) was added sodium borohydride (0.278 g, 7.35 mmol). After 2 h, the mixture was quenched with saturated aqueous ammonium chloride and extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated, and the residue was purified by flash column chromatography (50% to 100% EtOAc / heptane) to give the desired product, tert-butyl (3R)-3-((5-(((R)-tert-butylsulfinyl)amino)-7-(2-chloropyridin-3-yl)heptyl)oxy)pyrrolidine-1-carboxylate (3.05 g). Yield: 85%. 1 H NMR (400MHz, chloroform-d) δ8.28-8.22(m, 1H), 7.72-7.51(m, 1H), 7.22-7.15(m, 1H), 4.03-3.95(m, 1H), 3.49-3.22(m, 7H), 3.1 6-3.06(m, 1H), 2.96-2.64(m, 2H), 2.00-1.83(m, 4H), 1.80-1.70(m, 1H), 1.65-1.51(m, 3H), 1.51-1.37(m, 11H), 1.25(s, 9H).

[0433] Step 7: tert-butyl (3R)-3-(4-(1-((R)-tert-butylsulfinyl)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidine-1-carboxylate

[0434] [ka]

[0435] To a solution of tert-butyl (3R)-3-((5-(((R)-tert-butylsulfinyl)amino)-7-(2-chloropyridin-3-yl)heptyl)oxy)pyrrolidine-1-carboxylate (3.05 g, 5.20 mmol) in 1,4-dioxane (25 mL) was added Xantphos (0.602 g, 1.040 mmol) and cesium carbonate (3.39 g, 10.40 mmol). The mixture was sparged with argon for 15 minutes. Palladium(II) acetate (0.117 g, 0.520 mmol) was added, and the reaction was sparged with argon for 1 minute, stirred at 100° C. for 16 hours, cooled to room temperature, quenched with water, and extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, concentrated, and the residue was purified by flash column chromatography (40% to 100% EtOAc / heptane) to give the desired product tert-butyl (3R)-3-(4-(1-((R)-tert-butylsulfinyl)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidine-1-carboxylate (928 mg). Yield 36% (ESI 480 (M+H) + The compounds were separated by chiral SFC to give Stereoisomers A and B. Equipment: Waters Prep 100 SFC UV-directed system; Waters 2998 Photodiode Array (PDA) detector; Waters 2767 Sample Manager; Masslynx™ software; FractionLynx™ Application Manager, Acq. Method: Cell-2_f70_10_50_8mn_SW_120bar, Load: 50mg, Column: Phenomenex Lux Cellulose-2 (250 x 21.2mm, 5µm), Flow Rate: 70mL / min, Column Temperature: 35°C; ABPR: 120bar; Eluent A: CO₂, Eluent B: 20mM ammonia / methanol, Linear Gradient: t = 0min 10% B, t = 5min 50% B, t = 7.5min 50% B, t = 8min 10% B. Injection: Sandwich 100µL methanol, Detection: PDA: 210-320nm, Recovery: Based on PDA TIC.

[0436] tert-Butyl (3R)-3-(4-(1-((R)-tert-butylsulfinyl)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidine-1-carboxylate Stereoisomer A: 0.58 g, LC / MS ESI 480 (M+H) + . 1 H NMR (400 MHz, chloroform-d) δ 8.06-7.98 (m, 1H), 7.37-7.29 (m, 1H), 6.73-6.63 (m, 1H), 4.20-4.09 (m, 1H), 4.03-3.93 (m, 1H), 3.50-3.25 (m, 6H), 2.94-2.79 (m, 1H), 2.77-2.65 (m, 1H), 2.20-2.08 (m, 1H), 2.00-1.49 (m, 7H), 1.46 (s, 9H), 1.43-1.27 (m, 2H), 1.21 (s, 9H).

[0437] tert-Butyl (3R)-3-(4-(1-((R)-tert-butylsulfinyl)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidine-1-carboxylate stereoisomer B: 0.45 g, LC / MS ESI 480 (M+H) + . 1 H NMR (400 MHz, chloroform-d) δ 8.20-8.09 (m, 1H), 7.39-7.31 (m, 1H), 6.90-6.80 (m, 1H), 4.25-4.12 (m, 1H), 4.04-3.92 (m, 1H), 3.51-3.24 (m, 6H), 2.87-2.62 (m, 2H), 2.11-1.83 (m, 3H), 1.76-1.49 (m, 6H), 1.46 (s, 9H), 1.40-1.27 (m, 10H).

[0438] Step 8: 2-(4-(((R)-pyrrolidin-3-yl)oxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine stereoisomer A2 hydrochloride

[0439] [ka]

[0440] To a solution of tert-butyl (3R)-3-(4-(1-((R)-tert-butylsulfinyl)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidine-1-carboxylate Stereoisomer A (0.58 g, 1.209 mmol) in methanol (5 mL) was added hydrochloric acid (5 mL, 20.00 mmol, 4N solution in dioxane). The mixture was stirred at room temperature for 3 hours, concentrated under reduced pressure, and co-evaporated with methanol. Diethyl ether was added, and the product began to slowly crystallize. After standing overnight, the crystallized material was scraped off and the material was triturated with diethyl ether. After several hours, the solid was collected by filtration, washed with fresh diethyl ether, and dried under vacuum to give the desired product, 2-(4-(((R)-pyrrolidin-3-yl)oxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine stereoisomer A dihydrochloride (438 mg) as a beige solid. Yield: 100%. LC / MS ESI 276 (M-2HCl+H). + . 1 H NMR (400MHz, methanol-d4) δ7.75-7.66(m, 2H), 6.80(t, J=6.8Hz, 1H), 4.30-4.23(m, 1H), 3.67-3.56(m, 1H), 3.56-3.44(m, 2H), 3.44-3.3 3(m, 3H), 3.25(dd, J=12.5, 4.2Hz, 1H), 2.96-2.78(m, 2H), 2.26-2.16(m, 1H), 2.13-1.99(m, 2H), 1.77-1.46(m, 7H), 1.23-1.12(m, 1H). Specific optical rotation: 33.9° c=0.5, MeOH, 22.7°C, 589nm.

[0441] Step 9: 2-(4-(((R)-pyrrolidin-3-yl)oxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine stereoisomer B2 hydrochloride

[0442] [ka]

[0443] To a solution of tert-butyl (3R)-3-(4-(1-((R)-tert-butylsulfinyl)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidine-1-carboxylate stereoisomer B (0.45 g, 0.938 mmol) in methanol (5 mL) was added hydrochloric acid (5 mL, 20.00 mmol, 4N solution in dioxane). The mixture was stirred at room temperature for 3 hours, concentrated under reduced pressure, and co-evaporated with methanol. Diethyl ether was added, and the product began to slowly crystallize. After standing overnight, the crystallized material was scraped off and the material was triturated with diethyl ether. After several hours, the solid was collected by filtration, washed with fresh diethyl ether, and dried under vacuum to give the desired product, 2-(4-(((R)-pyrrolidin-3-yl)oxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine stereoisomer B dihydrochloride (289 mg) as a beige solid. Yield 85%. LC / MS ESI 276 (M-2HCl+H). + . 1 H NMR (400MHz, methanol-d4) δ7.74-7.66(m, 2H), 6.80(t, J=6.8Hz, 1H), 4.30-4.23(m, 1H), 3.66-3.57(m, 1H), 3.57-3.45(m, 2H), 3.45-3.33(m, 3H), 3.29-3.21(m, 1H), 2.96-2.78(m, 2H), 2.26-2.16(m, 1H), 2.13-1.97(m, 2H), 1.76-1.44(m, 7H). Specific optical rotation: -48.3° c=0.5, MeOH, 22.7°C, 589nm.

[0444] Compounds 1-21 were prepared using the following methods. [Example]

[0445] Example 1: Preparation of 2-(2-cyclopropylphenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (compounds 1-E1 and 1-E2)

[0446] Step 1: Ethyl 2-(2-cyclopropylphenyl)acetate

[0447] [ka]

[0448] A mixture of ethyl 2-(2-bromophenyl)acetate (5.0 g, 20.57 mmol), cyclopropylboronic acid (3.54 g, 41.14 mmol), Pd(OAc) (922 mg, 4.12 mmol), tricyclohexylphosphine (1.73 g, 6.17 mmol), and potassium phosphate tribasic (15.3 g, 72.01 mmol) in toluene (60 mL) and water (7.5 mL) was stirred at 120 °C overnight. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 20:1) to give the desired product, ethyl 2-(2-cyclopropylphenyl)acetate, as a colorless oil (4.0 g). Yield: 95%. 1 H NMR (400MHz, CDCl3) δ7.21-7.18(m, 4H), 4.18-4.16(q, 2H), 3.83(s, 2H), 1.52-1.48(m, 1H), 1.29-1.18(t, 3H), 0.94-0.64(m, 4H).

[0449] Step 2: Ethyl 2-bromo-2-(2-cyclopropylphenyl)acetate

[0450] [ka]

[0451] To a solution of ethyl 2-(2-cyclopropylphenyl)acetate (1 g, 4.9 mmol) in THF (16 mL) was added dropwise 2.0 M lithium diisopropylamide in THF / hexanes (6.2 mL, 12.4 mmol) at −78° C. The reaction was stirred at −78° C. for 30 minutes. Next, a solution of chlorotrimethylsilane (1.3 g, 12.25 mmol) in THF (5 mL) was added, and the reaction was stirred at −78° C. for an additional 30 minutes. Next, a solution of NBS (1.5 g, 12.25 mmol) in THF (10 mL) was added, and the reaction was stirred at −78° C. for 1 hour. The reaction was quenched with MeOH (2 mL), concentrated under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product ethyl 2-bromo-2-(2-cyclopropylphenyl)acetate as a yellow oil (350 mg), yield 25%.

[0452] Step 3: Ethyl 2-(2-cyclopropylphenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)acetate

[0453] [ka]

[0454] A mixture of ethyl 2-bromo-2-(2-cyclopropylphenyl)acetate (350 mg, 1.24 mmol), (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (341 mg, 1.24 mmol), and KCO (513 mg, 3.72 mmol) in acetonitrile (8 mL) was stirred at 60° C. for 16 hours. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (DCM:MeOH 20:1) to give the desired product, ethyl 2-(2-cyclopropylphenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (150 mg) as a yellow oil. Yield 25% (ESI 478 (M+H) + ).

[0455] Step 4: 2-(2-cyclopropylphenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (compounds 1-E1 and 1-E2)

[0456] [ka]

[0457] Ethyl 2-(2-cyclopropylphenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (150 mg, 0.31 mmol) was treated with LiOH—HO (52 mg, 1.24 mmol) in MeOH (4 mL) and HO (1 mL) at 60° C. for 2 h. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC A (30% to 65% MeCN) to give compound 1 as a white solid (110 mg, 77% yield). The racemic product was separated by preparative chiral SFC A to give diastereomeric products, compound 1-E1 (25 mg) and compound 1-E2 (26 mg), as white solids.

[0458] Compound 1-E1 LC / MS ESI 450.6(M+H) + . 1 H NMR (400MHz, MeOD) δ7.60(d, J=7.6Hz, 1H), 7.28(m, 2H), 7.15(d, J=7.3Hz, 2H), 6 .37(d, J=7.3Hz, 1H), 5.31(s, 1H), 4.21(s, 1H), 3.72-3.32(m, 6H), 3.24-3.02(m , 2H), 2.71(t, J=6.3Hz, 2H), 2.54(t, J=7.5Hz, 2H), 2.31-1.95(m, 3H), 1.94-1.7 9(m, 2H), 1.77-1.66(m, 2H), 1.58(m, 2H), 1.05-0.87(m, 3H), 0.67-0.38(m, 1H). Chiral SFC A (45%MeOH): ee98%, Rt=1.97 min.

[0459] Compound 1-E2 LC / MS ESI 450.6(M+H) + . 1 H NMR (400MHz, MeOD) δ7.60(d, J=7.6Hz, 1H), 7.28(m, 2H), 7.15(d, J=7.3Hz, 2H), 6 .37(d, J=7.3Hz, 1H), 5.31(s, 1H), 4.21(s, 1H), 3.72-3.32(m, 6H), 3.24-3.02(m , 2H), 2.71(t, J=6.3Hz, 2H), 2.54(t, J=7.5Hz, 2H), 2.31-1.95(m, 3H), 1.94-1.7 9(m, 2H), 1.77-1.66(m, 2H), 1.58(m, 2H), 1.05-0.87(m, 3H), 0.67-0.38(m, 1H). Chiral SFC A (45%MeOH): ee98%, Rt=2.59 min.

[0460] [Example 2]: Preparation of 2-(2-cyclopropoxyphenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (compounds 2-E1 and 2-E2)

[0461] Step 1: 1-Bromo-2-cyclopropoxybenzene

[0462] [ka]

[0463] A mixture of 2-bromophenol (2.0 g, 11.6 mmol), bromocyclopropane (4.6 g, 38.1 mmol), and K2CO3 (5.2 g, 38.1 mmol) in dry DMF (10 mL) was sealed in a tube and heated in a microwave at 140 °C for 2 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with diethyl ether (3 x 100 mL). The combined organic layers were washed with brine and concentrated under reduced pressure. The residue was purified by silica gel column (eluted with 0-10% EtOAc / hexane) to give the desired product (400 mg) as a colorless oil. Yield: 17% 1H NMR (400MHz, CDCl3) δ7.52(d, J=7.2Hz, 1H), 7.30-7.27(m, 2H), 6.88-6.84(m, 1H), 3.83-3.80(m, 1H), 0.90-0.82(m, 4H).

[0464] Step 2: 2-Cyclopropoxyphenylboronic acid

[0465] [ka]

[0466] To a solution of 1-bromo-2-cyclopropoxybenzene (800 mg, 3.75 mmol) in THF (20 mL) was added n-BuLi (2.5 M, 4.5 mmol) dropwise. The reaction was stirred at -78 °C for 1 h under Ar. A solution of trimethylborate (779 mg, 7.5 mmol) in THF (5 mL) was added dropwise, and the reaction was stirred at -78 °C for an additional 1 h, then slowly warmed to room temperature and stirred overnight. Aqueous HCl (1 N, 20 mL) was added, and the reaction was stirred at room temperature for 30 min and extracted with DCM (3 x 20 mL). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc = 1:1) to give the desired product (400 mg) as a white solid. Yield: 60% (ESI: 178 [MH] - ).

[0467] Step 3: 2-(2-Cyclopropoxyphenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 2-E1 and 2-E2)

[0468] [ka]

[0469] A mixture of 2-cyclopropoxyphenylboronic acid (400 mg, 2.25 mmol), (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (476 mg, 1.73 mmol), and 2-oxoacetic acid (304 mg, 3.45 mmol) in DCM (5 mL) was stirred at room temperature for 8 hours. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC A (30% to 65% MeCN) to give compound 2 as a white solid (205 mg, 26% yield). The racemic product was separated by preparative chiral SFC A to give diastereomeric products, compound 2-E1 (110 mg) and compound 2-E2 (79 mg), as white solids.

[0470] Compound 2-E1 LC / MS ESI 466(M+H) + . 1 H NMR (400MHz, MeOD) δ7.48(d, J=7.6Hz, 1H), 7.41-7.40(m, 2H), 7.13(d, J=7 .6Hz, 1H), 7.04-7.00(m, 1H), 6.38(d, J=7.6Hz, 1H), 4.92(s, 1H), 4.18-4.1 6(m, 1H), 3.90-3.85(m, 1H), 3.56-3.36(m, 5H), 3.27-3.01(m, 3H), 2.70(t, J=6.0Hz, 2H), 2.56(t, J=7.2Hz, 2H), 2.09-1.55(m, 8H), 0.85-0.70(m, 4H). Chiral SFC A (40% MeOH): ee 85.4%, Rt = 2.39 min.

[0471] Compound 2-E2 LC / MS ESI 466(M+H) + . 1H NMR (400MHz, MeOD) δ7.52(d, J=7.6Hz, 1H), 7.41-7.40(m, 2H), 7.13(d, J=7 .2Hz, 1H), 7.03-6.99(m, 1H), 6.37(d, J=7.2Hz, 1H), 4.86(s, 1H), 4.15-4.1 2(m, 1H), 3.92-3.75(m, 1H), 3.56-3.36(m, 5H), 3.27-3.14(m, 3H), 2.70(t, J=6.0Hz, 2H), 2.53(t, J=7.6Hz, 2H), 2.20-1.55(m, 8H), 0.85-0.70(m, 4H). Chiral SFC A (40% MeOH): ee 95.4%, Rt = 3.27 min.

[0472] [Example 3]: Preparation of 2-(2-cyclopropylpyridin-3-yl)-2-((R)-3-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentyl)pyrrolidin-1-yl)acetic acid (compounds 3-E1 and 3-E2)

[0473] Step 1: 3-Bromo-2-cyclopropylpyridine

[0474] [ka]

[0475] To a solution of 2,3-dibromopyridine (3 g, 12.8 mmol) and cyclopropylzinc(II) bromide (76 mL, 0.5 M in THF) in THF (30 mL) was added Pd(PPh3)4 (740 mg, 0.64 mmol). The mixture was stirred at 70 °C under N2 for 4 h, diluted with water (50 mL), and extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product, 3-bromo-2-cyclopropylpyridine, as a yellow oil (1.2 g). Yield 48% (ESI 198 (M+H) + ).

[0476] Step 2: Ethyl 2-(2-cyclopropylpyridin-3-yl)-2-hydroxyacetate

[0477] [ka]

[0478] To a solution of EtMgBr (1 M, 3.65 mL, 3.65 mmol) in THF (20 mL) at 0 °C under N was added n-BuLi (2.9 mL, 7.3 mmol). The solution was stirred at 0 °C for 30 min, and a solution of 3-bromo-2-cyclopropylpyridine (1.2 g, 6.1 mmol) in THF (5 mL) was added at -10 °C. The mixture was stirred at that temperature for 30 min, and ethyl 2-oxoacetate (50% solution in toluene, 5 g, 24.4 mmol) was added. The reaction was stirred at 0 °C for 2 h, quenched with saturated KCO solution (20 mL), and extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (petroleum ether: EtOAc 2:1) to give the desired product ethyl 2-(2-cyclopropylpyridin-3-yl)-2-hydroxyacetate as a yellow oil (700 mg). Yield 52% (ESI 222 (M+H) + ).

[0479] Step 3: Ethyl 2-(2-cyclopropylpyridin-3-yl)-2-(methylsulfonyloxy)acetate

[0480] [ka]

[0481] To a solution of ethyl 2-(2-cyclopropylpyridin-3-yl)-2-hydroxyacetate (300 mg, 1.36 mmol) and triethylamine (411 mg, 4.1 mmol) in DCM (5 mL) at 0° C. was added MsCl (232 mg, 2 mmol). The reaction was stirred at room temperature for 2 h, concentrated under reduced pressure, and purified by silica gel column (petroleum ether: EtOAc 4:1) to give the desired product, ethyl 2-(2-cyclopropylpyridin-3-yl)-2-(methylsulfonyloxy)acetate, as a yellow oil (190 mg). Yield 47% (ESI 300 (M+H) + ).

[0482] Step 4: Ethyl 2-(2-cyclopropylpyridin-3-yl)-2-((R)-3-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentyl)pyrrolidin-1-yl)acetate

[0483] [ka]

[0484] A mixture of (R)-7-(5-(pyrrolidin-3-yl)pentyl)-1,2,3,4-tetrahydro-1,8-naphthyridine hydrochloride (300 mg, 0.87 mmol), ethyl 2-(2-cyclopropylpyridin-3-yl)-2-(methylsulfonyloxy)acetate (286 mg, 0.96 mmol), and diisopropylethylamine (337 mg, 2.6 mmol) in acetonitrile (10 mL) was stirred at 50° C. overnight. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (DCM:MeOH=0% to 20%) to give the desired product as a yellow oil (245 mg). Yield 54% (ESI 477 (M+H) + ).

[0485] Step 2: 2-(2-cyclopropylpyridin-3-yl)-2-((R)-3-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentyl)pyrrolidin-1-yl)acetic acid (compounds 3-E1 and 3-E2)

[0486] [ka]

[0487] Ethyl 2-(2-cyclopropylpyridin-3-yl)-2-((R)-3-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentyl)pyrrolidin-1-yl)acetate (245 mg, 0.51 mmol) was treated with LiOH—HO (210 mg, 5.0 mmol) in MeOH (4 mL) and HO (1 mL) at room temperature for 2 hours. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC A (30% to 60% MeCN) to give compound 3 as a white solid (110 mg, 48% yield). The racemic product was separated by preparative chiral SFC H to give diastereomeric products, compound 3-E1 (42 mg) and compound 3-E2 (45 mg), as white solids.

[0488] Compound 3-E1 LC / MS ESI 449(M+H) + . 1 H NMR (400MHz, MeOD) δ8.39(t, J=6.1Hz, 1H), 7.98(d, J=7.9Hz, 1H), 7.19-7.10(m, 2H), 6.35(d , J=7.3Hz, 1H), 5.06(s, 1H), 3.40-3.31(m, 3H), 3.15-3.08(m, 2H), 2.84-2.81(m, 1H), 2.70- 2.67(m, 2H), 2.59-2.56(m, 1H), 2.55-2.47(m, 2H), 2.36-2.26(m, 1H), 2.21-2.13(m, 1H), 1. 90-1.84(m, 2H), 1.66-1.57(m, 3H), 1.44-1.26(m, 7H), 1.08-1.05(m, 2H), 0.93-0.90(m, 1H). Chiral SFC H(45%MeOH): ee92%, Rt=2.11 min.

[0489] Compound 3-E2 LC / MS ESI 449(M+H) + . 1H NMR (400MHz, MeOD) δ8.36(t, J=6.1Hz, 1H), 8.01(d, J=7.9Hz,1H), 7.20-7.11(m, 2H), 6.35(d, J=8Hz, 1H), 4.91(s, 1H), 3.51-3.36(m, 3H), 3.20-2. 91(m, 2H), 2.71-2.29(m, 7H), 2.14-2.09(m, 1H), 1.90-1.84(m, 2H), 1.64 -1.57(m, 3H), 1.433-1.23(m, 7H), 1.06-1.01(m, 2H), 0.92-0.88(m, 1H). Chiral SFC H(45% MeOH): ee 100%, Rt = 3.77 min.

[0490] Example 4: Preparation of 2-(2-cyclopropyl-5-fluorophenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (compounds 4-E1 and 4-E2)

[0491] Step 1: 2-Cyclopropyl-5-fluoroaniline

[0492] [ka]

[0493] A mixture of 2-bromo-5-fluoroaniline (3.0 g, 15.8 mmol), cyclopropylboronic acid (2.7 g, 31.4 mmol), PCy3 (440 mg, 1.57 mmol), Pd(OAc)2 (352 mg, 1.57 mmol), and K3PO4 (20 g, 94.3 mmol) in toluene (50 mL) and HO (10 mL) was stirred at 100 °C for 4 h. The reaction mixture was cooled to room temperature, diluted with HO (10 mL), and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 2:1) to give the desired product (1.8 g) as a colorless oil. Yield: 75% (ESI: 152 [M+H] + ).

[0494] Step 2: 1-Cyclopropyl-4-fluoro-2-iodobenzene

[0495] [ka]

[0496] 2-Cyclopropyl-5-fluoroaniline (1.8 g, 11.9 mmol) was added to a solution of para-toluenesulfonic acid monohydrate (6.8 g, 35.8 mmol) in acetonitrile (60 mL). The reaction was stirred at room temperature for 10 minutes and then cooled to 10°C. A solution of sodium nitrite (2.0 g, 29.0 mmol) and potassium iodide (4.0 g, 24.1 mmol) in water (20 mL) was added dropwise over 30 minutes. The reaction mixture was stirred at room temperature for 4 hours, basified to pH 9-10 with aqueous sodium bicarbonate, and diluted with EtOAc (100 mL) and 10% aqueous sodium metabisulfite (20 mL). The phases were separated, and the aqueous layer was extracted with EtOAc (2 x 100 mL). The organic layers were combined, washed with brine, dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product as a colorless oil (1.3 g), yield 42% (ESI: N / A).

[0497] Step 3: 2-Cyclopropyl-5-fluorophenylboronic acid

[0498] [ka]

[0499] To a solution of 1-cyclopropyl-4-fluoro-2-iodobenzene (1.3 g, 4.96 mmol) in THF (50 mL) was added n-BuLi (2.5 M, 2.2 mL, 5.5 mmol) dropwise. The reaction was stirred at -78 °C for 1 h under Ar. A solution of trimethylborate (1.0 g, 9.62 mmol) in THF (10 mL) was added dropwise, and the reaction was stirred at -78 °C for an additional 1 h, then slowly warmed to room temperature and stirred overnight. Aqueous HCl (1 N, 20 mL) was added, and the mixture was stirred at room temperature for 30 min and extracted with DCM (3 x 20 mL). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc = 1:1) to give the desired product (500 mg) as a white solid. Yield: 56% (ESI: 179 [MH] - ).

[0500] Step 4: 2-(2-cyclopropyl-5-fluorophenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (compounds 4-E1 and 4-E2)

[0501] [ka]

[0502] A mixture of 2-cyclopropyl-5-fluorophenylboronic acid (200 mg, 1.11 mmol), (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (306 mg, 1.11 mmol), and 2-oxoacetic acid (123 mg, 1.66 mmol) in MeCN (5 mL) was stirred at 60° C. for 15 hours. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC A (30% to 65% MeCN) to give compound 4 as a white solid (120 mg, 23% yield). The racemic product was separated by preparative chiral SFC A to give diastereomeric products, compound 4-E1 (34 mg) and compound 4-E2 (41 mg), as white solids.

[0503] Compound 4-E1 LC / MS ESI 468(M+H) + . 1 H NMR (400MHz, MeOD) δ7.41(d, J=10.0Hz, 1H), 7.20-7.01(m, 3H), 6.38(d, J=7.2Hz, 1H), 5.28(s, 1H), 4.21(s, 1H), 3.55-3.05(m, 8H), 2.71(t, J=6.4Hz, 2H), 2.55(t, J=7.6Hz, 2H), 2.19-2.05(m, 3H), 1.92-1.55(m, 6H), 0.95-0.80(m, 3H), 0.55-0.50(m, 1H). Chiral SFC A (35%MeOH): ee100%, Rt=2.69 min.

[0504] Compound 4-E2 LC / MS ESI 468(M+H) + . 1 H NMR (400MHz, MeOD) δ7.41(d, J=10.0Hz, 1H), 7.20-7.01(m, 3H), 6.38(d, J=7.2Hz, 1H), 5.19(s, 1H), 4.18(s, 1H), 3.54-3.19( m, 8H), 2.71(t, J=6.0Hz, 2H), 2.59-2.53(m, 2H), 2.22-2.14(m, 3H), 1.92-1.55(m, 6H), 0.98-0.85(m, 3H), 0.55-0.50(m, 1H). Chiral SFC A (35%MeOH): ee97%, Rt=3.26 min.

[0505] [Example 5]: Preparation of 2-(2-cyclopropylphenyl)-2-((R)-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)pyrrolidin-1-yl)acetic acid (compounds 5-E1 and 5-E2)

[0506] Step 1: 2-(2-cyclopropylphenyl)-2-((R)-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)pyrrolidin-1-yl)acetic acid (Compounds 5-E1 and 5-E2)

[0507] [ka]

[0508] A mixture of 2-cyclopropylphenylboronic acid (102 mg, 0.63 mmol), (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (140 mg, 0.42 mmol), and 2-oxoacetic acid (47 mg, 0.63 mmol) in DCM (5 mL) was stirred at room temperature for 8 hours. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC A (30% to 65% MeCN) to give compound 5 as a white solid (95 mg, 52% yield). The racemic product was separated by preparative chiral SFC H to give diastereomeric products, compound 5-E1 (15 mg) and compound 5-E2 (9 mg), as white solids.

[0509] Compound 5-E1 LC / MS ESI 436.4(M+H) + . 1 H NMR (400MHz, MeOD) δ7.64(d, J=7.6Hz, 1H), 7.33-7.12(m, 4H), 6.36(d, J=7.2Hz, 1H), 5.26(s, 1H), 4.18(s, 1H), 3.55-3.22(m, 8H), 2.69(t, J=6.4Hz, 2H), 2.60(t, J=7.2Hz, 2H), 2.30-2.13(m, 3H), 1.92-1.84(m, 4H), 1.08-0.90(m, 3H), 0.65-0.55(m, 1H). Chiral SFC H(35%MeOH): ee98%, Rt=2.74 min.

[0510] Compound 5-E2 LC / MS ESI 436.4(M+H) + . 1H NMR (400MHz, MeOD) δ7.61(d, J=7.6Hz, 1H), 7.32-7.12(m, 4H), 6.36(d, J=7.2Hz, 1H), 5.33(s, 1H), 4.21(s, 1H), 3.55-3.09(m, 8H), 2.70(t, J=6.4Hz, 2H), 2.60(t, J=7.2Hz, 2H), 2.25-2.00(m, 3H), 1.93-1.84(m, 4H), 1.08-0.90(m, 3H), 0.65-0.55(m, 1H). Chiral SFC H(35%MeOH): ee99%, Rt=3.55 min.

[0511] [Example 6]: Preparation of 2-(2,6-dicyclopropylpyridin-3-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 6-E1 and 6-E2)

[0512] Step 1: 2,6-Dicyclopropylpyridin-3-amine

[0513] [ka]

[0514] A mixture of ethyl 2,6-dibromopyridin-3-amine (6.0 g, 23.8 mmol), cyclopropylboronic acid (6.14 g, 71.4 mmol), Pd(OAc) (267 mg, 2.38 mmol), tricyclohexylphosphine (668 mg, 6.17 mmol), and potassium phosphate tripotassium (17.7 g, 83.3 mmol) in toluene (80 mL) and water (10 mL) was stirred at 120 °C overnight. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 4:1) to give the desired product, 2,6-dicyclopropylpyridin-3-amine, as a colorless oil (3.0 g). Yield 95% (ESI 175.0 (M+H) + ).

[0515] Step 2: 2,6-Dicyclopropylpyridin-3-amine

[0516] [ka]

[0517] A mixture of ethyl 2,6-dicyclopropylpyridin-3-amine (3.0 g, 17.2 mmol), tert-butyl nitrite (2.66 g, 25.8 mmol), and cuprous bromide (17.7 g, 25.8 mmol) in acetonitrile (20 mL) was stirred at 65° C. for 2 h. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 6:1) to give the desired product, 3-bromo-2,6-dicyclopropylpyridine, as a yellow oil (820 mg). Yield 20% (ESI 239.0 (M+H) + ).

[0518] Step 3: tert-Butyl 2-(2,6-dicyclopropylpyridin-3-yl)acetate

[0519] [ka]

[0520] A mixture of 3-bromo-2,6-dicyclopropylpyridine (800 mg, 3.36 mmol), (2-tert-butoxy-2-oxoethyl)zinc(II) bromide solution 0.5 M in THF (26.9 mL, 13.44 mmol), Pd2(dba)3 (156 mg, 0.17 mmol), and Qphos (121 mg, 0.17 mmol) in THF (12 mL) was stirred at 65 °C for 2 h. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 4:1) to give the desired product, tert-butyl 2-(2,6-dicyclopropylpyridin-3-yl)acetate, as a yellow oil (550 mg). Yield 60% (ESI 274.0 (M+H) + ).

[0521] Step 4: tert-Butyl 2-bromo-2-(2,6-dicyclopropylpyridin-3-yl)acetate

[0522] [ka]

[0523] To a solution of tert-butyl 2-(2,6-dicyclopropylpyridin-3-yl)acetate (300 mg, 1.1 mmol) in THF (10 mL) was added dropwise lithium diisopropylamide solution, 2.0 M in THF / hexane (1.4 mL, 2.8 mmol) at −78° C. The reaction was stirred at −78° C. for 30 minutes, and then a solution of chlorotrimethylsilane (297 mg, 2.75 mmol) in THF (5 mL) was added. The reaction was stirred at −78° C. for an additional 30 minutes. Next, a solution of NBS (325 mg, 2.75 mmol) in THF (5 mL) was added, and the reaction was stirred at −78° C. for 1 hour. The reaction was quenched with MeOH (2 mL), concentrated under reduced pressure, and purified by silica gel column (petroleum ether: EtOAc 4:1) to give the desired product tert-butyl 2-bromo-2-(2,6-dicyclopropylpyridin-3-yl)acetate as a yellow oil (80 mg). Yield 21% (ESI 353 (M+H) + ).

[0524] Step 5: tert-Butyl 2-(2,6-dicyclopropylpyridin-3-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate

[0525] [ka]

[0526] A mixture of tert-butyl 2-bromo-2-(2,6-dicyclopropylpyridin-3-yl)acetate (80 mg, 0.23 mmol), ((R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (64 mg, 0.23 mmol) and KCO (96 mg, 0.69 mmol) in acetonitrile (8 mL) was stirred at 60 °C for 16 h. The solvent was removed under reduced pressure and the residue was purified by silica gel column (DCM:MeOH 20:1) to give the desired product tert-butyl 2-(2,6-dicyclopropylpyridin-3-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate as a yellow oil (90 mg). Yield 72% (ESI 547 (M+H) + ).

[0527] Step 6: 2-(2,6-Dicyclopropylpyridin-3-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 6-E1 and 6-E2)

[0528] [ka]

[0529] tert-Butyl 2-(2,6-dicyclopropylpyridin-3-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (90 mg, 0.16 mmol) was treated with HCl / 1,4-dioxane (4 M, 4 mL) for 2 hours at 25° C. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC A (30% to 65% MeCN) to give diastereomeric products Compound 6-E1 (11 mg) and Compound 6-E2 (38 mg) as white solids.

[0530] Compound 6-E1 LC / MS ESI 491.6(M+H) + .1 H NMR (400MHz, MeOD) δ8.52(s, 1H), 7.77(d, J=7.9Hz, 1H), 7.67-7.44(m, 1H), 7.03(d, J=7.9Hz, 1H), 6.53(d, J=7.3Hz, 1H), 5.18(s, 1H), 4.22(s, 1H), 3.76-3.40(m, 6H), 3 .31-3.28(m, 2H), 2.79-2.66(m, 4H), 2.39(d, J=5.6Hz, 1H), 2.19(s, 2H), 1.98-1.93 (m, 3H), 1.76-1.74(m, 2H), 1.64-1.62(m, 2H), 1.25-1.14(m, 1H), 1.06-0.72(m, 8H).

[0531] Compound 6-E2 LC / MS ESI 491.6(M+H) + . 1 H NMR (400MHz, MeOD) δ8.52(s, 1H), 7.77(d, J=7.9Hz, 1H), 7.67-7.44(m, 1H), 7.03(d, J=7.9Hz, 1H), 6.53(d, J=7.3Hz, 1H), 5.27(s, 1H), 4.23(s, 1H), 3.76-3.40(m, 6H), 3 .31-3.28(m, 2H), 2.79-2.66(m, 4H), 2.39(d, J=5.6Hz, 1H), 2.19(s, 2H), 1.98-1.93 (m, 3H), 1.76-1.74(m, 2H), 1.64-1.62(m, 2H), 1.25-1.14(m, 1H), 1.06-0.72(m, 8H).

[0532] [Example 7]: Preparation of 2-(2-(isopropoxymethyl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 7-E1 and 7-E2)

[0533] Step 1: 1-Bromo-2-(isopropoxymethyl)benzene

[0534] [ka]

[0535] To a solution of isopropanol (0.72 g, 12 mmol) in DMF (15 mL) at 0 °C was added NaH (480 mg, 12 mmol). The reaction was stirred at 0 °C for 0.5 h, and 1-bromo-2-(bromomethyl)benzene (3.0 g, 12 mmol) in DMF (5 mL) was added dropwise. The reaction was stirred at room temperature for 16 h, quenched with HO (10 mL), and extracted with EtOAc (2 x 20 mL). The combined organic layers were concentrated under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc = 10:1) to give the desired product, 1-bromo-2-(isopropoxymethyl)benzene (1.6 g). Yield 58% (ESI 229 (M+H) + ).

[0536] Step 2: 2-(Isopropoxymethyl)phenylboronic acid

[0537] [ka]

[0538] To a solution of 1-bromo-2-(isopropoxymethyl)benzene (300 mg, 1.32 mmol) in THF (5 mL) at −78° C., nBuLi (2.5 M, 0.6 mL, 1.45 mmol) was added dropwise. The reaction was stirred at −78° C. for 1 h, and trimethylborate (500 mg, 2.64 mmol) in THF (2 mL) was added dropwise. The reaction was stirred at room temperature for 1 h, quenched with aqueous HCl (1N, 10 mL), and extracted with EtOAc (3×10 mL). The combined organic layers were concentrated under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc = 2:1) to give the desired product, 2-(isopropoxymethyl)phenylboronic acid (120 mg) as a white solid. Yield: 47% (ESI 193 (MH) - .

[0539] Step 3: 2-(2-(isopropoxymethyl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 7-E1 and 7-E2)

[0540] [ka]

[0541] A mixture of (3R)-tert-butyl 3-(4-(5-methyl-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidine-1-carboxylate (131 mg, 0.48 mmol), 2-(isopropoxymethyl)phenylboronic acid (120 mg, 0.62 mmol), and 50% 2-oxoacetic acid (92 mg, 0.62 mmol) in MeCN (5 mL) was stirred at 70° C. for 16 hours. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC B (30% to 65% MeCN) to give diastereomeric products Compound 7-E1 (40 mg) and Compound 7-E2 (34 mg) as HCOOH salts.

[0542] Compound 7-E1 LC / MS ESI 482(M+H) + . 1 H NMR (400MHz, MeOD) δ8.33(s, 2H), 7.68-7.66(m, 1H), 7.52-7.50(m, 1H), 7.46-7.42(m, 3H), 6.56(d, J=7.2Hz, 1H), 5.09(s, 1H), 4.90-4.88(m , 1H), 4.52-4.50(m, 1H), 4.23-4.21(m, 1H), 3.82-3.80(m, 1H), 3.66-3 .44(m, 7H), 3.21-3.19(m, 1H), 2.81-1.60(m, 12H), 1.25-1.23(m, 6H).

[0543] Compound 7-E2 LC / MS ESI 482(M+H) + . 1H NMR (400MHz, MeOD) δ8.33(s, 2H), 7.65-7.63(m, 1H), 7.52-7.50(m, 1H), 7.44-7.42(m, 3H), 6.56(d, J=7.2Hz, 1H), 4.97(s, 1H), 4.8 6-4.50(m, 2H), 4.26-4.24(m, 1H), 3.85-3.82(m, 1H), 3.61-3.40(m, 5H), 3.26-3.22(m, 3H), 2.81-1.60(m, 12H), 1.28-1.23(m, 6H).

[0544] [Example 8]: Preparation of 2-(2-(tert-butoxymethyl)-5-fluorophenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compound 8)

[0545] Step 1: 1-Bromo-2-(tert-butoxymethyl)-4-fluorobenzene

[0546] [ka]

[0547] NaH (60%, 600 mg, 15 mmol) was added to a solution of 2-methylpropan-2-ol (7.4 g, 100 mmol) in THF (30 mL) at 0 °C. The mixture was stirred at 0 °C for 0.5 h, and 2-bromo-1-(bromomethyl)-4-fluorobenzene (2.68 g, 10 mmol) was added. The mixture was stirred at 80 °C overnight, cooled to room temperature, quenched with water (50 mL), and extracted with EtOAc (50 mL). The organic layer was dried over Na2SO4. 、 Filtration and concentration under reduced pressure were carried out. The residue was purified by silica gel column (petroleum ether: EtOAc 15:1) to give the desired product as a yellow oil (300 mg). Yield 11% (ESI 261 (M+H) + ).

[0548] Step 2: 2-(tert-butoxymethyl)-4-fluorophenylboronic acid

[0549] [ka]

[0550] n-BuLi (0.4 mL, 2.5 M solution in hexane, 1 mmol) was added dropwise to a solution of 1-bromo-2-(tert-butoxymethyl)-4-fluorobenzene (150 mg, 0.57 mmol) and triisopropyl borate (188 mg, 1 mmol) in THF (5 mL) at −78° C. The mixture was stirred at −78° C. for 1 h and at 25° C. for an additional 1 h. The mixture was quenched with aqueous HCl (2 N) to pH=5 and extracted with EtOAc (10 mL). The organic layer was dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 2:1) to give the desired product (70 mg) as a colorless oil. Yield 54% (ESI 225 (MH) - ).

[0551] Step 3: 2-(2-(tert-butoxymethyl)-5-fluorophenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (compound 8)

[0552] [ka]

[0553] A mixture of 2-(tert-butoxymethyl)-4-fluorophenylboronic acid (75 mg, 0.33 mmol), 2-oxoacetic acid (88 mg, 50% aqueous solution, 0.6 mmol), and (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (91 mg, 0.33 mmol) in CHCN (5 mL) was stirred overnight at 60° C. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC A (33% to 65% MeCN) to give compound 8 as a white solid (22 mg, 13% yield).

[0554] Compound 8 LC / MS ESI 514(M+H) + . 1 H NMR (400MHz, MeOD) δ7.50-7.42(m, 2H), 7.17-7.08(m, 2H), 6.37(d, J=7.2Hz, 1H), 4.81-4.74(m, 2H), 4.55-4.43(m , 1H), 4.17(s, 1H), 3.55-3.32(m, 6H), 3.20-2.95(m, 2H), 2.72-2.52(m, 4H), 2.25-1.55(m, 8H), 1.34-1.28(m, 9H).

[0555] [Example 9]: Preparation of 2-(2-cyclopropylpyridin-3-yl)-2-(3-fluoro-3-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentyl)pyrrolidin-1-yl)acetic acid (Compounds 9-E1 and 9-E2)

[0556] Step 1: Ethyl 2-chloro-2-(2-cyclopropylpyridin-3-yl)acetate

[0557] [ka]

[0558] A solution of ethyl 2-(2-cyclopropylpyridin-3-yl)-2-hydroxyacetate (500 mg, 2.26 mmol) in SOCl (5 mL) was stirred at room temperature for 17 hours. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 4:1) to give the desired product, ethyl 2-chloro-2-(2-cyclopropylpyridin-3-yl)acetate, as a yellow oil (210 mg). Yield 39% (ESI 240 (M+H) + ).

[0559] Step 2: Ethyl 2-(2-cyclopropylpyridin-3-yl)-2-(3-fluoro-3-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentyl)pyrrolidin-1-yl)acetate

[0560] [ka]

[0561] A mixture of 7-(5-(3-fluoropyrrolidin-3-yl)pentyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (230 mg, 0.632 mmol), ethyl 2-chloro-2-(2-cyclopropylpyridin-3-yl)acetate (378 mg, 1.580 mmol), and KCO (262 mg, 1.896 mmol) in acetonitrile (8 mL) was stirred at 60° C. for 16 hours. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (DCM:MeOH 20:1) to give the desired product, ethyl 2-(2-cyclopropylpyridin-3-yl)-2-(3-fluoro-3-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentyl)pyrrolidin-1-yl)acetate (120 mg) as a yellow oil. Yield 38% (ESI 495 (M+H) + ).

[0562] Step 3: 2-(2-cyclopropylpyridin-3-yl)-2-(3-fluoro-3-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentyl)pyrrolidin-1-yl)acetic acid (Compounds 9-E1 and 9-E2)

[0563] [ka]

[0564] Ethyl 2-(2-cyclopropylpyridin-3-yl)-2-(3-fluoro-3-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentyl)pyrrolidin-1-yl)acetate (120 mg, 0.24 mmol) was treated with LiOH—HO (40 mg, 0.97 mmol) in MeOH (4 mL) and HO (1 mL) at 60° C. for 2 h. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC A (30% to 65% MeCN) to give compound 9 as a white solid (60 mg, 53% yield). The racemic product was separated by preparative chiral SFC F to give diastereomeric products, compound 9-E1 (10 mg) and compound 9-E2 (10 mg), each as a mixture of two stereoisomers, as white solids.

[0565] Compound 9-E1 (mixture of two stereoisomers) LC / MS ESI 467.4 (M+H) + . 1 H NMR (400MHz, MeOD) δ8.32(s, 1H), 8.03(d, J=7.3Hz, 1H) 7.28(m, 2H), 6.41(d, J=7.3Hz, 1H), 4.81(s, 1H), 3.40-2.95(m, 6H), 2.80-2.50(m, 5H), 2.25-1.20(m, 12H), 1.10-0.85(m, 4H). Chiral SFC F(45%MeOH): ee76%, Rt=2.72 min.

[0566] Compound 9-E1 (mixture of two stereoisomers) LC / MS ESI 467.4 (M+H) + . 1 H NMR (400MHz, MeOD) δ8.39(s, 1H), 8.01(d, J=7.3Hz, 1H) 7.33(m, 2H), 6.47(d, J=7.3Hz, 1H), 4.96(s, 1H), 3.45-2.95(m, 6H), 2.80-2.50(m, 5H), 2.25-1.20(m, 12H), 1.10-0.85(m, 4H). Chiral SFC F(45%MeOH): ee53%, Rt=3.36 min.

[0567] [Example 10]: Preparation of 2-(2-cyclopropylpyridin-3-yl)-2-((R)-3-(4-(4-methoxy-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compound 10)

[0568] Step 1: Ethyl 2-(2-cyclopropylpyridin-3-yl)-2-((R)-3-(4-(4-methoxy-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate

[0569] [ka]

[0570] A mixture of (R)-5-methoxy-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine hydrochloride (215 mg, 0.63 mmol), ethyl 2-chloro-2-(2-cyclopropylpyridin-3-yl)acetate (150 mg, 0.63 mmol) and diisopropylethylamine (245 mg, 1.89 mmol) in acetonitrile (8 mL) was stirred under reflux for 24 hours. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (DCM:MeOH 20:1) to give the desired product ethyl 2-(2-cyclopropylpyridin-3-yl)-2-((R)-3-(4-(4-methoxy-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate as a yellow oil (80 mg). Yield 25% (ESI 509 (M+H) + ).

[0571] Step 2: 2-(2-cyclopropylpyridin-3-yl)-2-((R)-3-(4-(4-methoxy-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (compound 10)

[0572] [ka]

[0573] Ethyl 2-(2-cyclopropylpyridin-3-yl)-2-((R)-3-(4-(4-methoxy-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (105 mg, 0.21 mmol) was treated with LiOH—HO (87 mg, 2.1 mmol) in MeOH (4 mL) and HO (1 mL) at room temperature for 17 h. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC A (30% to 65% MeCN) to give compound 10 as a white solid (25 mg, 25% yield).

[0574] Compound 10 LC / MS ESI 481(M+H) + . 1 H NMR (400MHz, MeOD) δ8.26-8.25(m, 1H), 8.08-8.06(m, 1H), 7.15-7.11(m, 1H), 6.26-6.24(m, 1H), 4.57-4.52(m, 1 H), 4.08-4.07(m, 1H), 3.85(s, 1H), 3.46-3.41(m, 2H), 3.25-2.50(m, 7H), 2.10-1.50(m, 8H), 1.10-0.80(m, 4H).

[0575] [Example 11]: Preparation of 2-(2-cyclobutylpyridin-3-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 11-E1 and 11-E2)

[0576] Step 1: 3-Bromo-2-cyclobutylpyridine

[0577] [ka]

[0578] A mixture of magnesium turnings (612 mg, 25.5 mmol) and cyclobutyl bromide (3.4 g, 25.5 mmol) in anhydrous THF (50 mL) was heated at 60 °C for 3 h until the magnesium was completely dissolved. The solution was cooled to -78 °C and treated with ZnCl (3.48 g, 25.5 mmol) in THF (50 mL). The resulting white suspension was gradually warmed to room temperature and stirred for 1 h. Next, a solution of 2,3-dibromopyridine (4 g, 17 mmol) and Pd(PPh) (983 mg, 0.85 mmol) in THF (30 mL) was added to the reaction mixture. The mixture was stirred at 60 °C under N for 1 h, diluted with water (100 mL), and extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc = 10:1) to give the desired product 3-bromo-2-cyclopropylpyridine as a yellow oil (2.3 g). Yield 94% (ESI 212 (M+H) + ).

[0579] Step 2: Ethyl 2-(2-cyclobutylpyridin-3-yl)-2-hydroxyacetate

[0580] [ka]

[0581] To a solution of EtMgBr (1 M, 6.54 mL, 6.54 mmol) in THF (20 mL) was added n-BuLi (2.5 M, 5.2 mL, 13.08 mmol) at 0 °C under N2. The solution was stirred at 0 °C for 30 min, and then a solution of 3-bromo-2-cyclobutylpyridine (2.3 g, 10.9 mmol) in THF (5 mL) was added at -10 °C. The mixture was stirred at that temperature for 30 min. Next, ethyl 2-oxoacetate (50% solution in toluene, 8.9 g, 43.6 mmol) was added, and the reaction was stirred at 0 °C for 2 h, poured into 20 mL of saturated K2CO3 solution, and extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc = 2:1) to give the desired product ethyl 2-(2-cyclopropylpyridin-3-yl)-2-hydroxyacetate as a yellow oil (1.1 g). Yield 43% (ESI 236 (M+H) + ).

[0582] Step 3: Ethyl 2-chloro-2-(2-cyclobutylpyridin-3-yl)acetate

[0583] [ka]

[0584] A solution of ethyl 2-(2-cyclobutylpyridin-3-yl)-2-hydroxyacetate (480 mg, 2 mmol) in SOCl (5 mL) was stirred at room temperature overnight. The mixture was concentrated under reduced pressure, adjusted to pH = 8 with aqueous NaHCO, and extracted with EtOAc (3 x 20 mL). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc = 10:1) to give the desired product, ethyl 2-chloro-2-(2-cyclobutylpyridin-3-yl)acetate, as a yellow oil (310 mg). Yield 47% (ESI 254 (M+H) + ).

[0585] Step 4: Ethyl 2-(2-cyclobutylpyridin-3-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate

[0586] [ka]

[0587] A mixture of ethyl 2-chloro-2-(2-cyclobutylpyridin-3-yl)acetate (310 mg, 1.2 mmol), (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (370 mg, 1.35 mmol) and diisopropylethylamine (464 mg, 3.6 mmol) in acetonitrile (10 mL) was stirred at 50° C. overnight. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (DCM:MeOH = 0% to 10%) to give the desired product ethyl 2-(2-cyclobutylpyridin-3-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate as a colorless oil (165 mg, 0.36 mmol). Yield 28% (ESI 493 (M+H) + ).

[0588] Step 5: 2-(2-Cyclobutylpyridin-3-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 11-E1 and 11-E2)

[0589] [ka]

[0590] Ethyl 2-(2-cyclobutylpyridin-3-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (165 mg, 0.36 mmol) was treated with LiOH—HO (70 mg, 1.8 mmol) in MeOH (4 mL) and HO (1 mL) at room temperature for 2 h. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC A (30% to 60% MeCN) to give compound 11 as a white solid (110 mg, 70% yield). The racemic product was separated by preparative chiral SFC A to give diastereomeric products 11-E1 (35 mg) and 11-E2 (35 mg) as white solids.

[0591] Compound 11-E1 LC / MS ESI 465(M+H) + . 1 H NMR (500MHz, MeOD) δ8.54(d, J=4.5Hz,1H), 8.02(d, J=7.5Hz,1H), 7.29-7.23(m, 2H), 6.43(d, J=7.0Hz,1H), 4.71(s, 1H), 4.26-4.15(m, 2H), 3.54- 3.38(m, 4H), 3.22-3.07(m, 4H), 2.75-2.55(m, 5H), 2.44-2.33(m, 3H), 2. 13-2.05(m, 3H), 1.92-1.87(m, 3H), 1.79-1.74(m, 2H), 1.67-1.63(m, 2H). Chiral SFC E (45% MeOH): ee 100%, Rt = 2.99 min.

[0592] Compound 11-E2 LC / MS ESI 465(M+H) + . 1H NMR (500MHz, MeOD) δ8.55(d, J=4.5Hz,1H), 7.99(d, J=7.5Hz,1H), 7.30-7.22(m, 2H), 6.44(d, J=6.0Hz,1H), 4.80(s, 1H), 4.20-4.16(m, 2 H), 3.51-3.39(m, 5H), 3.24-3.22(m, 1H), 3.01-2.91(m, 2H), 2.75-2.59(m, 5H), 2.42-2.30(m, 3H), 2.08-2.02(m, 3H), 1.92-1.64(m, 7H). Chiral SFC E (45% MeOH): ee 100%, Rt = 5.21 min.

[0593] [Example 12]: Preparation of 2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)-2-(2-(tetrahydro-2H-pyran-4-yl)phenyl)acetic acid (Compound 12)

[0594] Step 1: Methyl 2-(2-iodophenyl)acetate

[0595] [ka]

[0596] To a solution of 2-(2-iodophenyl)acetic acid (3.67 g, 14 mmol) in MeOH (35 mL) was added 2 mL of concentrated H2SO4. The reaction was stirred at 85 °C for 2 h, concentrated under reduced pressure, adjusted to pH = 7-8 with saturated NaHCO3 solution, and extracted with EtOAc (2 x 30 mL). The combined organic phases were washed with brine, dried over Na2SO4, and concentrated to give the desired product, methyl 2-(2-iodophenyl)acetate (3.7 g), as an orange-red oil. Yield 96% (ESI 277 (M+H) + ).

[0597] Step 2: Methyl 2-(2-(3,6-dihydro-2H-pyran-4-yl)phenyl)acetate

[0598] [ka]

[0599] A mixture of methyl 2-(2-iodophenyl)acetate (828 mg, 3.0 mmol), 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (945 mg, 4.5 mmol), PdCl(PPh) (89 mg, 0.12 mmol), and NaCO (636 mg, 6 mmol) in 1,4-dioxane (30 mL) and water (6 mL) was stirred under N at 90 °C overnight. The mixture was diluted with HO (10 mL) and extracted with EtOAc (20 mL). The organic phase was concentrated under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product tert-butyl 2-(3-(2-methoxypropan-2-yl)isochroman-5-yl)acetate as a pale orange oil (488 mg). Yield 70% (ESI 255.1 (M+Na) + ).

[0600] Step 3: Methyl 2-(2-(tetrahydro-2H-pyran-4-yl)phenyl)acetate

[0601] [ka]

[0602] A mixture of tert-butyl 2-(3-(2-methoxypropan-2-yl)isochroman-5-yl)acetate (488 mg, 2.1 mmol) and Pd(OH)2 / C (20%, 120 mg) in MeOH (20 mL) was stirred under balloon hydrogen at 35° C. for 6 h. The reaction was filtered and concentrated under reduced pressure to give the desired product, methyl 2-(2-(tetrahydro-2H-pyran-4-yl)phenyl)acetate (460 mg), as a colorless oil. Yield 95% (ESI 235.2 (M+H) + ).

[0603] Step 4: tert-butyl 2-bromo-2-(3-(2-methoxypropan-2-yl)isochroman-5-yl)acetate

[0604] [ka]

[0605] To a solution of 2-(2-(tetrahydro-2H-pyran-4-yl)phenyl)acetate (234 mg, 1.0 mmol) in THF (10 mL) was added dropwise lithium diisopropylamide solution, 2.0 M in THF / hexane (1.0 mL, 2.0 mmol) at −78° C. The reaction was stirred at −78° C. for 20 minutes. Next, a solution of chlorotrimethylsilane (218 mg, 2.0 mmol) in THF (0.5 mL) was added, and the reaction was stirred at −78° C. for an additional 10 minutes. Next, a solution of NBS (356 mg, 2.0 mmol) in THF (4 mL) was added, and the reaction was stirred at −78° C. for 10 minutes, poured into water (10 mL), and extracted with EtOAc (20 mL). The organic phase was washed with saturated NaHCO3 solution and water and concentrated under reduced pressure to give the crude product (320 mg) as a yellow oil. Yield 48% (ESI 315.1 (M+H) + ).

[0606] Step 5: Methyl 2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)-2-(2-(tetrahydro-2H-pyran-4-yl)phenyl)acetate

[0607] [ka]

[0608] A mixture of tert-butyl 2-bromo-2-(3-(2-methoxypropan-2-yl)isochroman-5-yl)acetate (320 mg, 47% purity, 0.48 mmol), (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (132 mg, 0.48 mmol), and diisopropylethylamine (186 mg, 1.44 mmol) in acetonitrile (12 mL) was stirred at room temperature for 1 hour. The mixture was diluted with water (8 mL) and extracted with EtOAc (25 mL). The organic phase was washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by preparative HPLC (NH4HCO3, HO / MeCN) to give methyl 2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)-2-(2-(tetrahydro-2H-pyran-4-yl)phenyl)acetate as a white solid (135 mg). Yield 55% (ESI 508.1 (M+H) + ).

[0609] Step 6: Preparation of 2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)-2-(2-(tetrahydro-2H-pyran-4-yl)phenyl)acetic acid (compound 12)

[0610] [ka]

[0611] A solution of methyl 2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)-2-(2-(tetrahydro-2H-pyran-4-yl)phenyl)acetate (115 mg) in THF (5 mL) was treated with LiOH (1 M in HO, 2.7 mL) at room temperature overnight. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC A (30% to 64% MeCN / HO) to give compound 12 (82 mg) as a white solid.

[0612] Compound 12 LC / MS ESI 494.2(M+H) + . 1 H NMR (500MHz, MeOD) δ7.64(m, 1H), 7.41(m, 2H), 7.28(m, 1H), 7.16(m, 1H), 6.39(m, 1H), 4.94(m, 1H), 4.22(m, 1H), 4.01(m, 2H), 3.55-3.64(m, 4H), 3.40(m, 3H), 3.33-3.37(m, 3H), 2.72(t, J=6.5Hz, 2H), 2.57(t, J=6.5Hz, 2H), 2.01-2.24(m, 2H), 1.88-1.98(m, 4H), 1.61-1.77(m, 6H).

[0613] [Example 13]: Preparation of 2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)-2-(2-(tetrahydro-2H-pyran-4-yl)phenyl)acetic acid (Compounds 13-E1 and 13-E2)

[0614] Step 1: Methyl 2-(2-chloropyridin-3-yl)acetate

[0615] [ka]

[0616] To a solution of 2-(2-chloropyridin-3-yl)acetic acid (1.71 g, 10 mmol) in MeOH (35 mL) was added concentrated H2SO4 (2 mL). The reaction was stirred at 85 °C for 2 h, concentrated under reduced pressure, adjusted to pH = 7-8 with saturated NaHCO3 solution, and extracted with EtOAc (2 x 30 mL). The combined organic phases were washed with brine, dried over Na2SO4, and concentrated to give the desired product, methyl 2-(2-chloropyridin-3-yl)acetate, as an orange oil (1.51 g, 81% yield). (ESI 186 (M+H) + ).

[0617] Step 2: Methyl 2-(2-(3,4-dihydro-2H-pyran-6-yl)pyridin-3-yl)acetate

[0618] [ka]

[0619] A mixture of methyl 2-(2-chloropyridin-3-yl)acetate (372 mg, 2.0 mmol), 2-(3,4-dihydro-2H-pyran-6-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (420 mg, 2.0 mmol), X-Phos Pd G4 (68 mg, 0.08 mmol), and KCO (552 mg, 4 mmol) in 1,4-dioxane (10 mL) and water (2.5 mL) was heated in a microwave at 115° C. for 2 hours. The mixture was diluted with HO (10 mL) and extracted with EtOAc (20 mL). The organic phase was concentrated under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product methyl 2-(2-(3,4-dihydro-2H-pyran-6-yl)pyridin-3-yl)acetate as a pale orange oil (308 mg). Yield 66% (ESI 234.1 (M+H) + ).

[0620] Step 3: Methyl 2-(2-(tetrahydro-2H-pyran-4-yl)phenyl)acetate

[0621] [ka]

[0622] A mixture of methyl 2-(2-(3,4-dihydro-2H-pyran-6-yl)pyridin-3-yl)acetate (302 mg, 1.3 mmol) and Pd(OH) / C (20%, 100 mg) in MeOH (16 mL) was stirred under a balloon of H at 35° C. for 4 h. The reaction was filtered and concentrated under reduced pressure to give the desired product, methyl 2-(2-(tetrahydro-2H-pyran-2-yl)pyridin-3-yl)acetate, as an orange oil (301 mg). Yield: 94% (ESI 236.2 (M+H)). + ).

[0623] Step 4: Methyl 2-bromo-2-(2-(tetrahydro-2H-pyran-2-yl)pyridin-3-yl)acetate

[0624] [ka]

[0625] To a solution of 2-(2-(tetrahydro-2H-pyran-4-yl)phenyl)acetate methyl 2-(2-(tetrahydro-2H-pyran-2-yl)pyridin-3-yl)acetate (301 mg, 1.28 mmol) in THF (8 mL) was added dropwise lithium diisopropylamide solution 2.0 M in THF / hexane (1.28 mL, 2.56 mmol) at −78° C. The reaction was stirred at −78° C. for 20 minutes. Next, a solution of chlorotrimethylsilane (278 mg, 2.56 mmol) in THF (0.5 mL) was added and the reaction was stirred at −78° C. for an additional 10 minutes. Next, a solution of NBS (456 mg, 2.56 mmol) in THF (4 mL) was added and the reaction was stirred at −78° C. for 10 minutes, poured into water (10 mL), and extracted with EtOAc (20 mL). The organic phase was washed with saturated NaHCO3 solution and water and concentrated under reduced pressure to give the crude product as a yellow oil (390 mg, purity 40%). Yield 39%. (ESI 315.1 (M+H) + ).

[0626] Step 5: Methyl 2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)-2-(2-(tetrahydro-2H-pyran-2-yl)pyridin-3-yl)acetate

[0627] [ka]

[0628] A mixture of methyl 2-bromo-2-(2-(tetrahydro-2H-pyran-2-yl)pyridin-3-yl)acetate (390 mg, 40% purity), (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (137 mg, 0.50 mmol), and diisopropylethylamine (194 mg, 1.50 mmol) in acetonitrile (10 mL) was stirred at room temperature for 2 hours. The mixture was diluted with water (8 mL) and extracted with EtOAc (25 mL). The organic phase was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by preparative HPLC A (40% to 75% MeCN) to give the desired product, methyl 2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)-2-(2-(tetrahydro-2H-pyran-2-yl)pyridin-3-yl)acetate (105 mg) as a white solid. Yield 41% (ESI 509.2 (M+H) + ).

[0629] Step 6: Preparation of 2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)-2-(2-(tetrahydro-2H-pyran-4-yl)phenyl)acetic acid (Compounds 13-E1 and 13-E2)

[0630] [ka]

[0631] A solution of ethyl 2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)-2-(2-(tetrahydro-2H-pyran-4-yl)phenyl)acetate (71 mg, 0.14 mmol) in THF (5 mL) was treated with LiOH (1 M in HO, 2.1 mL) at room temperature overnight. The mixture was adjusted to pH 5-6 with aqueous HCl (1N), concentrated under reduced pressure, and the residue was purified by preparative HPLC A (30% to 64% MeCN) to give the diastereomeric products Compound 13-E1 (23 mg) and Compound 13-E2 ​​(12 mg) as white solids, each a mixture of two stereoisomers.

[0632] Compound 13-E1 (mixture of two stereoisomers) LC / MS ESI 495.3 (M+H) + . 1 H NMR (500MHz, MeOD) δ8.46(m, 1H), 8.21(m, 1H), 7.33(m, H), 7.16(m, 1H), 6.38(m, 1H), 5.12(m, 1H), 4.41(m, 1H), 4.05(m, 2H), 3.75(m, 1H), 3.75-3.37(m, 4H), 3.30-2.80(m, 2H), 2.73-2.69(m, 4H), 2.64-2.54(m, 2H), 1.96(m, 1H), 1.91-1.87(m, 6H), 1.78-1.58(m, 7H).

[0633] Compound 13-E2 ​​(mixture of two stereoisomers) LC / MS ESI 495.3 (M+H) + . 1 H NMR (500MHz, MeOD) δ8.46(m, 1H), 8.14(m, 1H), 7.34(m, 1H), 7.16(m, 1H), 6.38(m, 1H), 5.04(m, 1H), 4.11(m, 2H), 3.68(m , 1H), 3.69-3.37(m, 5H), 3.11-2.98(m, 2H), 2.87-2.70(m, 4H), 2.56-2.54(m, 2H), 2.06-1.80(m, 7H), 1.78-1.59(m, 7H).

[0634] [Example 14]: Preparation of 2-(2-cyclopropylpyridin-3-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 14-E1 and 14-E2)

[0635] Step 1: Sodium (2-cyclopropylpyridin-3-yl)(hydroxy)methanesulfonate

[0636] [ka]

[0637] 2-Bromo-3-pyridinecarboxaldehyde (1 g, 5.38 mmol), cyclopropylboronic acid (1.385 g, 16.13 mmol), and sodium carbonate (2.279 g, 21.50 mmol) were dissolved in 1,2-dimethoxyethane (20 mL) and water (5 mL). The mixture was flushed with argon, and bis(triphenylphosphine)palladium(II) dichloride (0.377 g, 0.538 mmol) was added. The reaction was sealed and heated at 100 °C for 16 h, diluted with water, and extracted with diethyl ether. The organic layer was washed twice with water, and a solution of sodium bisulfite (1.119 g, 10.75 mmol) in water and a small amount of methanol was added. The diethyl ether was evaporated under reduced pressure, and the resulting water / methanol mixture was used directly in the next step.

[0638] Step 2: 2-(2-cyclopropylpyridin-3-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetonitrile

[0639] [ka]

[0640] A water / methanol mixture containing sodium (2-cyclopropylpyridin-3-yl)(hydroxy)methanesulfonate (1.352 g, 5.38 mmol) was added to (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (0.963 g, 3.50 mmol), followed by potassium cyanide (1.752 g, 26.9 mmol). After 16 h, a small amount of methanol was added. After 64 h, the reaction mixture was diluted with water and extracted three times with ethyl acetate. The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure to give the desired product, 2-(2-cyclopropylpyridin-3-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetonitrile (1.511 g). Yield 65% (ESI 430 (MH) - ).

[0641] Step 3: 2-(2-cyclopropylpyridin-3-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetamide

[0642] [ka]

[0643] To a solution of 2-(2-cyclopropylpyridin-3-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetonitrile (1.511 g, 3.5 mmol) in dichloromethane (10 mL) was added sulfuric acid (25 mL, 469 mmol). The reaction was stirred at room temperature for 24 hours, then quenched with ice, neutralized with aqueous ammonia, and extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, concentrated, and the residue was purified by reverse-phase chromatography (10 mM aqueous ammonium bicarbonate, 20% to 60% acetonitrile) to give the desired product, 2-(2-cyclopropylpyridin-3-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetamide (399 mg). Yield 25% (ESI 450 (M+H) + ).

[0644] Step 4: 2-(2-cyclopropylpyridin-3-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 14-E1 and 14-E2)

[0645] [ka]

[0646] A solution of 2-(2-cyclopropylpyridin-3-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetamide (399 mg, 0.887 mmol) in hydrochloric acid (10 mL, 40 mmol, 4N aqueous solution) was stirred at 70° C. for 88 hours. The mixture was concentrated, and the residue was dissolved in water and lyophilized. The residue was dissolved in water (10 mL) and purified using reverse-phase chromatography to give 2-(2-cyclopropylpyridin-3-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid Compound 14 (311 mg) as a diastereomeric mixture. Yield 78% (ESI 451 (M+H) + The mixture was separated by chiral SFC to give the diastereomeric products, Compound 14-E1 (107 mg) and Compound 14-E2 (100 mg). Method: Water Acquity UPC2 (Binary Solvent Manager, Isocratic Solvent Manager, Sample Manager, Column Manager 30S, Convergence Manager, PDA Detector, Acquity QDa Detector); Column: Chiralpak IC for SFC (100 × 4.6 mm, 5 μm). Temperature: 35 °C. Backpressure: 170 bar. Flow rate: 2.5 mL / min. Eluent A: CO2. Eluent B: methanol + 20 mM ammonia. Gradient: t0 = 5% B, t2.5 min = 50% B, t30 min = 50% B, Post Time: 0.5 min. Detection: PDA: 210-320 nm. Detection MS: ESI, mass range: 700-1250 (positive) 1 Hz, Cone: 15 V.

[0647] Compound 14-E1: 107mg, LC / MS ESI 451(M+H) + . 1H NMR (400MHz, methanol-d4) δ8.37 (dd, J=4.7, 1.7Hz, 1H), 7.97 (dd, J=8.0, 1.8Hz, 1H) , 7.24-7.08(m, 2H), 6.40(d, J=7.3Hz, 1H), 5.04(s, 1H), 4.22-4.13(m, 1H), 3.55-3 .33(m, 5H), 3.23-3.10(m, 2H), 2.79-2.66(m, 2H), 2.66-2.46(m, 3H), 2.22-2.05(m , 2H), 1.94-1.82(m, 2H), 1.80-1.45(m, 5H), 1.27-1.15(m, 1H), 1.07-0.88(m, 3H).

[0648] Compound 14-E2: 100mg, LC / MS ESI 451(M+H) + . 1 H NMR (400MHz, methanol-d4) δ8.38 (dd, J=4.8, 1.7Hz, 1H), 7.94 (dd, J=7.8, 1.7Hz, 1H), 7.24-7. 13(m, 2H), 6.40(d, J=7.3Hz, 1H), 5.13(s, 1H), 4.25-4.14(m, 1H), 3.58-3.32(m, 6H), 3.27-3 .14(m, 1H), 3.07-2.95(m, 1H), 2.78-2.66(m, 2H), 2.64-2.49(m, 2H), 2.49-2.38(m, 1H), 2.1 8-2.02(m, 2H), 1.95-1.82(m, 2H), 1.81-1.45(m, 5H), 1.30-1.15(m, 1H), 1.06-0.86(m, 3H).

[0649] [Example 15]: Preparation of 2-(2-cyclopropylphenyl)-2-((R)-3-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentyloxy)pyrrolidin-1-yl)acetic acid (Compounds 15-E1 and 15-E2)

[0650] Step 1: 2-(2-cyclopropylphenyl)-2-((R)-3-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentyloxy)pyrrolidin-1-yl)acetic acid (Compounds 15-E1 and 15-E2)

[0651] [ka]

[0652] To a solution of (R)-7-(5-(pyrrolidin-3-yloxy)pentyl)-1,2,3,4-tetrahydro-1,8-naphthyridine dihydrochloride (200 mg, 0.55 mmol) in DMF (2 mL) was added 2-cyclopropylphenylboronic acid (116 mg, 0.72 mmol) and 2-oxoacetic acid (56 mg, 0.6 mmol). The reaction mixture was stirred at 80 °C for 1 h. The reaction mixture was purified by preparative HPLC (40% to 65% MeCN) to give 90 mg of racemic compound 15. The racemic products were separated by preparative chiral SFC A to give diastereomeric products, compound 15-E1 (23 mg) and compound 15-E2 (22 mg), as white solids.

[0653] Compound 15-E1 LC / MS ESI 464.2(M+H) + . 1 H NMR (500MHz, MeOD) δ7.61(d, J=7.1Hz, 1H), 7.31(m, 2H), 7.16(dd, J=21.5, 7.4H z, 2H), 6.37(d, J=7.3Hz, 1H), 5.35(s, 1H), 4.23(s, 1H), 3.65(m, 1H), 3.49(t, J= 6.4Hz, 2H), 3.42-3.36(m, 2H), 3.30-2.99(m, 3H), 2.70(t, J=6.3Hz, 2H), 2.53(t , J=7.5Hz, 2H), 2.21(m, 3H), 1.88(m, 2H), 1.12-0.94(m, 3H), 0.70-0.51(m, 1H). Chiral SFC A (40%MeOH): ee98%, Rt=2.46 min.

[0654] Compound 15-E2 LC / MS ESI 464.2(M+H) + . 1H NMR (500MHz, MeOD) δ7.54(d, J=7.5Hz, 1H), 7.17(m, 2H), 7.07-6.97(m, 2H), 6. 26(d, J=7.3Hz, 1H), 5.08(s, 1H), 4.06(s, 1H), 3.43-3.24(m, 5H), 3.14-2.98(m , 2H), 2.59(t, J=6.2Hz, 2H), 2.48-2.36(m, 2H), 2.15(m, 3H), 1.81-1.70(m, 2H) ), 1.63-1.45(m, 4H), 1.39-1.26(m, 2H), 0.96-0.77(m, 3H), 0.55-0.42(m, 1H). Chiral SFC A (40%MeOH): ee98%, Rt=3.5 min.

[0655] [Example 16]: Preparation of 2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)-2-(2-(tetrahydrofuran-2-yl)phenyl)acetic acid (Compounds 16-E1 and 16-E2)

[0656] Step 1: Methyl 2-(2-(furan-2-yl)phenyl)acetate

[0657] [ka]

[0658] To a solution of methyl 2-(2-iodophenyl)acetate (552 mg, 2 mmol) in anhydrous DMF (5 mL) was added furan-2-ylboronic acid (224 mg, 2 mmol), tris(dibenzylideneacetone)dipalladium(0) (91.5 mg, 0.1 mmol), X-Phos (47.6 mg, 0.1 mmol), and potassium phosphate (424 mg, 2 mmol). The mixture was stirred at 60 °C under N for 1 h. The reaction was allowed to cool and diluted with ethyl acetate (20 mL) and water (20 mL). The organic layer was separated, and the aqueous layer was extracted three times with ethyl acetate (2 x 20 mL). The combined organic layers were washed with brine and dried over anhydrous NaSO. After filtration and concentration, the residue was purified chromatographically (Combiflash) using 5% to 20% EtOAc / petroleum ether as eluent to give 340 mg (78.3%) of methyl 2-(2-(furan-2-yl)phenyl)acetate; (ESI 217 (M+H) + ).

[0659] Step 2: Methyl 2-(2-(tetrahydrofuran-2-yl)phenyl)acetate

[0660] [ka]

[0661] To a solution of methyl 2-(2-(furan-2-yl)phenyl)acetate (340 mg, 1.57 mmol) in anhydrous MeOH (10 mL) was added Pd / C (30 mg). The mixture was stirred under a H atmosphere (balloon) at 40 °C for 3 h. After completion of the reaction, the catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified chromatographically (Combiflash) using 5% to 20% EtOAc / petroleum ether as the eluent to give methyl 2-(2-(tetrahydrofuran-2-yl)phenyl)acetate (290 mg, 84%) as an oil. (ESI 221 (M+H) + ).

[0662] Step 3: Methyl 2-bromo-2-(2-(tetrahydrofuran-2-yl)phenyl)acetate

[0663] [ka]

[0664] A solution of methyl 2-(2-(tetrahydrofuran-2-yl)phenyl)acetate (220 mg, 1 mmol) in THF (10 mL) was cooled to −78 °C under N and treated with LDA (1.25 mL, 2.5 mmol, 2 M solution in THF). The reaction was stirred for 0.5 h and treated with TMSCl (324 mg, 3 mmol) and, after 0.25 h, NBS (534 mg, 3 mmol) as a solution in 10 mL of dry THF. The mixture was stirred at −78 °C for 0.5 h and quenched by the addition of water (10 mL). The mixture was extracted with ethyl acetate (2×20 mL). The combined organic layers were washed with brine and dried over anhydrous NaSO. After filtration and concentration, the residue was purified chromatographically (Combiflash) using 0% to 20% EtOAc / petroleum ether as eluent to give methyl 2-bromo-2-(2-(tetrahydrofuran-2-yl)phenyl)acetate (210 mg, 70.5%); (ESI 299 (M+H) + ).

[0665] Step 4: Methyl 2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)-2-(2-(tetrahydrofuran-2-yl)phenyl)acetate

[0666] [ka]

[0667] To a solution of methyl 2-bromo-2-(2-(tetrahydrofuran-2-yl)phenyl)acetate (100 mg, 0.33 mmol) in acetonitrile (5 mL) was added (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (92 mg, 0.33 mmol) and diisopropylethylamine (129 mg, 1 mmol). The reaction was stirred for 2 hours, diluted with water (10 mL), and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine and dried over anhydrous NaSO. After filtration and concentration, the residue was purified chromatographically (Combiflash) using 20% ​​to 80% EtOAc / petroleum ether as eluent to give methyl 2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)-2-(2-(tetrahydrofuran-2-yl)phenyl)acetate (90 mg, 54.4%). (ESI 494 (M+H) + ).

[0668] Step 5: 2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)-2-(2-(tetrahydrofuran-2-yl)phenyl)acetic acid (Compounds 16-E1 and 16-E2)

[0669] [ka]

[0670] To a solution of methyl 2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)-2-(2-(tetrahydrofuran-2-yl)phenyl)acetate (90 mg, 0.18 mmol) in methanol (5 mL) was added LiOH (9 mg, 0.4 mmol) and water (2 mL). The reaction was stirred for 5 hours, filtered, and concentrated under reduced pressure. The residue was purified using reverse-phase semi-preparative HPLC to give the diastereomeric products Compound 16-E1 (40 mg, 45.7% yield) and Compound 16-E2 (19 mg, 22.7% yield), each a mixture of two stereoisomers.

[0671] Compound 16-E1 (mixture of two stereoisomers): LC / MS ESI 480.2 (M+H) + . 1 H NMR (500MHz, MeOD) δ7.69(dd, J=11.4, 7.8Hz, 1H), 7.55(d, J=7.8Hz, 1H), 7.41(t, J=7.5Hz, 1H), 7.38-7.29(m, 1H), 7.15(d, J=7. 3Hz, 1H), 6.39(dd, J=7.3, 2.7Hz, 1H), 5.30(dt, J=33.4, 7.0Hz, 1H), 4.97(s, 1H), 4.17(d, J=21.0Hz, 1H), 4.08(dd, J=14.1, 6.9H) z, 1H), 3.90(ddt, J=14.0, 9.6, 6.9Hz, 1H), 3.57(s, 1H), 3.51-3.35(m, 4H), 3.29-2.98(m, 3H), 2.71(t, J=6.3Hz, 2H), 2.56(t, J= 7.6Hz, 2H), 2.52-2.42(m, 1H), 2.18-1.94(m, 5H), 1.88(dd, J=11.5, 6.1Hz, 2H), 1.77-1.69(m, 2H), 1.62(dd, J=13.6, 6.7Hz, 2H).

[0672] Compound 16-E2 (mixture of two stereoisomers) LC / MS ESI 480.2 (M+H) + . 1H NMR (500MHz, MeOD) δ7.65(d, J=5.5Hz, 1H), 7.46(d, J=7.6Hz, 1H), 7.41-7.30(m, 2H), 7.16(d, J=7.3Hz , 1H), 6.39(dd, J=7.3, 1.6Hz, 1H), 5.23-5.10(m, 1H), 4.96(s, 1H), 4.19-4.06(m, 2H), 3.93-3.84(m, 1 H), 3.57(s, 1H), 3.50-3.36(m, 5H), 3.16-2.96(m, 2H), 2.75-2.65(m, 2H), 2.56(t, J=7.4Hz, 2H), 2.45 -2.35(m, 1H), 2.16-1.99(m, 5H), 1.88(dd, J=11.4, 5.8Hz, 2H), 1.76-1.68(m, 2H), 1.65-1.59(m, 2H).

[0673] [Example 17]: Preparation of 2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)-2-(2-(tetrahydro-2H-pyran-2-yl)phenyl)acetic acid (Compound 17)

[0674] Step 1: Methyl 2-(2-(3,4-dihydro-2H-pyran-6-yl)phenyl)acetate

[0675] [ka]

[0676] To a solution of methyl 2-(2-iodophenyl)acetate (1.3 g, 4.8 mmol) in anhydrous DME (20 mL) and EtOH (5 mL) was added 3,4-dihydro-2H-pyran-6-boronic acid pinacol ester (1.0 g, 4.8 mmol), tetrakis(triphenylphosphine)palladium(0) (277 mg, 0.24 mmol), and sodium carbonate (1.0 g, 9.6 mmol), and the mixture was heated at 100 °C for 12 h under N. The mixture was allowed to cool to room temperature and diluted with ethyl acetate (50 mL) and water (10 mL). The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (3 x 50 mL). The combined organic phases were washed with brine and dried over anhydrous NaSO. After filtration and concentration, the residue was chromatographed (Combiflash) using 0% to 20% EtOAc / petroleum ether as eluent to give methyl 2-(2-(3,4-dihydro-2H-pyran-6-yl)phenyl)acetate (0.4 g, 36%) as an oil. (ESI 233.1 (m+1) + ).

[0677] Step 2: Methyl 2-(2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate

[0678] [ka]

[0679] A mixture of methyl 2-(2-(3,4-dihydro-2H-pyran-6-yl)phenyl)acetate (300 mg, 1.3 mmol) and Pd(OH)2 / C (100 mg) in MeOH (25 mL) was hydrogenated (balloon) at 35 °C for 3 h. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure. The resulting residue was purified chromatographically (Combiflash) using 0% to 20% EtOAc / petroleum ether as eluent to give methyl 2-(2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate (180 mg, 60%) as an oil. (ESI 235.1 (m+1) + ).

[0680] Step 3: Methyl 2-bromo-2-(2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate

[0681] [ka]

[0682] To a stirring solution of methyl 2-(2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate (150 mg, 0.64 mmol) in THF (10 mL) was added LDA (1.25 mL, 2.5 mmol, 2 M solution in THF) under N at −78 °C. The reaction was stirred for 0.5 h, TMSCl (324 mg, 3.0 mmol) was added, the reaction was stirred for 0.25 h, and NBS (445 mg, 2.5 mmol) was added as a solution in THF (10 mL). The reaction was stirred at −78 °C for 0.5 h and quenched by the addition of water (10 mL). The mixture was extracted with ethyl acetate (3 x 30 mL), and the combined organic phase was washed with brine and dried over anhydrous NaSO. After filtration and concentration, the product was purified chromatographically (Combiflash) using 0% to 20% EtOAc / petroleum ether as eluent to give methyl 2-bromo-2-(2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate (65 mg, 33%). (ESI 313.2 (m+1) + ) was obtained.

[0683] Step 4: Methyl 2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)-2-(2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate

[0684] [ka]

[0685] A mixture of methyl 2-bromo-2-(2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate (65 mg, 0.21 mmol), (57 mg, 0.21 mmol) and diisopropylethylamine (65 mg, 0.5 mmol) in acetonitrile (8 mL) was stirred at 25° C. for 16 h. The solvent was removed under reduced pressure and the residue was purified by chromatography on silica gel (DCM:MeOH 20:1) to give ethyl methyl 2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)-2-(2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate (30 mg, 28%) as an oil. (ESI 508.1(m+1) + ).

[0686] Step 5: 2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)-2-(2-(tetrahydro-2H-pyran-2-yl)phenyl)acetic acid (Compound 17)

[0687] [ka]

[0688] Methyl 2-(2-cyclopropylphenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (30 mg, 0.28 mmol) was treated with LiOH (52 mg, 1.24 mmol) in MeOH (4 mL) and HO (1 mL) at 25° C. for 3 h. The solvent was removed under reduced pressure, and the residue was separated using semi-preparative reverse-phase HPLC (preparative HPLC A, 30% to 65% MeCN) to give compound 17 as a solid (10 mg, 34%).

[0689] Compound 17: LC / MS ESI 494.2(M+H) + . 1 H NMR (400 MHz, MeOD) δ 1H NMR (500MHz, MeOD) δ7.68(t, J=8.3Hz, 1H), 7.57(d, J=7.8Hz, 1H), 7.40(dt, J=13.8, 7.5Hz, 2H), 7.15(d, J=7 .3Hz, 1H), 6.38(dd, J=7.3, 3.3Hz, 1H), 4.89-4.76(m, 2H), 4.18(d, J=17.9Hz, 1H), 4.09-3.94(m, 1H), 3.72( dd, J=22.4, 10.7Hz, 1H), 3.54-3.43(m, 2H), 3.38(dd, J=10.1, 4.5Hz, 3H), 2.77-2.65(m, 2H), 2.55(t, J=6.7 Hz, 2H), 2.17-1.97(m, 4H), 1.93-1.85(m, 2H), 1.81-1.58(m, 8H), 1.51-1.45(m, 1H), 1.33(d, J=22.7Hz, 3H).

[0690] [Example 18]: Preparation of 2-(5-fluoro-2-(tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 18-E1 and 18-E2)

[0691] Step 1: Methyl 2-(2-bromo-5-fluorophenyl)acetate

[0692] [ka]

[0693] To a solution of 2-(2-bromo-5-fluorophenyl)acetic acid (10 g, 43 mmol) in MeOH (60 mL) was added 0.5 mL of HSO. The mixture was refluxed for 4 h, allowed to cool to room temperature, and concentrated under reduced pressure. The resulting pale yellow oil (10 g, 94.3%) was used without further purification. (ESI 246.1 (M+H) + ).

[0694] Step 2: Methyl 2-(2-(3,4-dihydro-2H-pyran-6-yl)-5-fluorophenyl)acetate

[0695] [ka]

[0696] To a solution of methyl 2-(2-bromo-5-fluorophenyl)acetate (6.3 g, 25.6 mmol) in DMF (60 mL) was added 3,4-dihydro-2H-pyran-6-boronic acid pinacol ester (5 g, 23.8 mmol), tris(dibenzylideneacetone)dipalladium(0) (468 mg, 0.52 mmol), X-Phos (238 mg, 0.52 mmol), and potassium phosphate (2.1 g, 25.6 mmol). The mixture was stirred at 60 °C under N for 12 h. The mixture was allowed to cool to room temperature and partitioned between ethyl acetate (120 mL) and water (120 mL). The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (3 x 60 mL). The combined organic phase was washed with brine and dried over anhydrous NaSO. After filtration and concentration, the residue was chromatographed (Combiflash) using 0% to 20% EtOAc / petroleum ether as eluent to give methyl 2-(2-(3,4-dihydro-2H-pyran-6-yl)-5-fluorophenyl)acetate (5.2 g, 87.4%). (ESI 251.1 (M+H) + ).

[0697] Step 3: Methyl 2-(5-fluoro-2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate

[0698] [ka]

[0699] To a solution of methyl 2-(2-(3,4-dihydro-2H-pyran-6-yl)-5-fluorophenyl)acetate (500 mg, 2 mmol) in anhydrous MeOH (25 mL) was added diisopropylethylamine (0.5 mL) and Pd / C (100 mg). The mixture was stirred under H (balloon) at 40 °C for 3 h. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified chromatographically (Combiflash) using 0% to 20% EtOAc / petroleum ether as eluent to give methyl 2-(2-(3,4-dihydro-2H-pyran-6-yl)-5-fluorophenyl)acetate (260 mg, 52%) as an oil. (ESI 253.1 (M+H) + ).

[0700] Step 4: Methyl 2-bromo-2-(5-fluoro-2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate

[0701] [ka]

[0702] LDA (1.25 mL, 2.5 mmol, 2 M solution in THF) was added to a solution of methyl 2-(5-fluoro-2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate (260 mg, 1.03 mmol) in THF (10 mL) at −78 °C under N. The reaction was stirred for 0.5 h, and TMSCl (324 mg, 3 mmol) was added. After an additional 0.25 h, a solution of NBS (534 mg, 3 mmol) in THF (10 mL) was added, and the reaction was stirred at −78 °C for 0.5 h. The mixture was allowed to warm to room temperature and diluted with water (10 mL). The mixture was extracted with ethyl acetate (3×30 mL), and the combined organic phase was washed with brine and dried over anhydrous NaSO. After filtration and concentration, the residue was purified chromatographically (Combiflash) using 0% to 20% EtOAc / petroleum ether as eluent to give methyl 2-bromo-2-(5-fluoro-2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate (280 mg, 84.8%). (ESI 333.1 (M+H)+ ).

[0703] Step 5: Methyl 2-(5-fluoro-2-(tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate

[0704] [ka]

[0705] To a solution of methyl 2-bromo-2-(5-fluoro-2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate (70 mg, 0.21 mmol) in DMF (5 mL) was added (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (57 mg, 0.21 mmol) and diisopropylethylamine (81 mg, 0.63 mmol), and the reaction was stirred for 2 h. The mixture was diluted with water (10 mL) and extracted with EtOAc (2 x 20 mL). The combined organic phase was washed with brine and dried over anhydrous NaSO. After filtration and concentration, the residue was purified chromatographically (Combiflash) using 20% ​​to 80% EtOAc / petroleum ether as eluent to give methyl 2-(5-fluoro-2-(tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (70 mg, 62.8%). (ESI 526.2 (M+H) + ).

[0706] Step 6: 2-(5-Fluoro-2-(tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 18-E1 and 18-E2)

[0707] [ka]

[0708] To a solution of methyl 2-(5-fluoro-2-(tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (70 mg, 0.13 mmol) in MeOH (5 mL) was added LiOH (10 mg, 0.4 mmol) and water (2 mL). The reaction was stirred for 2 hours, filtered, and concentrated under reduced pressure. The residue was purified by semi-preparative reverse-phase HPLC to give the diastereomeric products Compound 18-E1 (25 mg, 36.7%) and Compound 18-E2 (13 mg, 18.3% yield), each a mixture of two stereoisomers.

[0709] Compound 18-E1 (mixture of two stereoisomers): LC / MS ESI 512.2 (M+H) + . 1 H NMR (500MHz, MeOD) δ7.58(dd, J=8.8, 5.9Hz, 1H), 7.52-7.42(m, 1H), 7.21-7.11(m, 2H), 6.40(d, J=7.3Hz, 1 H), 4.80(dd, J=21.1, 11.7Hz, 2H), 4.22-4.12(m, 1H), 4.04(dd, J=10.4, 5.6Hz, 1H), 3.76-3.66(m, 1H), 3.61 (d, J=8.1Hz, 1H), 3.49(dtd, J=12.6, 6.3, 3.3Hz, 2H), 3.42-3.34(m, 3H), 3.22-2.99(m, 2H), 2.72(t, J=6.2H) z, 2H), 2.60-2.51(m, 2H), 2.16-1.96(m, 4H), 1.92-1.82(m, 2H), 1.70(dddd, J=28.3, 22.6, 9.4, 4.8Hz, 9H).

[0710] Compound 18-E2 (mixture of two stereoisomers): LC / MS ESI 512.2 (M+H) + . 1H NMR (500MHz, MeOD) δ7.44 (dt, J=8.5, 6.0Hz, 2H), 7.18 (t, J=7.7Hz, 1H), 7.10 (qd, J=8.4, 2.6Hz, 1H), 6. 39(dd, J=7.3, 4.0Hz, 1H), 5.21(s, 1H), 4.74(dd, J=29.6, 11.1Hz, 1H), 4.10(dd, J=26.7, 15.4Hz, 2H), 3. 66(dd, J=20.8, 9.7Hz, 1H), 3.54-3.37(m, 6H), 3.15-2.96(m, 2H), 2.72(t, J=6.2Hz, 2H), 2.58(dt, J=14 .9, 6.9Hz, 2H), 2.10(dd, J=34.9, 11.9Hz, 2H), 1.99-1.80(m, 5H), 1.77-1.66(m, 4H), 1.63-1.55(m, 3H).

[0711] [Example 19]: Preparation of 2-(5-fluoro-2-(tetrahydrofuran-3-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 19-E1, 19-E2, 19-E3, and 19-E4)

[0712] Step 1: Methyl 2-(2-bromo-5-fluorophenyl)acetate

[0713] [ka]

[0714] To a solution of 2-(2-bromo-5-fluorophenyl)acetic acid (10 g, 43 mmol) in MeOH (60 mL) was added 0.5 mL of HSO. The mixture was refluxed for 4 h, allowed to cool to room temperature, and the solvent was removed under reduced pressure. The resulting oil (10 g, 94.3%) was used without further purification. (ESI 246.1 (M+H) + ).

[0715] Step 2: Methyl 2-(2-(2,5-dihydrofuran-3-yl)-5-fluorophenyl)acetate

[0716] [ka]

[0717] To a solution of methyl 2-(2-bromo-5-fluorophenyl)acetate (492 mg, 2 mmol) in DMF (5 mL) was added 2-(2,5-dihydrofuran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (392 mg, 2 mmol), tris(dibenzylideneacetone)dipalladium(0) (91 mg, 0.1 mmol), X-Phos (47.6 mg, 0.1 mmol), and potassium phosphate (424 mg, 2 mmol). The resulting mixture was stirred at 60 °C under N for 2 h, allowed to cool to room temperature, and partitioned between ethyl acetate (20 mL) and water (20 mL). The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (3 x 20 mL). The combined organic phases were washed with brine and dried over anhydrous NaSO. After filtration and concentration, the residue was chromatographed (Combiflash) using 20% ​​to 80% EtOAc / petroleum ether as eluent to give methyl 2-(2-(2,5-dihydrofuran-3-yl)-5-fluorophenyl)acetate (350 mg, 73%). (ESI 237.2 (M+H) + ).

[0718] Step 3: Methyl 2-(5-fluoro-2-(tetrahydrofuran-3-yl)phenyl)acetate

[0719] [ka]

[0720] To a solution of methyl 2-(2-(2,5-dihydrofuran-3-yl)-5-fluorophenyl)acetate (350 mg, 1.48 mmol) in methanol (10 mL) was added Pd / C (50 mg). The mixture was stirred under H (balloon) at 40 °C for 3 h. The catalyst was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified chromatographically (Combiflash) using 5% to 20% EtOAc / petroleum ether as eluent to give methyl 2-(5-fluoro-2-(tetrahydrofuran-3-yl)phenyl)acetate (260 mg, 73%) as an oil. LCMS: 239 (M+H) + .

[0721] Step 4: Methyl 2-bromo-2-(5-fluoro-2-(tetrahydrofuran-3-yl)phenyl)acetate

[0722] [ka]

[0723] A solution of methyl 2-(5-fluoro-2-(tetrahydrofuran-3-yl)phenyl)acetate (260 mg, 1.09 mmol) in THF (10 mL) was cooled to −78 °C under N and treated with LDA (1.25 mL, 2.5 mmol, 2 M solution in THF), and the mixture was stirred for 0.5 h. TMSCl (324 mg, 3 mmol) was added, the reaction was stirred for 0.25 h, and NBS (534 mg, 3 mmol) in THF (10 mL) was added. The reaction was stirred for 0.5 h, diluted with water, and extracted with ethyl acetate (3×30 mL). The combined organic phase was washed with brine and dried over anhydrous NaSO. After filtration and concentration, the residue was chromatographed (Combiflash) using 5% to 20% EtOAc / petroleum ether as eluent to give methyl 2-bromo-2-(5-fluoro-2-(tetrahydrofuran-3-yl)phenyl)acetate (250 mg, 71.8%) as an oil. (ESI 317.2) (M+H) + ).

[0724] Step 5: Methyl 2-(5-fluoro-2-(tetrahydrofuran-3-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate

[0725] [ka]

[0726] To a solution of methyl 2-bromo-2-(5-fluoro-2-(tetrahydrofuran-3-yl)phenyl)acetate (100 mg, 0.31 mmol) in anhydrous DMF (5 mL) was added (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (87 mg, 0.31 mmol) and diisopropylethylamine (120 mg, 0.93 mmol). The reaction was stirred for 2 hours, diluted with water (10 mL), and extracted with ethyl acetate (3 x 20 mL). The combined organic phase was washed with brine and dried over anhydrous NaSO. After filtration and concentration, the residue was purified chromatographically (Combiflash) using 20% ​​to 80% EtOAc / petroleum ether as eluent to give methyl 2-(5-fluoro-2-(tetrahydrofuran-3-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (110 mg, 68%) as a solid. (ESI 512 (M+H) + ).

[0727] Step 6: 2-(5-Fluoro-2-(tetrahydrofuran-3-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 19-E1, 19-E2, 19-E3, and 19-E4)

[0728] [ka]

[0729] To a solution of methyl 2-(5-fluoro-2-(tetrahydrofuran-3-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (110 mg, 0.21 mmol) in methanol (5 mL) was added LiOH (20 mg, 0.8 mmol) and water (4 mL). The reaction was stirred for 2 hours, filtered, and concentrated under reduced pressure. The resulting residue was purified by semi-preparative reverse-phase HPLC chromatography to give diastereomeric compounds 19-E1 (10 mg, 9.3% yield), 19-E2 (10 mg, 9.3% yield), 19-E3 (10 mg, 9.3% yield), and 19-E4 (10 mg, 9.3% yield).

[0730] Compound 19-E1: LC / MS ESI 498.2(M+H) + . 1 H NMR (500MHz, MeOD) δ7.48 (dd, J=8.8, 5.7Hz, 1H), 7.42 (dd, J=10.1, 2.7Hz, 1H), 7.23 (d, J=7.3Hz, 1H), 7.14 (td, J=8.4, 2.8Hz, 1H), 6.41 (dd, J=20.8, 7.3Hz, 1H), 4.95(s, 1H), 4.58-4.46(m, 1H), 4.18(d, J=18.9Hz, 1H), 4.05-3.98(m, 2H), 3.86(dd, J=15.5, 7.5Hz, 2H), 3.79 (dd, J=8.3, 6.3Hz, 1H), 3.50(t, J=6.2Hz, 2H), 3.42(dd, J=14.2, 8.7Hz, 3H), 3.28(s, 1H), 3.12-2.98(m, 2H), 2.73(t, J=6.2Hz, 2H), 2.6 0(ddd, J=15.0, 9.5, 5.5Hz, 2H), 2.51-2.38(m, 1H), 2.08(ddd, J=14.9, 8.4, 4.6Hz, 3H), 1.90(dd, J=11.8, 5.7Hz, 2H), 1.80-1.60(m, 4H).

[0731] Compound 19-E2: LC / MS ESI 498.2(M+H) + . 11H NMR (500 MHz, MeOD) δ 7.51 - 7.46 (m, 1H), 7.42 (dd, J = 10.1, 2.7 Hz, 1H), 7.23 (d, J = 7.3 Hz, 1H), 7.13 (td, J = 8.4, 2.8 Hz, 1H), 6.43 (d, J = 7.3 Hz, 1H), 4.94 (s, 1H), 4.17 (dd, J = 19.1, 11.5 Hz, 2H), 4.11 - 4.03 (m, 1H), 3.95 - 3.80 (m, 3H), 3.76 - 3.68 (m, 1H), 3.52 - 3.46 (m, 3H), 3.43 - 3.37 (m, 2H), 3.26 (d, J = 12.5 Hz, 1H), 3.13 - 2.99 (m, 2H), 2.73 (t, J = 6.2 Hz, 2H), 2.60 (t, J = 7.2 Hz, 2H), 2.42 - 2.29 (m, 1H), 2.07 (dtd, J = 42.5, 12.5, 7.8 Hz, 4H), 1.94 - 1.86 (m, 2H), 1.78 - 1.69 (m, 2H), 1.68 - 1.58 (m, 3H).

[0732] Compound 19 - E3: LC / MS ESI 498.2 (M + H) + . 1 1H NMR (500 MHz, MeOD) δ 7.52 - 7.39 (m, 2H), 7.23 (d, J = 7.3 Hz, 1H), 7.13 (td, J = 8.4, 2.8 Hz, 1H), 6.42 (t, J = 10.9 Hz, 1H), 4.87 - 4.81 (m, 1H), 4.17 (s, 1H), 4.04 (ddt, J = 33.6, 28.5, 7.3 Hz, 3H), 3.88 (dd, J = 15.7, 7.6 Hz, 1H), 3.79 (dd, J = 8.2, 6.2 Hz, 1H), 3.56 - 3.51 (m, 1H), 3.46 - 3.34 (m, 4H), 3.16 (ddd, J = 16.9, 15.7, 6.6 Hz, 3H), 2.73 (t, J = 6.2 Hz, 2H), 2.62 (dd, J = 16.3, 7.8 Hz, 2H), 2.48 (d, J = 7.6 Hz, 1H), 2.18 - 2.12 (m, 2H), 2.09 - 2.01 (m, 1H), 1.92 - 1.86 (m, 2H), 1.75 (dd, J = 12.1, 7.4 Hz, 2H), 1.68 - 1.60 (m, 2H).

[0733] Compound 19 - E4: LC / MS ESI 498.2 (M + H)+ . 1 H NMR (500MHz, MeOD) δ7.46 (ddd, J=13.0, 9.5, 4.3Hz, 2H), 7.24 (d, J=7.3Hz, 1H), 7.13 (td, J=8.4, 2.8Hz, 1H), 6.43 (d, J=7.3Hz, 1H), 4.86 (s, 1H), 4.23-4.14(m, 2H), 4.09(td, J=8.3, 4.6Hz, 1H), 3.98(dd, J=14.8, 7.4Hz, 1H), 3.86(dd, J=15.9, 7.7Hz, 1H), 3.71(dd, J=8.6, 6.5 Hz, 1H), 3.54(dt, J=9.1, 6.1Hz, 1H), 3.46-3.35(m, 4H), 3.25-3.08(m, 3H), 2.73(t, J=6.2Hz, 2H), 2.69-2.54(m, 2H), 2.39(d, J=7.8Hz, 1H), 2.16(d, J=3.6Hz, 2H), 2.02(dq, J=12.4, 7.8Hz, 1H), 1.95-1.83(m, 2H), 1.75(dd, J=12.3, 7.4Hz, 2H), 1.62(dd, J=13.6, 7.0Hz, 2H).

[0734] [Example 20]: Preparation of 2-(2-cyclopropoxy-5-fluorophenyl)-2-((R)-3-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentyl)pyrrolidin-1-yl)acetic acid (Compounds 20-E1 and 20-E2)

[0735] Step 1: 2-Bromo-1-cyclopropoxy-4-fluorobenzene

[0736] [ka]

[0737] A mixture of 2-bromo-4-fluorophenol (250 mg, 1.31 mmol), bromocyclopropane (792 mg, 6.54 mmol), NaI (2 mg, 0.013 mmol), and KCO (543 mg, 3.93 mmol) in DMF (4 mL) was stirred and heated to 150 °C under microwave irradiation (Biotage) for 2 h. The reaction mixture was diluted with water (10 mL) and ethyl acetate (10 mL). The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (3 x 10 mL). The combined organic layers were washed with brine and dried over anhydrous NaSO. After filtration and concentration, the residue was chromatographed (Combiflash) using 1:10 EtOAc / petroleum ether to give 2-bromo-1-cyclopropoxy-4-fluorobenzene (50 mg, 16.5%). 1 H NMR (500MHz, CDCl3) δ7.28-7.22(m, 1H), 7.18(dd, J=9.1, 4.9Hz, 1H), 7.03-6.94(m, 1H), 3.76(tt, J=5.9, 3.1Hz, 1H), 0.87-0.69(m, 4H).

[0738] Step 2: 2-Cyclopropoxy-5-fluorophenylboronic acid

[0739] [ka]

[0740] To a solution of 2-bromo-1-cyclopropoxy-4-fluorobenzene (250 mg, 1.08 mmol) in THF (15 mL) at −78 °C under Ar, nBuLi (0.87 mL, 2.16 mmol, 2.5 M solution in THF) was added. The mixture was stirred for 0.5 h, and triisopropylborate (224 mg, 1.19 mmol) was added slowly via syringe. The mixture was continuously stirred at −78 °C for 2 h and quenched by the addition of saturated aqueous NH₄Cl (5 mL). The mixture was warmed to room temperature and partitioned between water (10 mL) and ethyl acetate (10 mL). The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (3×15 mL), washed with brine, and dried over anhydrous Na₂SO₄. The organic phase was concentrated to dryness to give 2-bromo-1-cyclopropoxy-4-fluorobenzene (70 mg, 33.0% yield).

[0741] Step 3: 2-(2-Cyclopropoxy-5-fluorophenyl)-2-((R)-3-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentyl)pyrrolidin-1-yl)acetic acid (Compounds 20-E1 and 20-E2)

[0742] [ka]

[0743] A mixture of (R)-7-(5-(pyrrolidin-3-yl)pentyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (60 mg, 0.22 mmol), 2-cyclopropoxy-5-fluorophenylboronic acid (47 mg, 0.24 mmol), and 2-oxoacetic acid (18 mg, 0.24 mmol) in MeCN (4 mL) was stirred for 2 h. The residue was purified by semi-preparative reverse-phase HPLC (30% to 65% MeCN) to give compound 20 (45 mg, 42.6%). The racemic product was separated into diastereomeric products, compound 20-E1 (9.3 mg) and compound 20-E2 (11.1 mg), by chiral SFC.

[0744] Compound 20-E1 LC / MS ESI 482.2(M+H) + 。 1 H NMR(500 MHz, MeOD) δ 7.42 (dd, J = 9.1, 4.5 Hz, 1H), 7.31 (dd, J = 8.9, 2.8 Hz, 1H), 7.16 (ddd, J = 20.7, 12.9, 5.2 Hz, 2H), 6.35 (d, J = 7.3 Hz, 1H), 4.86 (s, 1H), 4.11 - 3.80 (m, 1H), 3.48 - 3.35 (m, 3H), 3.17 (dd, J = 23.9, 15.4 Hz, 2H), 2.87 (s, 1H), 2.71 (t, J = 6.3 Hz, 2H), 2.50 (t, J = 7.6 Hz, 2H), 2.38 - 2.25 (m, 1H), 2.24 - 2.08 (m, 1H), 1.89 (dt, J = 12.2, 6.1 Hz, 2H), 1.62 (dd, J = 13.5, 7.4 Hz, 3H), 1.41 (s, 2H), 1.32 (dd, J = 22.3, 9.5 Hz, 5H), 0.98 - 0.71 (m, 4H).

[0745] Compound 20-E2 LC / MS ESI 482.2(M+H) + 。 1 H NMR(500 MHz, MeOD) δ 7.43 (dd, J = 9.1, 4.5 Hz, 1H), 7.33 (dd, J = 8.9, 2.9 Hz, 1H), 7.22 - 7.15 (m, 1H), 7.14 (d, J = 7.3 Hz, 1H), 6.36 (t, J = 5.8 Hz, 1H), 4.88 - 4.82 (m, 1H), 4.00 - 3.87 (m, 1H), 3.60 (s, 1H), 3.44 - 3.34 (m, 3H), 3.16 - 3.04 (m, 1H), 2.72 (dd, J = 15.9, 9.5 Hz, 3H), 2.56 - 2.46 (m, 2H), 2.42 - 2.31 (m, 1H), 2.22 - 2.07 (m, 1H), 1.94 - 1.83 (m, 2H), 1.67 - 1.60 (m, 3H), 1.43 (s, 2H), 1.35 (d, J = 4.6 Hz, 5H), 0.95 - 0.70 (m, 4H).

[0746] [Example 21]: Preparation of 2-(2-cyclobutylpyridin-3-yl)-2-((3R)-3-(4-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 21-B-E1, 21-B-E2, and 21-A)

[0747] Step 1: Ethyl 2-(2-cyclobutylpyridin-3-yl)-2-((R)-3-(4-((R)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate Stereoisomer B

[0748] [ka]

[0749] A mixture of 2-(4-(((R)-pyrrolidin-3-yl)oxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine stereoisomer B (120 mg, 0.44 mmol), ethyl 2-chloro-2-(2-cyclobutylpyridin-3-yl)acetate (110 mg, 0.44 mmol) and diisopropylethylamine (513 mg, 3.72 mmol) in acetonitrile (8 mL) was stirred at 50° C. for 16 hours. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (DCM:MeOH 20:1) to give the desired product ethyl 2-(2-cyclobutylpyridin-3-yl)-2-((R)-3-(4-((R)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate stereoisomer B as a yellow oil (95 mg). Yield 44% (ESI 493 (M+H) + ).

[0750] Step 2: 2-(2-Cyclobutylpyridin-3-yl)-2-((3R)-3-(4-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid stereoisomer B (compounds 21-B-E1 and 21-B-E2)

[0751] [ka]

[0752] Ethyl 2-(2-cyclobutylpyridin-3-yl)-2-((R)-3-(4-((R)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate stereoisomer B (95 mg, 0.19 mmol) was treated with LiOH—HO (52 mg, 1.24 mmol) in MeOH (4 mL) and HO (1 mL) at 40° C. for 4 h. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC A (30% to 65% MeCN) to give compound 21-B as a white solid (68 mg, 77% yield). The racemic product was separated by preparative chiral SFC F to give diastereomeric products compound 21-B-E1 (4 mg) and compound 21-B-E2 (6 mg) as white solids.

[0753] Compound 21-B-E1 LC / MS ESI 465(M+H) + . 1 H NMR (500MHz, MeOD) δ8.68(m, 1H), 8.08(d, J=9.5Hz, 1H), 7.71(m, 1H), 7.31(m, 2H), 6.52(m, 1H), 4.82(s, 1H) ), 4.23(m, 2H), 3.55-3.35(m, 4H), 3.20(m, 3H), 2.76(m, 2H), 2.63-1.86(m, 9H), 1.75-1.50(m, 7H), Chiral SFC F:ee100%, Rt=7.78 minutes.

[0754] Compound 21-B-E2 LC / MS ESI 465(M+H) + . 1H NMR (500MHz, MeOD) δ8.58(m, 1H), 8.08(d, J=9.5Hz, 1H), 7.75(m, 1H), 7.31(m, 2H), 6.52(m, 1H), 4.82(s, 1H) ), 4.23(m, 2H), 3.55-3.35(m, 4H), 3.20(m, 3H), 2.76(m, 2H), 2.63-1.86(m, 9H), 1.75-1.50(m, 7H), Chiral SFC F:ee100%, Rt=12.02 minutes.

[0755] Step 3: 2-(2-cyclobutylpyridin-3-yl)-2-((R)-3-(4-((S)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid stereoisomer A (compound 21-A)

[0756] [ka]

[0757] By the same procedure as for stereoisomer B, 2-(2-cyclobutylpyridin-3-yl)-2-((R)-3-(4-((S)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid stereoisomer A (compound 21-A) was synthesized from 2-(4-(((R)-pyrrolidin-3-yl)oxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine stereoisomer A.

[0758] Compound 21-A LC / MS ESI 465.3(M+H) + . 1 H NMR (500MHz, MeOD) δ8.56-8.54(m, 1H), 8.08-8.01(m, 1H), 7.72-7.70(m, 1H), 7.32-7.29(m, 2H), 6.56-6.52(m, 1H), 4.82-4. 73(m, 1H), 4.30-4.18(m, 2H), 3.78-3.35(m, 4H), 3.28-2.95(m, 3H), 2.81-2.28(m, 6H), 2.24-1.88(m, 5H), 1.74-1.48(m, 7H).

[0759] [Example 22]: Preparation of 2-(5-fluoro-2-(tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (diastereomeric compounds 92-A-E1, 92-A-E2, 92-B-E1, and 92-B-E2)

[0760] Step 1: Methyl 2-(5-fluoro-2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate

[0761] [ka]

[0762] To a solution of methyl 2-(5-fluoro-2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate (2.4 g, 9.6 mmol) in anhydrous MeOH (100 mL) was added Pd(OH) (100 mg) and TEA (2 mL). The mixture was stirred under an H (balloon) atmosphere at 40 °C for 8 h.

[0763] The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by chromatography on silica (Combiflash) using 5% to 20% EtOAc / petroleum ether as eluent to give racemic methyl 2-(5-fluoro-2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate (2.2 g, 92%). Chiral separation using SFC (AY-H (250 × 4.6 mm 5 μm) mobile phase = hexane (0.1% DEA):EtOH (0.1% DEA) = 95:5) gave stereoisomer A (identified as methyl (R)-2-(5-fluoro-2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate, 960 mg, 43.5%) and stereoisomer B (identified as methyl (S)-2-(5-fluoro-2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate, 904 mg, 40.7%); (ESI 253.2 (M+H) + ).

[0764] Step 2: Methyl 2-bromo-2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)acetate (stereoisomer B)

[0765] [ka]

[0766] LDA (25 mL, 50 mmol, 2 M solution in THF) was added to a solution of (S)-methyl 2-(5-fluoro-2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate (stereoisomer B, 4.2 g, 16.7 mmol) in THF (100 mL) at −78° C. under a N atmosphere. The reaction was stirred for 0.5 h, and TMSCl (5.4 g, 50 mmol) was added. After an additional 15 min, a solution of NBS (8.9 g, 50 mmol) in THF (50 mL) was added, and the reaction was stirred at −78° C. for 0.5 h. The reaction was diluted with water (10 mL) and extracted with ethyl acetate (2×50 mL). The combined organic phase was washed with brine and dried over anhydrous NaSO. After filtration and concentration, the residue was purified by chromatography on silica (Combiflash) using 0% to 20% EtOAc / petroleum ether as eluent to give methyl 2-bromo-2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)acetate (stereoisomer B, 4.1 g, 74.5%); (ESI 331.3 (M+H) + .

[0767] Step 3: Methyl 2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (Stereoisomer B)

[0768] [ka]

[0769] To a solution of methyl 2-bromo-2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)acetate (stereoisomer B, 4.1 g, 12.4 mmol) in acetonitrile (30 mL) was added (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (3.4 g, 12.4 mmol) and DIPEA (4.8 g, 37.2 mmol). The reaction was stirred for 1 h, diluted with water (50 mL), and extracted with ethyl acetate (3 x 50 mL). The combined organic phase was washed with brine and dried over anhydrous NaSO. After filtration and concentration, the residue was purified by chromatography on silica (Combiflash) using 20% ​​to 80% EtOAc / petroleum ether as eluent to give methyl 2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate as a mixture of diastereomers (stereoisomer B, 4.9 g, 75%); (ESI 526.2 (M+H) + ); 1 H NMR (500MHz, MeOD) δ7.51 (ddd, J=20.9, 8.7, 5.9Hz, 1H), 7.34 (dt, J=10.3, 3.4Hz, 1H), 7.11(d, J=7.3Hz, 1H), 7.09-7.03(m, 1H), 6.36(d, J=7.3Hz, 1H), 4.86(m, 2H), 4.47(m, 1H), 4.08-3.97(m, 2H), 3.69-3.61(m, 4H), 3.39(m, 3H), 2.87(m, 1H), 2.75-2.63(m, 3H) ), 2.56-2.35(m, 4H), 2.00(m, 1H), 1.97-1.75(m, 5H), 1.72-1.63(m, 4H), 1.57(m, 4H).

[0770] Step 4: 2-(5-Fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 92-B-E1 and 92-B-E2)

[0771] [ka]

[0772] To a solution of methyl 2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (stereoisomer B, 4.9 g, 9.3 mmol) in methanol (50 mL) was added LiOH (480 mg, 20 mmol) and water (20 mL). The reaction was stirred at 25° C. for 16 hours, filtered, concentrated under reduced pressure, and purified by semi-preparative reverse phase HPLC to give the individual diastereomeric (S)-2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid compounds. Compound 92-B-E1 (1.88 g) (yield 39.4%) and (R)-2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid compound 92-B-E2 (1.33 g) (yield 27.9%) were obtained.

[0773] Compound 92-B-E1: LC / MS ESI 512.3(M+H) + . 1H NMR (400MHz, MeOD) δ7.58 (dd, J=8.8, 5.9Hz, 1H), 7.46 (dd, J=10.0, 2.7Hz, 1H), 7.22-7.11 (m, 2H), 6.40 (d , J=7.3Hz, 1H), 4.90 (s, 1H), 4.77 (d, J=10.3Hz, 1H), 4.20 (m, 1H), 4.04 (dd, J=7.5, 5.6Hz, 1H), 3.68 (t, J=1 1.6Hz, 1H), 3.62 (d, J=9.2Hz, 1H), 3.49 (t, J=5.6Hz, 2H), 3.42-3.35 (m, 3H), 3.23 (d, J=12.6Hz, 1H), 3.04 (m, 1H), 2.72 (t, J=6.2Hz, 2H), 2.57 (t, J=7.6Hz, 2H), 2.2-1.95 (m, 4H), 1.9-1.8 (m, 2H), 1.8-1.55 (m, 8H).

[0774] Compound 92-B-E2: LC / MS ESI 512.3 (M+H) + . 1 H NMR (500MHz, MeOD) δ7.47-7.39 (m, 2H), 7.19 (d, J=7.3Hz, 1H), 7.11 (td, J=8.4, 2.6Hz, 1H), 6.40 (d, J=7.3Hz, 1H), 4.75 (d, J=11.1Hz, 2H), 4.15 (d, J=9.4Hz, 1H), 4.08 (s, 1H), 3.67 (t, J=10.7Hz , 1H), 3.53-3.42(m, 3H), 3.38(d, J=5.3Hz, 2H), 3.10(m, 2H), 2.72(t, J=6.2Hz, 2H), 2.58(m, 2H) , 2.15 (s, 1H), 2.09 (s, 1H), 1.95 (d, J=7.8Hz, 2H), 1.92-1.82 (m, 3H), 1.73 (m, 4H), 1.61 (m, 4H).

[0775] Stage 5: 2-(5-フルオロ-2-((R)-テトラヒドロ-2H-ピラン-2-イル)フェニル)-2-((R)-3-(4-(5,6,7 ,8-テトラヒドロ-1,8-ナフチリジン-2-イル)ブトキシ)ピロリジン-1-イル) anhydrous acid (compounds 92-A-E1 and び92-A-E2)

[0776]

change

[0777] (R)-2-(5-Fluoro-2-((R)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid compound 92-A-E1 and (S)-2-(5-Fluoro-2-((R)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid compound 92-A-E2 were synthesized from methyl (R)-2-(5-fluoro-2-(tetrahydro-2H-pyran-2-yl)phenyl)acetate (stereoisomer A) by the same procedure as for stereoisomer B.

[0778] Compound 92-A-E1: LC / MS ESI 512.1(M+H) + , 1 H NMR (500MHz, MeOD) δ7.58-7.50(m, 2H), 7.16(d, J=7.4Hz, 1H), 7.11-7.04(m, 1H), 6.38 (d, J=7.3Hz, 1H), 4.87(d, J=10.9Hz, 1H), 4.62(s, 1H), 4.11(d, J=2.5Hz, 1H), 4.04(m, 1 H), 3.72(m, 1H), 3.47-3.35(m, 5H), 3.16-3.03(m, 2H), 2.70(d, J=6.1Hz, 2H), 2.58-2. 50(m, 2H), 2.16-1.95(m, 4H), 1.90-1.85(m, 2H), 1.73-1.65(m, 4H), 1.64-1.56(m, 4H).

[0779] Compound 92-A-E2: LC / MS ESI 512.1(M+H) + , 1H NMR (500MHz, MeOD) δ7.50-7.39(m, 2H), 7.16(d, J=7.3Hz, 1H), 7.09(td, J=8.4, 2.7Hz, 1H), 6 .38(d, J=7.3Hz, 1H), 5.08(s, 1H), 4.76(d, J=11.0Hz, 1H), 4.14(d, J=3.5Hz, 1H), 4.07(d, J= 12.2Hz, 1H), 3.44(m, 3H), 3.38(d, J=5.5Hz, 3H), 2.99-2.92(m, 1H), 2.71(t, J=6.2Hz, 2H), 2 .55(t, J=7.5Hz, 2H), 2.10-2.03(m, 2H), 1.95-1.81(m, 5H), 1.73-1.67(m, 4H), 1.60(m, 4H).

[0780] [Example 23]: Preparation of 2-(5-fluoro-2-(tetrahydrofuran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 93-A-E1, 93-A-E2, 93-B-E1, and 93-B-E2)

[0781] Step 1: Methyl 2-(2-bromo-5-fluorophenyl)acetate

[0782] [ka]

[0783] To a solution of 2-(2-bromo-5-fluorophenyl)acetic acid (10 g, 43 mmol) in MeOH (60 mL) was added 0.5 mL of HSO, and the mixture was heated under reflux for 4 h. The solvent was removed under reduced pressure to give methyl 2-(2-bromo-5-fluorophenyl)acetate as an oil (10 g, yield: 94.3%), which was used without further purification. (ESI 246.1 (M+H) + ).

[0784] Step 2: Methyl 2-(5-fluoro-2-(furan-2-yl)phenyl)acetate

[0785] [ka]

[0786] To a solution of methyl 2-(2-bromo-5-fluorophenyl)acetate (5 g, 20.2 mmol) in DMF (100 mL) was added furan-2-ylboronic acid (2.72 g, 24 mmol), tris(dibenzylideneacetone)dipalladium(0) (915 mg, 1 mmol), X-Phos (476 mg, 1 mmol), and potassium phosphate (8.5 g, 40 mmol). The mixture was stirred at 60 °C under N for 8 h. The reaction was diluted with 200 mL of ethyl acetate and 200 mL of water, and the organic layer was separated. The aqueous layer was extracted three times with ethyl acetate (3 x 200 mL), and the combined organic layers were washed with brine and dried over anhydrous NaSO. After filtration and concentration, the residue was purified by chromatography on silica (Combiflash) using 0% to 20% EtOAc / petroleum ether as eluent to give methyl 2-(5-fluoro-2-(furan-2-yl)phenyl)acetate (3.9 g, 82.7% yield); ESI 237.2 (M+H). + .

[0787] Step 3: Methyl 2-(5-fluoro-2-(tetrahydrofuran-2-yl)phenyl)acetate

[0788] [ka]

[0789] To a solution of methyl 2-(5-fluoro-2-(furan-2-yl)phenyl)acetate (2.34 g, 10 mmol) in EtOAc (30 mL) was added Pd / C (1 g) and DIEA (2.58 g, 20 mmol). The mixture was stirred under a H atmosphere (balloon) at 35 °C for 5 h. After completion of the reaction, the catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by chromatography on silica (Combiflash) using 5% to 20% EtOAc / petroleum ether as eluent to give methyl 2-(5-fluoro-2-(tetrahydrofuran-2-yl)phenyl)acetate (1.56 g, 66.7%) as an oil.

[0790] The racemate was separated by SFC (SFC (AY-H (250 × 4.6 mm 5 μm) mobile phase: hexane (0.1% DEA): EtOH (0.1% DEA) = 95:5) to give Stereoisomer A (950 mg) and Stereoisomer B (920 mg) as oils; ESI 239.1 (M+H) + .

[0791] Step 4: Methyl 2-bromo-2-(5-fluoro-2-(tetrahydrofuran-2-yl)phenyl)acetate Stereoisomer A

[0792] [ka]

[0793] To a solution of methyl 2-(5-fluoro-2-(tetrahydrofuran-2-yl)phenyl)acetate stereoisomer A (250 mg, 1.05 mmol) in anhydrous THF (10 mL) at −78 °C under N was added LDA (1.25 mL, 2.5 mmol, 2 M solution in THF). The reaction was stirred for 0.5 h, and TMSCl (324 mg, 3 mmol) was added. After stirring for 15 min, NBS (534 mg, 3 mmol) in THF (10 mL) was added, and the mixture was stirred at −78 °C for 0.5 h. The mixture was diluted with water and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine and dried over anhydrous NaSO. After filtration and concentration, the residue was purified by chromatography on silica (Combiflash) using 5% to 20% EtOAc / petroleum ether as eluent to give methyl 2-bromo-2-(5-fluoro-2-(tetrahydrofuran-2-yl)phenyl)acetate stereoisomer A (240 mg, 71%) as an oil; ESI 317.2 (M+H). + .

[0794] Step 5: Methyl 2-(5-fluoro-2-(tetrahydrofuran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate Stereoisomer A

[0795] [ka]

[0796] To a solution of methyl 2-bromo-2-(5-fluoro-2-(tetrahydrofuran-2-yl)phenyl)acetate Stereoisomer A (240 mg, 0.76 mmol) in ACN (10 mL) was added (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (213 mg, 0.76 mmol) and DIPEA (295 mg, 2.28 mmol). The reaction was stirred for 4 hours, diluted with water (30 mL), and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on silica (Combiflash) using 20% ​​to 80% EtOAc / petroleum ether as eluent to give methyl 2-(5-fluoro-2-((S)-tetrahydrofuran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate stereoisomer A (300 mg, 77%) as a solid; ESI 512 (M+H). + .

[0797] Step 6: 2-(5-Fluoro-2-((S)-tetrahydrofuran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid stereoisomer B (compounds 93-A-E1 and 93-A-E2)

[0798] [ka]

[0799] To a solution of methyl 2-(5-fluoro-2-(tetrahydrofuran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate stereoisomer A (330 mg, 0.59 mmol) in methanol (10 mL) was added LiOH (40 mg, 1.6 mmol) and water (10 mL). The reaction was stirred at 25 °C for 16 h. The pH of the mixture was adjusted to 5-6 by the addition of 1N HCl. The mixture was concentrated under reduced pressure, and the residue was purified by semi-preparative HPLC to give compound 93-A-E1 (56 mg, 18%) as a solid and compound 93-A-E2 (45 mg, 15%) as a solid.

[0800] Compound 93-A-E1 ESI 498.2(M+H) + , 1 H NMR (500MHz, MeOD) δ7.58(dd, J=8.8, 5.9Hz, 1H), 7.45(dd, J=10.0, 2.7Hz, 1H), 7.18(d, J=7.4Hz, 1H), 7.15(dd, J=8.4, 5.8Hz , 1H), 6.41(d, J=7.3Hz, 1H), 5.22(t, J=7.0Hz, 1H), 4.96(s, 1H), 4.19(s, 1H), 4.07(dd, J=14.4, 7.3Hz, 1H), 3.88(dt, J=14.1, 7.0Hz, 1H), 3.60-3.43(m, 3H), 3.43-3.37(m, 2H), 3.26(dd, J=33.4, 10.4Hz, 2H), 3.04(t, J=7.6Hz, 1H), 2.72(t, J=6.2Hz, 2H) ), 2.58(t, J=7.6Hz, 2H), 2.44(dt, J=12.0, 5.9Hz, 1H), 2.16-1.93(m, 5H), 1.92-1.86(m, 2H), 1.75(m, 2H), 1.68-1.56(m, 2H).

[0801] Compound 93-A-E2 ESI 498.2(M+H) + , 1H NMR (500MHz, MeOD) δ7.49 (dd, J=8.7, 5.9Hz, 1H), 7.46 (d, J=10.3Hz, 1H), 7.21 (d, J=7.2Hz, 1H), 7.11 (t, J =6.9Hz, 1H), 6.42(d, J=7.3Hz, 1H), 5.18(s, 1H), 4.87-4.81(m, 1H), 4.16(s, 1H), 4.16-4.09(m, 1H), 3.88( t, J=7.1Hz, 1H), 3.50 (t, J=6.1Hz, 3H), 3.42-3.36 (m, 2H), 3.10 (d, J=7.6Hz, 2H), 2.73 (t, J=6.2Hz, 2H), 2 .67-2.54(m, 2H), 2.41(d, J=10.7Hz, 1H), 2.16-1.96(m, 5H), 1.93-1.85(m, 2H), 1.75(m, 2H), 1.64(m, 2H).

[0802] Stage 7: メチル2-ブロモ-2-(5-フルオロ-2-(テトラヒドロフラン-2-イル)フェニル)アセテートstereoisomorph B

[0803]

change

[0804] To a solution of methyl 2-(5-fluoro-2-(tetrahydrofuran-2-yl)phenyl)acetate stereoisomer B (250 mg, 1.05 mmol) in anhydrous THF (10 mL) at −78 °C under N was added LDA (1.25 mL, 2.5 mmol, 2 M solution in THF). The reaction was stirred for 0.5 h, and TMSCl (324 mg, 3 mmol) was added. After stirring for 15 min, NBS (534 mg, 3 mmol) in THF (10 mL) was added, and the mixture was stirred at −78 °C for 0.5 h. The mixture was diluted with water and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine and dried over anhydrous NaSO. After filtration and concentration, the residue was purified by chromatography on silica (Combiflash) using 5% to 20% EtOAc / petroleum ether as eluent to give methyl 2-bromo-2-(5-fluoro-2-(tetrahydrofuran-2-yl)phenyl)acetate stereoisomer B (235 mg, 70.8%) as an oil; ESI 317.2 (M+H). + .

[0805] Step 8: Methyl 2-(5-fluoro-2-(tetrahydrofuran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate Stereoisomer B

[0806] [ka]

[0807] To a solution of methyl 2-bromo-2-(5-fluoro-2-(tetrahydrofuran-2-yl)phenyl)acetate stereoisomer B (100 mg, 0.31 mmol) in ACN (5 mL) was added (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (87 mg, 0.31 mmol) and DIPEA (120 mg, 0.93 mmol). The reaction was stirred for 4 h, diluted with water (10 mL), and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on silica (Combiflash) using 20% ​​to 80% EtOAc / petroleum ether as eluent to give methyl 2-(5-fluoro-2-((S)-tetrahydrofuran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate stereoisomer B (120 mg, 78%) as a solid; ESI 512.2 (M+H). + .

[0808] Step 9: 2-(5-Fluoro-2-(tetrahydrofuran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid stereoisomer B (compounds 93-B-E1 and 93-B-E2)

[0809] [ka]

[0810] To a solution of methyl 2-(5-fluoro-2-(tetrahydrofuran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate stereoisomer B (300 mg, 0.59 mmol) in methanol (10 mL) was added LiOH (40 mg, 1.6 mmol) and water (10 mL). The reaction was stirred at 25 °C for 16 h. 1N HCl was added to the mixture to adjust the pH to 5-6. The mixture was concentrated under reduced pressure, and the residue was purified by semi-preparative HPLC to give compound 93-B-E1 (27 mg, 9%) as a solid and compound 93-B-E2 (30 mg, 10%) as a solid.

[0811] Compound 93-B-E1 ESI 498.2(M+H) + , 1 H NMR (500MHz, MeOD) δ7.58(dd, J=8.8, 6.0Hz, 1H), 7.48(d, J=10.1Hz, 1H), 7.17(dd, J=20.5, 7.7Hz, 2H), 6.41( d, J=7.3Hz, 1H), 5.29(t, J=7.1Hz, 1H), 4.9(s, 1H), 4.17(s, 1H), 4.08(dd, J=14.6, 7.2Hz, 1H), 3.89(dd, J=13 .8, 7.8Hz, 1H), 3.60-3.38(m, 5H), 3.16(d, J=7.5Hz, 1H), 2.72(t, J=6.2Hz, 2H), 2.59(dd, J=14.4, 7.2Hz, 2H) , 2.48(dd, J=11.9, 5.2Hz, 1H), 2.18(s, 2H), 2.12-1.99(m, 2H), 2.01-1.85(m, 4H), 1.74(m, 2H), 1.64(m, 2H).

[0812] Compound 93-B-E2 ESI 498.2(M+H) + , 1H NMR (500MHz, MeOD) δ7.49(dd, J=8.7, 5.8Hz, 1H), 7.44(d, J=10.1Hz, 1H), 7.19(d, J=7.3Hz, 1H), 7.12(t , J=7.0Hz, 1H), 6.41(d, J=7.3Hz, 1H), 5.12(s, 1H), 4.97(s, 1H), 4.18(s, 1H), 4.14-4.08(m, 1H), 3.86(t , J=6.9Hz, 1H), 3.48(t, J=6.2Hz, 3H), 3.42-3.38(m, 3H), 3.19(s, 1H), 3.04(s, 1H), 2.73(t, J=6.3Hz, 2 H), 2.58(t, J=6.2Hz, 2H), 2.37(s, 1H), 2.17-1.99(m, 5H), 1.94-1.84(m, 2H), 1.74(m, 2H), 1.64(m, 2H).

[0813] [Example 24]: Preparation of 2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)methyl)pyrrolidin-1-yl)acetic acid (Compounds 94-E1 and 94-E2)

[0814] Step 1: (R)-tert-butyl 3-(allyloxymethyl)pyrrolidine-1-carboxylate

[0815] [ka]

[0816] A mixture of (R)-tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate (5 g, 24.8 mmol) and NaH (1.09 g, 27.3 mmol) in DMF (20 mL) was stirred at 0° C. for 1 h. A solution of 3-bromoprop-1-ene (4.5 g, 37.2 mmol) in DMF (10 mL) was added dropwise to the above mixture at 0° C., and the reaction mixture was stirred at 50° C. overnight. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 1:1) to give the desired product as a colorless oil (5.1 g). Yield 85% (ESI 186 (M+H −56) + ).

[0817] Step 2: (R)-tert-butyl 3-((3-(1,8-naphthyridin-2-yl)propoxy)methyl)pyrrolidine-1-carboxylate

[0818] [ka]

[0819] To a solution of (R)-tert-butyl 3-(allyloxymethyl)pyrrolidine-1-carboxylate (600 mg, 2.49 mmol) in THF (anhydrous, 5 mL) under Ar, 9-BBN (0.5 M solution in THF, 9.95 mL, 4.97 mmol) was added. The reaction was stirred at 50 °C for 2 h and then cooled to room temperature. This solution was added to a mixture of 2-bromo-1,8-naphthyridine (520 mg, 2.49 mmol), cesium carbonate (2.44 g, 7.47 mmol), and Pd(PPh) (144 mg, 0.125 mmol) in 1,4-dioxane (10 mL). The reaction was stirred at 90 °C for 1.5 h. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (DCM:MeOH 30:1) to give the desired product (R)-tert-butyl 3-((3-(1,8-naphthyridin-2-yl)propoxy)methyl)pyrrolidine-1-carboxylate as a yellow oil (200 mg). Yield 22% (ESI 372 (M+H) + ).

[0820] Step 3: (R)-tert-butyl 3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)methyl)pyrrolidine-1-carboxylate

[0821] [ka]

[0822] A mixture of (R)-tert-butyl 3-((3-(1,8-naphthyridin-2-yl)propoxy)methyl)pyrrolidine-1-carboxylate (200 mg, 0.54 mmol) and Pd / C (40 mg, 20 wt%) in ethyl acetate (10 mL) was stirred under a H balloon at 40° C. for 16 hours. The solids were removed by filtration, and the filtrate was concentrated under reduced pressure to give the desired product, (R)-tert-butyl 3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)methyl)pyrrolidine-1-carboxylate, as a yellow oil (200 mg). Yield 99% (ESI 376 (M+H)). + ).

[0823] Step 4: (R)-7-(3-(pyrrolidin-3-ylmethoxy)propyl)-1,2,3,4-tetrahydro-1,8-naphthyridine

[0824] [ka]

[0825] (R)-tert-Butyl 3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)methyl)pyrrolidine-1-carboxylate (200 mg, 0.53 mmol) was treated with HCl / 1,4-dioxane (4 M, 10 mL) at room temperature for 2 hours. The solvent was removed under reduced pressure to give the desired product (R)-7-(3-(pyrrolidin-3-ylmethoxy)propyl)-1,2,3,4-tetrahydro-1,8-naphthyridine as the HCl salt (150 mg). Yield 81% (ESI 276 (M+H) + ).

[0826] Step 5: Methyl 2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)methyl)pyrrolidin-1-yl)acetate

[0827] [ka]

[0828] A mixture of (R)-7-(3-(pyrrolidin-3-ylmethoxy)propyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (150 mg, 0.43 mmol), methyl 2-bromo-2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)acetate (142 mg, 0.43 mmol) and DIPEA (166 mg, 1.29 mmol) in acetonitrile (10 mL) was stirred at room temperature for 3 hours. The solvent was removed under reduced pressure and the residue was purified by silica gel column (DCM:MeOH 10:1) to give the desired product methyl 2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)methyl)pyrrolidin-1-yl)acetate as a yellow oil (140 mg). Yield 62%. (ESI 526(M+H) + ).

[0829] Step 6: 2-(5-Fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)methyl)pyrrolidin-1-yl)acetic acid (Compounds 94-E1 and 94-E2)

[0830] [ka]

[0831] Methyl 2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)methyl)pyrrolidin-1-yl)acetate (140 mg, 0.27 mmol) was treated with LiOH—HO (126 mg, 3.0 mmol) in MeOH (4 mL) and HO (1 mL) at room temperature for 2 hours. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC A (30% to 60% MeCN) to give diastereomeric products Compound 94-E1 (17 mg) and Compound 94-E2 (49 mg) as white solids.

[0832] Compound 94-E1 LC / MS ESI 512(M+H) + . 1 H NMR (500MHz, MeOD) δ7.65-7.54(m, 2H), 7.36-7.21(m, 2H), 6.62(d, J=7.5Hz, 1H), 5.06(s, 1H), 4.77-4.75 (m, 1H), 4.11-4.08(m, 1H), 3.81-3.33(m, 8H), 3.25-3.14(m, 2H), 2.95-2.66(m, 5H), 2.37-1.58(m, 13H).

[0833] Compound 94-E2 LC / MS ESI 512(M+H) + . 1 H NMR (500MHz, MeOD) δ7.48-7.39(m, 2H), 7.15-7.08(m, 2H), 6.35(d, J=7.0Hz, 1H), 5.25(s, 1H), 4.73-4.71 (m, 1H), 4.14-4.12(m, 1H), 3.81-3.33(m, 8H), 3.25-3.14(m, 2H), 2.73-2.56(m, 5H), 2.18-1.52(m, 13H).

[0834] [Example 25]: Preparation of 2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((S)-3-(2-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy)ethyl)pyrrolidin-1-yl)acetic acid (Compounds 95-E1 and 95-E2)

[0835] Step 1: (S)-tert-butyl 3-(2-(3-methoxy-3-oxoprop-1-enyloxy)ethyl)pyrrolidine-1-carboxylate

[0836] [ka]

[0837] To a solution of (S)-tert-butyl 3-(2-hydroxyethyl)pyrrolidine-1-carboxylate (3.3 g, 15.5 mmol) and 4-methylmorpholine (1.85 g, 18.5 mmol) in DCM (40 mL) was added methyl propiolate (1.55 g, 18.5 mmol) at room temperature. The mixture was stirred at room temperature for 15 hours and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 4:1) to give (S)-tert-butyl 3-(2-(3-methoxy-3-oxoprop-1-enyloxy)ethyl)pyrrolidine-1-carboxylate as a colorless oil (4.0 g). Yield 87% (ESI 200 (M+H-Boc) + ).

[0838] Step 2: (S)-tert-butyl 3-(2-(3-methoxy-3-oxopropoxy)ethyl)pyrrolidine-1-carboxylate

[0839] [ka]

[0840] A mixture of (S)-tert-butyl 3-(2-(3-methoxy-3-oxoprop-1-enyloxy)ethyl)pyrrolidine-1-carboxylate (4.0 g, 16.0 mmol) and Pd / C (10%, 200 mg) in EtOAc (25 mL) was stirred under H at room temperature overnight. The solids were removed by filtration, and the filtrate was concentrated under reduced pressure to give the desired product, (S)-tert-butyl 3-(2-(3-methoxy-3-oxopropoxy)ethyl)pyrrolidine-1-carboxylate, as a yellow oil (4.0 g). Yield 96% (ESI 202 (M+H-Boc) + ).

[0841] Step 3: (S)-tert-butyl 3-(2-(4-(dimethoxyphosphoryl)-3-oxobutoxy)ethyl)pyrrolidine-1-carboxylate

[0842] [ka]

[0843] To a solution of (S)-tert-butyl 3-(2-(3-methoxy-3-oxopropoxy)ethyl)pyrrolidine-1-carboxylate (1.5 g, 5.0 mmol) and dimethylmethylphosphonate (0.682 g, 5.5 mmol) in anhydrous THF (10 mL) at 0 °C under Ar, LDA (2 M in THF, 5.25 mL, 10.5 mmol) was added dropwise. After stirring at 0 °C for 10 min, the reaction was quenched with MeOH (5 mL). The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 2:1) to give the desired product (S)-tert-butyl 3-(2-(4-(dimethoxyphosphoryl)-3-oxobutoxy)ethyl)pyrrolidine-1-carboxylate as a yellow oil (1.1 g). Yield 57% (ESI 394 (M+H) + ).

[0844] Step 4: (S)-tert-butyl 3-(2-(2-(1,8-naphthyridin-2-yl)ethoxy)ethyl)pyrrolidine-1-carboxylate

[0845] [ka]

[0846] A mixture of 2-aminonicotinaldehyde (128 mg, 1.1 mmol), (S)-tert-butyl 3-(2-(4-(dimethoxyphosphoryl)-3-oxobutoxy)ethyl)pyrrolidine-1-carboxylate (400 mg, 1.1 mmol), and NaOH (81 mg, 2.2 mmol) in MeOH (6 mL) and HO (2 mL) was stirred at room temperature overnight. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC A (40% to 70% MeCN) to give the desired product, (S)-tert-butyl 3-(2-(2-(1,8-naphthyridin-2-yl)ethoxy)ethyl)pyrrolidine-1-carboxylate, as a colorless oil (60 mg). Yield 16% (ESI 372 (M+H) + ).

[0847] Step 5: (S)-7-(2-(2-(pyrrolidin-3-yl)ethoxy)ethyl)-1,2,3,4-tetrahydro-1,8-naphthyridine hydrochloride

[0848] [ka]

[0849] A mixture of (S)-tert-butyl 3-(2-(2-(1,8-naphthyridin-2-yl)ethoxy)ethyl)pyrrolidine-1-carboxylate (400 mg, 1.08 mmol) and Pd / C (80 mg, 10%) in EtOAc (20 mL) was stirred under H at room temperature overnight. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was treated with HCl / dioxane solution (4.0 M, 4 mL) at room temperature for 2 hours, and the solvent was removed under reduced pressure to give the desired product, (S)-7-(2-(2-(pyrrolidin-3-yl)ethoxy)ethyl)-1,2,3,4-tetrahydro-1,8-naphthyridine hydrochloride, as a white solid (325 mg). Yield 96% (ESI 276.2 (M+H) + ).

[0850] Step 6: Methyl 2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((S)-3-(2-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy)ethyl)pyrrolidin-1-yl)acetate

[0851] [ka]

[0852] A mixture of (S)-7-(2-(2-(pyrrolidin-3-yl)ethoxy)ethyl)-1,2,3,4-tetrahydro-1,8-naphthyridine hydrochloride (226 mg, 0.65 mmol), methyl 2-bromo-2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)acetate (240 mg, 0.65 mmol) and DIEA (252 mg, 1.95 mmol) in acetonitrile (10 mL) was stirred at room temperature overnight. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (DCM:MeOH 20:1) to give the desired product methyl 2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((S)-3-(2-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy)ethyl)pyrrolidin-1-yl)acetate as a yellow oil (310 mg). Yield 84% (ESI 526 (M+H) + ).

[0853] Step 7: 2-(5-Fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((S)-3-(2-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy)ethyl)pyrrolidin-1-yl)acetic acid (Compounds 95-E1 and 95-E2)

[0854] [ka]

[0855] Methyl 2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((S)-3-(2-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy)ethyl)pyrrolidin-1-yl)acetate (310 mg, 0.55 mmol) was treated with LiOH—HO (250 mg, 5.95 mmol) in MeOH (5 mL) and HO (1 mL) at 40° C. overnight. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC A (30% to 60% MeCN) to give diastereomeric products Compound 95-E1 (67 mg) and Compound 95-E2 (37 mg) as white solids.

[0856] Compound 95-E1 LC / MS ESI 512.3(M+H) + . 1 H NMR (400MHz, MeOD) δ7.62-7.55(m, 1H), 7.54-7.50(m, 1H), 7.20-7.10(m, 2H), 6.35(d, J=7.3Hz, 1H), 4.88-4.78(m, 2H), 4.08-4.04(m, 1H), 3.82-3.75(m, 1H) ), 3.70-3.61(m, 3H), 3.49-3.40(m, 3H), 3.38-3.31(m, 2H), 3.06-2.99(m, 1H) , 2.68-2.77(m, 5H), 2.50-2.39(m, 1H), 2.20-1.90(m, 3H), 1.95-1.60(m, 9H).

[0857] Compound 95-E2 LC / MS ESI 512.3(M+H) + . 1H NMR (400MHz, MeOD) δ7.43-7.36(m, 2H), 7.18-7.09(m, 2H), 6.38-6.33(d, J=7. 3Hz, 1H), 5.42(s, 1H), 4.80-4.50(m, 1H), 4.18-4.04(m, 1H), 3.65-3.62(m, 3H) ), 3.50-3.41(m, 2H), 3.38-3.31(m, 3H), 3.20-3.00(m, 3H), 2.75-2.65(m, 4H) , 2.40-2.30(m, 1H), 2.20-2.05(m, 2H), 1.98-1.93(m, 1H), 1.90-1.58(m, 9H).

[0858] [Example 26]: Preparation of 2-(2-(5,5-dimethyltetrahydrofuran-2-yl)-5-fluorophenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 96-E1 and 96-E2)

[0859] Step 1: 1-(2-bromo-4-fluorophenyl)-4-methylpent-4-en-1-ol

[0860] [ka]

[0861] Magnesium (0.489 g, 20.1 mmol) was placed in an oven-dried, three-necked round-bottom flask equipped with a magnetic stir bar, condenser, nitrogen inlet, and septum. The magnesium was dried with a heat gun under a nitrogen stream while stirring and stirred overnight under a nitrogen stream. Anhydrous tetrahydrofuran (12 mL) was then added, and the mixture was brought to reflux using a heat gun. A small amount of 1,2-dibromoethane (0.116 mL, 1.34 mmol) was added, and the mixture was again brought to reflux. A solution of 4-bromo-2-methylbut-1-ene (1.6 mL, 13.4 mmol) in anhydrous tetrahydrofuran (10 mL) was added dropwise at a rate sufficient to maintain the exothermic reaction. Upon complete addition, the grayish-brown reaction mixture was stirred for an additional 20 minutes and then slowly cooled to room temperature. The Grignard reagent was withdrawn into a syringe and added dropwise to a solution of 2-bromo-4-fluorobenzaldehyde (2.72 g, 13.4 mmol) in anhydrous tetrahydrofuran (15 mL) under argon at 0°C. Upon complete addition, the mixture was allowed to reach room temperature, stirred for 30 minutes, quenched with saturated ammonium chloride, and extracted twice with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. Purification by column chromatography (silica, 1% to 15% diisopropyl ether / heptane) afforded the desired product, 1-(2-bromo-4-fluorophenyl)-4-methylpent-4-en-1-ol (1.43 g). Yield: 39%. 1 H NMR (400 MHz, chloroform-d) δ 7.58-7.51 (m, 1H), 7.30-7.23 (m, 1H), 7.11-7.02 (m, 1H), 5.09-5.01 (m, 1H), 4.76 (s, 2H), 2.29-2.10 (m, 2H), 2.03 (d, J = 3.6 Hz, 1H), 1.96-1.83 (m, 1H), 1.83-1.68 (m, 4H).

[0862] Step 2: 5-(2-bromo-4-fluorophenyl)-2,2-dimethyltetrahydrofuran

[0863] [ka]

[0864] To a solution of 1-(2-bromo-4-fluorophenyl)-4-methylpent-4-en-1-ol (1.43 g, 5.24 mmol) in toluene (30 mL) was added p-toluenesulfonic acid monohydrate (0.996 g, 5.24 mmol). The mixture was stirred at 80 °C for 1 hour, cooled to room temperature, quenched with saturated aqueous sodium bicarbonate, and extracted three times with dichloromethane. The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. Purification by column chromatography (silica, 0% to 8% diisopropyl ether / heptane) afforded the desired product, 5-(2-bromo-4-fluorophenyl)-2,2-dimethyltetrahydrofuran (1.28 g). Yield: 89%. 1 H NMR (400 MHz, chloroform-d) δ 7.60-7.52 (m, 1H), 7.29-7.21 (m, 1H), 7.07-6.98 (m, 1H), 5.19 (t, J = 7.2 Hz, 1H), 2.64-2.53 (m, 1H), 1.93-1.77 (m, 2H), 1.74-1.61 (m, 1H), 1.42 (s, 3H), 1.36 (s, 3H).

[0865] Step 3: tert-butyl 2-(2-(5,5-dimethyltetrahydrofuran-2-yl)-5-fluorophenyl)acetate

[0866] [ka]

[0867] Zinc dust (1.202 g, 18.4 mmol) was placed in an oven-dried flask and heated with a heat gun under a stream of argon. After cooling to room temperature, anhydrous tetrahydrofuran (26 mL) was added, followed by 1,2-dibromoethane (0.04 mL, 0.46 mmol). The mixture was heated to reflux and cooled to room temperature three times. Trimethylsilyl chloride (0.059 mL, 0.46 mmol) was then added, causing the mixture to reflux spontaneously and the zinc to convert. After stirring for 20 minutes, tert-butyl bromoacetate (1.34 mL, 9.19 mmol) was added dropwise, resulting in an exotherm. The mixture was maintained at elevated temperature (45°C) for 30 minutes and then allowed to cool to room temperature. A separate flask was charged with 5-(2-bromo-4-fluorophenyl)-2,2-dimethyltetrahydrofuran (1.26 g, 4.59 mmol), tri-tert-butylphosphine tetrafluoroborate (0.147 g, 0.505 mmol), and bis-(dibenzylideneacetone)palladium (0.264 g, 0.459 mmol). The reaction vessel was flushed with argon, and anhydrous tetrahydrofuran (26 mL) was added. Argon was then bubbled through for 5 minutes. The zincate solution was added via syringe, and the reaction mixture was heated to reflux for 1 hour. The mixture was cooled to room temperature overnight, quenched with saturated aqueous ammonium chloride, and extracted three times with heptane / ethyl acetate (1 / 1, by volume). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. Purification by column chromatography (silica, 1% to 6% acetone / heptane) gave the desired product tert-butyl 2-(2-(5,5-dimethyltetrahydrofuran-2-yl)-5-fluorophenyl)acetate (1.31 g), 92% yield. 1 H NMR (400 MHz, chloroform-d) δ 7.51 (dd, J = 8.6, 6.0 Hz, 1H), 7.00-6.88 (m, 2H), 5.10 (dd, J = 8.5, 6.2 Hz, 1H), 3.57 (q, J = 15.5 Hz, 2H), 2.38-2.28 (m, 1H), 1.92-1.71 (m, 3H), 1.43 (s, 9H), 1.40 (s, 3H), 1.34 (s, 3H).

[0868] Step 4: tert-butyl 2-bromo-2-(2-(5,5-dimethyltetrahydrofuran-2-yl)-5-fluorophenyl)acetate

[0869] [ka]

[0870] To a solution of tert-butyl 2-(2-(5,5-dimethyltetrahydrofuran-2-yl)-5-fluorophenyl)acetate (200 mg, 0.65 mmol) in THF (4 mL) at −78° C. was added dropwise lithium diisopropylamide solution, 1.0 M in THF / hexane (1.3 mL, 1.3 mmol). The reaction was stirred at −78° C. for 30 minutes, and then chlorotrimethylsilane (141 mg, 1.3 mmol) was added and the reaction was stirred at −78° C. for an additional 30 minutes. Next, a solution of NBS (231 mg, 1.3 mmol) in THF (2 mL) was added, and the reaction was stirred at −78° C. for 1 hour. The reaction was quenched with MeOH (2 mL), the solvent was removed under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product tert-butyl 2-bromo-2-(2-(5,5-dimethyltetrahydrofuran-2-yl)-5-fluorophenyl)acetate as a colorless oil (180 mg). Yield: 72%. (ESI 387 (M+H) + ).

[0871] Step 5: tert-butyl 2-(2-(5,5-dimethyltetrahydrofuran-2-yl)-5-fluorophenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate

[0872] [ka]

[0873] A mixture of tert-butyl 2-bromo-2-(2-(5,5-dimethyltetrahydrofuran-2-yl)-5-fluorophenyl)acetate (650 mg, 1.68 mmol), (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (584 mg, 1.68 mmol) and DIPEA (650 mg, 5.04 mmol) in acetonitrile (20 mL) was stirred at room temperature for 3 hours. The solvent was removed under reduced pressure and the residue was purified by silica gel column (DCM:MeOH 10:1) to give the desired product tert-butyl 2-(2-(5,5-dimethyltetrahydrofuran-2-yl)-5-fluorophenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate as a yellow oil (550 mg). Yield 56%. (ESI 582 (M+H) + ).

[0874] Step 6: 2-(2-(5,5-dimethyltetrahydrofuran-2-yl)-5-fluorophenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 96-E1 and 96-E2)

[0875] [ka]

[0876] tert-Butyl 2-(2-(5,5-dimethyltetrahydrofuran-2-yl)-5-fluorophenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (550 mg, 0.95 mmol) was treated with HCl / 1,4-dioxane (4 M, 10 mL) at 25° C. for 2 h. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC A (33% to 65% MeCN) to give 96 as a white solid (220 mg, 44% yield). The racemic product was separated by preparative chiral SFC E to give diastereomeric products 96-E1 (44 mg) and 96-E2 (49 mg) as white solids, each a mixture of two stereoisomers.

[0877] Compound 96-E1 (mixture of two stereoisomers) LC / MS ESI 526 (M+H) + . 1 H NMR (500MHz, MeOD) δ7.65-7.61(m, 1H), 7.48(dd, J=10Hz, 2.5Hz, 1H), 7.18-7.15(m, 2H), 6.39(d, J=7.5Hz, 1H), 5.42(m, 1H), 4.85(s, 1H), 4.20(s, 1H), 3.49-3.36(m, 5H), 3.22-3.18(m, 2H), 2.73-2.52(m, 5H), 2.21-1.87(m, 7H), 1.75-1.61(m, 4H), 1.45-1.36(m, 7H). Chiral SFC E(45%MeOH): ee100%, Rt=3.49 min.

[0878] Compound 96-E2 (mixture of two stereoisomers) LC / MS ESI 526 (M+H) + . 1H NMR (500MHz, MeOD) δ7.65-7.61(m, 1H), 7.45(dd, J=10Hz, 2.5Hz, 1H), 7.18-7.16(m, 2H), 6.39(d, J=7.5Hz, 1H), 5.35(m, 1H), 4.97(s, 1H), 4.20(s, 1H), 3.54-3.36(m, 5H), 3.22-3.05(m, 2H), 2.73-2.50(m, 5H), 2.22-1.88(m, 7H), 1.76-1.62(m, 4H), 1.41-1.36(m, 7H). Chiral SFC E(45%MeOH): ee98%, Rt=4.52 min.

[0879] [Example 27]: Preparation of 2-(2-(4,4-dimethyltetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 97-A-E1, 97-A-E2, 97-B-E1, and 97-B-E2)

[0880] Step 1: 4,4-Dimethyltetrahydro-2H-pyran-2-one

[0881] [ka]

[0882] To a suspension of lithium aluminum hydride (220 mg, 5.79 mmol) in anhydrous THF (15 mL) was added dropwise a solution of 4,4-dimethyldihydro-2H-pyran-2,6(3H)-dione (1.42 g, 10.0 mmol) in THF (10 mL) at −55° C. The reaction was gradually warmed to 0° C., stirred for 20 min, cooled to −15° C., and quenched by the dropwise addition of aqueous HCl (6 N, 4 mL). The mixture was extracted with ether (3×15 mL), and the combined organic layers were dried over NaSO. The solvent was removed under reduced pressure to give the desired product, 4,4-dimethyltetrahydro-2H-pyran-2-one, as an oil (0.91 g, 71% yield). 1H NMR (400MHz, CDCl3) δ4.40(t, J=6.0Hz, 2H), 2.35(s, 2H), 1.75(t, J=6.0Hz, 2H), 1.10(s, 6H).

[0883] Step 2: 2-(2-bromophenyl)-4,4-dimethyltetrahydro-2H-pyran-2-ol

[0884] [ka]

[0885] To a solution of 1-bromo-2-iodobenzene (727 mg, 2.58 mmol) in THF (15 mL) was added dropwise isopropylmagnesium chloride solution (2 M in THF, 1.3 mL, 2.6 mmol) at −25° C. The reaction mixture was stirred at −25° C. for 1 h, and then a solution of 4,4-dimethyltetrahydro-2H-pyran-2-one (300 mg, 2.34 mmol) in THF (3 mL) was added dropwise at −25° C. The reaction mixture was warmed to room temperature within 1 h, quenched with MeOH (5 mL), and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 4:1) to give the desired product, 2-(2-bromophenyl)-4,4-dimethyltetrahydro-2H-pyran-2-ol (130 mg) as a yellow oil. Yield 18% (ESI 285 / 287 [M+H] + ).

[0886] Step 3: 2-(2-bromophenyl)-4,4-dimethyltetrahydro-2H-pyran

[0887] [ka]

[0888] To a solution of 2-(2-bromophenyl)-4,4-dimethyltetrahydro-2H-pyran-2-ol (130 mg, 0.46 mmol) and TFA (0.23 mL) in DCM (6 mL) was added EtSiH (267 mg, 2.3 mmol) dropwise at 0 °C. The reaction mixture was stirred at room temperature for 1 h, quenched with saturated NaHCO solution (20 mL), and extracted with DCM (3 x 10 mL). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product, 2-(2-bromophenyl)-4,4-dimethyltetrahydro-2H-pyran, as a yellow oil (90 mg). Yield 78% (ESI 269 / 271 [M+H] + ).

[0889] Step 4: tert-butyl 2-(2-(4,4-dimethyltetrahydro-2H-pyran-2-yl)phenyl)acetate

[0890] [ka]

[0891] A mixture of 2-(2-bromophenyl)-4,4-dimethyltetrahydro-2H-pyran (180 mg, 0.68 mmol), (2-tert-butoxy-2-oxoethyl)zinc(II) bromide solution (0.5 M in THF, 6.8 mL, 3.4 mmol), Pd(dba) (35 mg, 0.034 mmol), and Q-phos (25 mg, 0.034 mmol) in THF (2 mL) was stirred at 80 °C for 2 h. The reaction mixture was then poured into saturated NaHCO solution (50 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product tert-butyl 2-(2-(4,4-dimethyltetrahydro-2H-pyran-2-yl)phenyl)acetate as a red oil (150 mg). Yield 73% (ESI 327 [M+Na] + ).

[0892] Step 5: tert-butyl 2-bromo-2-(2-(4,4-dimethyltetrahydro-2H-pyran-2-yl)phenyl)acetate

[0893] [ka]

[0894] To a solution of tert-butyl 2-(3-isopropyl-3,4-dihydro-1H-pyrano[3,4-c]pyridin-5-yl)acetate (600 mg, 2.0 mmol) in THF (10 mL) was added dropwise a solution of lithium diisopropylamide (2.0 M, 2.5 mL, 5.0 mmol) at −78° C. The reaction was stirred at −78° C. for 30 minutes, and then a solution of chlorotrimethylsilane (540 mg, 5.0 mmol) in THF (1 mL) was added, and the reaction was stirred at −78° C. for an additional 30 minutes. Next, a solution of NBS (890 mg, 5.0 mmol) in THF (10 mL) was added, and the reaction was stirred at −78° C. for 1 hour. The reaction was quenched with MeOH (2 mL), the solvent was removed under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product tert-butyl 2-bromo-2-(2-(4,4-dimethyltetrahydro-2H-pyran-2-yl)phenyl)acetate as a colorless oil (650 mg). Yield 86% (ESI 327 [M-Bu+H] + ).

[0895] Step 6: tert-butyl 2-(2-(4,4-dimethyltetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate

[0896] [ka]

[0897] A mixture of tert-butyl 2-bromo-2-(2-(4,4-dimethyltetrahydro-2H-pyran-2-yl)phenyl)acetate (375 mg, 1.0 mmol), (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (306 mg, 1.0 mmol), DIPEA (774 mg, 6.0 mmol), and NaI (50 mg) in acetonitrile (10 mL) was stirred at 40° C. for 12 hours. The mixture was diluted with water (8 mL) and EtOAc (25 mL). The organic phase was washed with brine, dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (DCM:MeOH 20:1) to give the desired product tert-butyl 2-(2-(4,4-dimethyltetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate as a colorless oil (410 mg). Yield 72% (ESI 578 [M+H] + ).

[0898] Step 7: 2-(2-(4,4-dimethyltetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 97-A-E1, 97-A-E2, 97-B-E1, and 97-B-E2)

[0899] [ka]

[0900] tert-Butyl 2-(2-(4,4-dimethyltetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (570 mg, 1.0 mmol) was treated with HCl / 1,4-dioxane (4 M, 10 mL) at 25° C. for 6 h. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC A (40% to 70% MeCN) to give 97-A (102 mg) and 97-B (130 mg). 97-A was separated by preparative chiral SFC H to give products 97-A-E1 (36 mg) and 97-A-E2 (31 mg) as white solids. 97-B was separated by preparative chiral SFC H to give products 97-B-E1 (30 mg) and 97-B-E2 (44 mg) as white solids.

[0901] Compound 97-A-E1 LC / MS ESI 522(M+H) + . 1 H NMR (400MHz, MeOD) δ7.68-7.66(m, 1H), 7.54-7.52(m, 1H), 7.41-7.34(m, 2H), 7.15-7.13(m, 1 H), 6.36(d, J=7.6Hz, 1H), 5.02-4.95(m, 2H), 4.21-4.19(m, 1H), 3.88-3.86(m, 2H), 3.62-3.60 (m, 1H), 3.50-3.41(m, 5H), 3.20-3.18(m, 1H), 3.05-3.02(m, 1H), 2.70-2.68(m, 2H), 2.55-2. 52(m, 2H), 2.10-2.07(m, 2H), 1.90-1.50(m, 9H), 1.31-1.29(m, 1H), 1.20(s, 3H), 1.05(s, 3H). Chiral SFC H(40%MeOH): ee100%, Rt=2.81 min.

[0902] Compound 97-A-E2 LC / MS ESI 522(M+H) + . 1H NMR (400MHz, MeOD) δ7.69-7.67(m, 1H), 7.54-7.52(m, 1H), 7.41-7.31(m, 2H), 7.15-7.13(m, 1H), 6.36(d, J=7.6Hz, 1H), 5.02-5.00(m, 1H), 4.84(s, 1H), 4.16-4.14(m, 1H), 3.90-3.88(m HPLC-MS / MS: 500-500 nm (m, 4H), 1.57-1.62 (m, 2H), 3.62-3.60 (m, 1H), 3.50-3.41 (m, 5H), 3.20-3.18 (m, 2H), 2.70-2.68 (m, 2H), 2.54-2.52 (m, 2H), 2.10-2.07 (m, 2H), 1.90-1.50 (m, 9H), 1.31-1.29 (m, 1H), 1.20 (s, 3H), 1.05 (s, 3H). Kirar SFC H (40% MeOH): ee 100%, Rt = 3.78 min.

[0903] Compound 97-B-E1 LC / MS ESI 522 (M+H) + . 1 H NMR (400MHz, MeOD) δ7.68-7.66 (m, 1H), 7.54-7.52 (m, 1H), 7.41-7.34 (m, 2H), 7.15-7.13 (m, 1 H), 6.36 (d, J=7.6Hz, 1H), 5.02-4.90 (m, 2H), 4.16-4.14 (m, 1H), 3.90-3.88 (m, 2H), 3.62-3.60 (m, 1H), 3.50-3.41 (m, 5H), 3.20-3.18 (m, 1H), 3.05-3.02 (m, 1H), 2.70-2.68 (m, 2H), 2.54-2.52 (m, 2H), 2.10-2.07 (m, 2H), 1.90-1.50 (m, 9H), 1.31-1.29 (m, 1H), 1.20 (s, 3H), 1.05 (s, 3H). Kirar SFC H (40% MeOH): ee 100%, Rt = 2.76 min.

[0904] Compound 97-B-E2 LC / MS ESI 522 (M+H) + . 1H NMR (400MHz, MeOD) δ7.68-7.66(m, 1H), 7.54-7.52(m, 1H), 7.44-7.34(m, 3 H), 6.49(d, J=7.2Hz, 1H), 5.02-4.90(m, 2H), 4.16-4.14(m, 1H), 3.92-3.90 (m, 2H), 3.70-3.20(m, 8H), 2.70-2.68(m, 2H), 2.54-2.52(m, 2H), 2.10-2. 07(m, 2H), 1.90-1.50(m, 9H), 1.31-1.29(m, 1H), 1.20(s, 3H), 1.05(s, 3H). Chiral SFC H(40% MeOH): ee 100%, Rt = 3.85 min.

[0905] [Example 28]: Preparation of 2-(5-fluoro-2-(5-oxaspiro[2.5]octan-6-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 98-A-E1, 98-A-E2, and 98-B)

[0906] Step 1: Cyanomethyl 2-bromo-4-fluorobenzoate

[0907] [ka]

[0908] To a solution of 2-bromo-4-fluorobenzoic acid (5.0 g, 0.23 mol) in anhydrous DCM (20 mL) at 0 °C was added triethylamine (9.2 g, 0.69 mol) and chloroacetonitrile (3.5 g, 0.46 mol). The reaction was heated to reflux and stirred overnight. After cooling to room temperature, the reaction mixture was washed successively with aqueous HCl (2 M, 20 mL) and saturated NaHCO3 solution (20 mL). The organic phase was dried over anhydrous MgSO4 and concentrated under reduced pressure to give the desired product, cyanomethyl 2-bromo-4-fluorobenzoate, as a pale yellow oil (4.0 g). Yield: 68% (ESI 258 / 260 [M+H] + ).

[0909] Step 2: 1-(2-bromo-4-fluorophenyl)-5-hydroxypentane-1,4-dione

[0910] [ka]

[0911] To a solution of cyanomethyl 2-bromo-4-fluorobenzoate (3.4 g, 13.2 mmol) and Ti(OiPr) (4.15 g, 14.6 mmol) in EtO (70 mL) at 0 °C under argon was added EtMgBr (28 mL, 28 mmol, 1 M solution in THF) dropwise. After the Grignard reagent was added, the mixture was warmed to room temperature and stirred for 1 h. The cloudy yellow mixture was quenched with water (10 mL), 1 M HCl (30 mL) was added, and the mixture was extracted with EtOAc (3 x 50 mL). The combined organic phase was washed with saturated aqueous NaHCO and dried (MgSO). After evaporation of the solvent, the residue was purified by silica gel column (petroleum ether: EtOAc 3:1) to give the desired product 1-(2-bromo-4-fluorophenyl)-5-hydroxypentane-1,4-dione (901 mg) as a colorless oil. Yield 25% (ESI 289 / 271 [M+H] + ).

[0912] Step 3: 6-(2-bromo-4-fluorophenyl)tetrahydro-2H-pyran-3-ol

[0913] [ka]

[0914] To a solution of 1-(2-bromo-4-fluorophenyl)-5-hydroxypentane-1,4-dione (900 mg, 3.13 mmol) in DCM (40 mL) was added boron trifluoride (diethyl ether complex, 1110 mg, 7.8 mmol) dropwise at 0 °C. After the addition, triethylsilane (910 mg, 7.8 mmol) was added, and the reaction was stirred at 0 °C for 1 h. The reaction mixture was quenched with saturated NaHCO (20 mL) and extracted with DCM (2 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 3:1) to give the desired product, 6-(2-bromo-4-fluorophenyl)tetrahydro-2H-pyran-3-ol (650 mg) as a colorless oil. Yield 80% (ESI 275 / 277 [M+H] + ).

[0915] Step 4: 6-(2-bromo-4-fluorophenyl)dihydro-2H-pyran-3(4H)-one

[0916] [ka]

[0917] To a solution of 6-(2-bromo-4-fluorophenyl)tetrahydro-2H-pyran-3-ol (100 mg, 0.37 mmol) in DCM (5 mL) was added Dess-Martin periodonan (150 mg, 0.50 mmol) in several portions. After the addition, the reaction mixture was stirred at room temperature for 2 h and quenched with saturated NaHCO3 solution (5 mL). The organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product, 6-(2-bromo-4-fluorophenyl)dihydro-2H-pyran-3(4H)-one, as a colorless oil (20 mg). Yield 20% (ESI 273 / 275 [M+H] + ).

[0918] Step 5: 2-(2-bromo-4-fluorophenyl)-5-methylenetetrahydro-2H-pyran

[0919] [ka]

[0920] To a solution of methyltriphenylphosphonium bromide (134 mg, 0.52 mmol) in THF (3 mL) at 0 °C was added n-BuLi (2.5 M in hexane, 0.21 mL, 0.52 mmol). The reaction was stirred at 0 °C for 30 min, followed by the addition of a solution of 6-(2-bromo-4-fluorophenyl)dihydro-2H-pyran-3(4H)-one (70 mg, 0.26 mmol) in THF (2 mL). The reaction was stirred at room temperature for 12 h, quenched with saturated aqueous NH4Cl, and extracted with DCM (2 x 10 mL). The combined organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product 2-(2-bromo-4-fluorophenyl)-5-methylenetetrahydro-2H-pyran as a colorless oil (51 mg, 70% yield). 1 H NMR (400MHz, CDCl3) δ7.52-7.50(m, 1H), 7.27-7.25(m, 1H), 7.05-7.01(m, 1H), 4.89-4.88(m, 2H), 4.75-4. 73(m, 1H), 4.37-4.34(m, 1H), 4.20-4.17(m, 1H), 2.50-2.46(m, 2H), 2.15-2.10(m, 1H), 1.52-1.50(m, 1H).

[0921] Step 6: 6-(2-bromo-4-fluorophenyl)-5-oxaspiro[2.5]octane

[0922] [ka]

[0923] To a solution of ZnEt (1 M in THF, 6 mL, 6.0 mmol) in DCM (20 mL) at 0 °C was added TFA (690 mg, 6.0 mmol). The reaction was stirred at 0 °C for 0.5 h, then CHCl (1.7 g, 6.0 mmol) was added dropwise. The reaction was stirred at 0 °C for 0.5 h, and then 2-(2-bromo-4-fluorophenyl)-5-methylenetetrahydro-2H-pyran (280 mg, 1.0 mmol) in DCM (1 mL) was added. The reaction mixture was stirred at room temperature for 2 h, quenched with saturated NaHCO solution (20 mL), and the DCM layer was dried over NaSO. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 50:1) to give the desired product 6-(2-bromo-4-fluorophenyl)-5-oxaspiro[2.5]octane as a yellow oil (250 mg). Yield 80% (ESI 267 / 269 [M+H-HO] + ).

[0924] Step 7: tert-butyl 2-(5-fluoro-2-(5-oxaspiro[2.5]octan-6-yl)phenyl)acetate

[0925] [ka]

[0926] A mixture of 6-(2-bromo-4-fluorophenyl)-5-oxaspiro[2.5]octane (250 mg, 0.88 mmol), (2-tert-butoxy-2-oxoethyl)zinc(II) bromide solution 0.5 M in THF (10 mL, 5 mmol), Pd(dba) (40 mg, 0.05 mmol), and Q-phos (31 mg, 0.05 mmol) in THF (2 mL) was stirred at 80 °C for 2 h. The mixture was then poured into saturated NaHCO solution (50 mL) and EtOAc (60 mL). The mixture was filtered, the organic layer was washed with brine, dried over NaSO, concentrated under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product tert-butyl 2-(5-fluoro-2-(5-oxaspiro[2.5]octan-6-yl)phenyl)acetate as a red oil (160 mg). Yield 53% (ESI 343 [M+Na] + ).

[0927] Step 8: tert-butyl 2-bromo-2-(5-fluoro-2-(5-oxaspiro[2.5]octan-6-yl)phenyl)acetate

[0928] [ka]

[0929] To a solution of tert-butyl 2-(5-fluoro-2-(5-oxaspiro[2.5]octan-6-yl)phenyl)acetate (160 mg, 0.5 mmol) in THF (5 mL) was added dropwise lithium diisopropylamide solution, 2.0 M in THF / hexane (0.62 mL, 1.25 mmol) at −78° C. The reaction was stirred at −78° C. for 30 minutes, and then a solution of chlorotrimethylsilane (135 mg, 1.25 mmol) in THF (1 mL) was added and the reaction was stirred at −78° C. for an additional 30 minutes. Next, a solution of NBS (221 mg, 1.25 mmol) in THF (10 mL) was added and the reaction was stirred at −78° C. for 1 hour. The reaction was quenched with MeOH (2 mL), the solvent was removed under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product tert-butyl 2-bromo-2-(5-fluoro-2-(5-oxaspiro[2.5]octan-6-yl)phenyl)acetate as a colorless oil (130 mg). Yield 60% (ESI 419 / 421 [M+Na] + ).

[0930] Step 9: tert-butyl 2-(5-fluoro-2-(5-oxaspiro[2.5]octan-6-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate

[0931] [ka]

[0932] A mixture of tert-butyl 2-bromo-2-(5-fluoro-2-(5-oxaspiro[2.5]octan-6-yl)phenyl)acetate (130 mg, 0.33 mmol), (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (101 mg, 0.33 mmol), DIPEA (126 mg, 0.99 mmol), and NaI (50 mg) in acetonitrile (10 mL) was stirred at 40° C. for 12 hours. The mixture was diluted with water (8 mL) and EtOAc (25 mL). The organic phase was washed with brine, dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (DCM:MeOH 20:1) to give the desired product tert-butyl 2-(5-fluoro-2-(5-oxaspiro[2.5]octan-6-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate as a colorless oil (101 mg). Yield=52% (ESI 595 [M+H] + ).

[0933] Step 10: 2-(5-fluoro-2-(5-oxaspiro[2.5]octan-6-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 98-A-E1, 98-A-E2, and 98-B)

[0934] [ka]

[0935] A solution of tert-butyl 2-(5-fluoro-2-(5-oxaspiro[2.5]octan-6-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (210 mg, 0.35 mmol) in TFA (2 mL) and DCM (2 mL) was stirred at room temperature for 15 h. It was then concentrated and purified by preparative HPLC A (40% to 70% MeCN) to give 98-A (106 mg) and 98-B (16 mg). 98-A was separated by preparative chiral SFC C to give products 98-A-E1 (35 mg) and 98-A-E2 (31 mg) as white solids.

[0936] Compound 98-A-E1 LC / MS ESI 538(M+H) + . 1 H NMR (500MHz, MeOD) δ7.64-7.61(m, 1H), 7.49-7.46(m, 1H), 7.18-7.16(m, 2H), 6.39(d, J=7.5Hz, 1H), 4.93(s , 1H), 4.82-4.85(m, 1H), 4.19(brs, 1H), 4.12-4.10(m, 1H), 3.61(m, 1H), 3.49(t, J=6.5Hz, 2H), 3.341-3.38( m, 3H), 3.23(d, J=12.5H, 1H), 3.11-3.09(m, 2H), 2.72(t, J=6.0Hz, 2H), 2.56(t, J=7.5Hz, 2H), 2.3-2.2-(m, 1 H), 2.11-2.00(m, 4H), 1.90-1.88(m, 2H), 1.74-1.72(m, 2H), 1.65-1.63(m, 2H), 1.2(m, 1H), 0.6-0.3(m, 4H). Chiral SFC C(20%EtOH): ee100%, Rt=1.29 min.

[0937] Compound 98-A-E2 LC / MS ESI 538(M+H) + . 1H NMR (400MHz, MeOD) δ7.63-7.61(m, 1H), 7.50-7.48(m, 1H), 7.22-7.16(m, 2H), 6.39(d, J=7.6Hz, 1H), 4.82-4.80(m, 1H) ), 4.20-4.12(m, 2H), 3.60-3.32(m, 6H), 3.30-3.05(m, 4H), 2.75-2.55(m, 4H), 2.25-1.58(m, 12H), 0.58-0.30(m, 4H). Chiral SFC C(20%EtOH): ee100%, Rt=2.17 min.

[0938] Compound 98-B (mixture of two stereoisomers) LC / MS ESI 538 (M+H) + . 1 H NMR (400MHz, MeOD) δ7.41-7.32(m, 2H), 7.08-6.98(m, 2H), 6.28-6.22(m, 1H), 4.80-4.75(m, 1H), 4.05-3.85(m, 2H), 3.60-3.32(m, 6H), 3.10-2.85(m, 4H), 2.62-2.58(m, 2H), 2.47-2.41(m, 2H), 2.21-1.40(m, 12H), 0.55-0.20(m, 4H).

[0939] [Example 29]: Preparation of 2-(2-(5,5-difluorotetrahydro-2H-pyran-2-yl)-5-fluorophenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 99-E1 and 99-E2)

[0940] Step 1: 1-(2-bromo-4-fluorophenyl)cyclopropanol

[0941] [ka]

[0942] To a solution of 1-(2-bromo-4-fluorophenyl)ethanone (5.0 g, 23.1 mmol) and EtN (3.51 g, 34.7 mmol) in DCM (50 mL) at 0 °C under nitrogen, TMSOTf (6.17 g, 27.8 mmol) was added dropwise via syringe over 10 min. The reaction mixture was stirred overnight at room temperature, quenched with saturated aqueous NaHCO (20 mL), and the aqueous solution was extracted with DCM (2 x 30 mL). The combined organic phases were washed with brine, dried over NaSO, filtered, and concentrated under reduced pressure to give the crude ether. The crude ether was dissolved in anhydrous DCM (50 mL), diiodomethane (25.0 g, 92.4 mmol) was added, cooled to 0 °C, and diethylzinc (1 M solution in THF, 93 mL, 93 mmol) was added dropwise. The reaction was stirred at room temperature for 16 hours, quenched with saturated NH4Cl solution (30 mL), and extracted with DCM (2 x 50 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give the crude material. The crude material was dissolved in MeOH (20 mL), followed by the addition of K2CO3 (3.2 g, 23.1 mmol), and then stirred at room temperature for 30 minutes. The solvent was removed under reduced pressure, H2O (20 mL) was added, and extracted with EtOAc (2 x 40 mL). The combined organic phases were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 5:1) to give the desired product, 1-(2-bromo-4-fluorophenyl)cyclopropanol, as a colorless oil (3.1 g). Yield 86% (ESI 213 / 215 [M+H] + ).

[0943] Step 2: Ethyl 5-(2-bromo-4-fluorophenyl)-2,2-difluoro-5-oxopentanoate

[0944] [ka]

[0945] A mixture of 1-(2-bromo-4-fluorophenyl)cyclopropanol (100 mg, 0.44 mmol), ethyl 2-bromo-2,2-difluoroacetate (351 mg, 1.74 mmol), CuI (8.2 mg, 0.044 mmol), phenanthroline (17.2 mg, 0.088 mmol), and KCO (120 mg, 0.88 mmol) in MeCN (5 mL) was stirred at 90° C. for 17 h. The reaction was quenched with water (10 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine, dried over NaSO, concentrated under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 5:1) to give the desired product ethyl 5-(2-bromo-4-fluorophenyl)-2,2-difluoro-5-oxopentanoate as a colorless oil (81 mg). Yield 53% (ESI 353 / 355 [M+H] + ).

[0946] Step 3: 2-(2-bromo-4-fluorophenyl)-5,5-difluorotetrahydro-2H-pyran

[0947] [ka]

[0948] To a solution of ethyl 5-(2-bromo-4-fluorophenyl)-2,2-difluoro-5-oxopentanoate (100 mg, 0.28 mmol) in MeOH (5 mL) was added NaBH (44 mg, 1.12 mmol) at 0 °C. The reaction was stirred at room temperature for 15 h. The solvent was removed under reduced pressure, HO (10 mL) was added, and the mixture was extracted with DCM (3 x 10 mL). The combined organic phases were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was dissolved in DCM (3 mL), and triflic acid (100 mg, 0.32 mmol) was added. The reaction was stirred at room temperature for 15 h, quenched with saturated aqueous NaHCO (5 mL), and extracted with DCM (2 x 10 mL). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product, 2-(2-bromo-4-fluorophenyl)-5,5-difluorotetrahydro-2H-pyran, as a colorless oil (40 mg). Yield 47% (ESI 297 / 299 [M+H] + ).

[0949] Step 4: tert-butyl 2-(2-(5,5-difluorotetrahydro-2H-pyran-2-yl)-5-fluorophenyl)acetate

[0950] [ka]

[0951] A mixture of 2-(2-bromo-4-fluorophenyl)-5,5-difluorotetrahydro-2H-pyran (800 mg, 2.93 mmol), (2-tert-butoxy-2-oxoethyl)zinc(II) bromide solution (0.5 M in THF, 30 mL, 15 mmol), Pd(dba) (152 mg, 0.15 mmol), and Q-phos (105 mg, 0.15 mmol) in THF (2 mL) was stirred at 80° C. for 2 h. The reaction mixture was poured into saturated NaHCO solution (20 mL) and EtOAc (30 mL). The mixture was filtered, the organic layer was washed with brine, dried over Na2SO4, concentrated under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product tert-butyl 2-(2-(5,5-difluorotetrahydro-2H-pyran-2-yl)-5-fluorophenyl)acetate as a red oil (703 mg). Yield 78% (ESI 275 [M+H-tBu] + ).

[0952] Step 5: tert-butyl 2-bromo-2-(2-(5,5-difluorotetrahydro-2H-pyran-2-yl)-5-fluorophenyl)acetate

[0953] [ka]

[0954] To a solution of tert-butyl 2-(2-(5,5-difluorotetrahydro-2H-pyran-2-yl)-5-fluorophenyl)acetate (703 mg, 2.12 mmol) in THF (5 mL) was added dropwise a solution of lithium diisopropylamide (2 M, 2.65 mL, 5.3 mmol) at −78° C. The reaction was stirred at −78° C. for 30 minutes, and then a solution of chlorotrimethylsilane (573 mg, 5.3 mmol) in THF (1 mL) was added and the reaction was stirred at −78° C. for an additional 30 minutes. Next, a solution of NBS (944 mg, 5.3 mmol) in THF (10 mL) was added and the reaction was stirred at −78° C. for 1 hour. The reaction was quenched with MeOH (2 mL), the solvent was removed under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product tert-butyl 2-bromo-2-(2-(5,5-difluorotetrahydro-2H-pyran-2-yl)-5-fluorophenyl)acetate as a red oil (816 mg). Yield 66% (ESI 352 / 354 [M+H-tBu] + ).

[0955] Step 6: tert-butyl 2-(2-(5,5-difluorotetrahydro-2H-pyran-2-yl)-5-fluorophenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate

[0956] [ka]

[0957] A mixture of tert-butyl 2-bromo-2-(2-(5,5-difluorotetrahydro-2H-pyran-2-yl)-5-fluorophenyl)acetate (816 mg, 2.0 mmol), (R)-7-(4-(pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (660 mg, 2.0 mmol), DIPEA (821 mg, 6.0 mmol), and NaI (50 mg) in acetonitrile (20 mL) was stirred at 40° C. for 6 hours. The mixture was diluted with water (8 mL) and EtOAc (25 mL). The organic phase was washed with brine, dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (DCM:MeOH 20:1) to give the desired product tert-butyl 2-(2-(5,5-difluorotetrahydro-2H-pyran-2-yl)-5-fluorophenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate as a colorless oil (710 mg). Yield 58% (ESI 604 [M+H] + ).

[0958] Step 7: 2-(2-(5,5-difluorotetrahydro-2H-pyran-2-yl)-5-fluorophenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (compounds 99-E1 and 99-E2)

[0959] [ka]

[0960] To a solution of tert-butyl 2-(2-(5,5-difluorotetrahydro-2H-pyran-2-yl)-5-fluorophenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (710 mg, 1.2 mmol) in DCM (10 mL) was added TFA (10 mL). The reaction was stirred at room temperature for 15 h. It was then concentrated and purified by preparative HPLC (40% to 70% MeCN) to give 99 as a white solid (400 mg, 63% yield). The racemic product was separated by preparative chiral SFC A to give diastereomeric products 99-E1 (74 mg) and 99-E2 (88 mg) as white solids.

[0961] Compound 99-E1 LC / MS ESI 548(M+H) + . 1 H NMR (400MHz, MeOD) δ7.61-7.59(m, 1H), 7.51-7.48(m, 1H), 7.22-7.13(m, 2H), 6. 41(d, J=7.2Hz, 1H), 4.99-4.90(m, 1H), 4.80(s, 1H), 4.19-4.17(m, 1H), 4.01-3.8 0(m, 2H), 3.50-3.35(m, 6H), 3.20-3.18(m, 1H), 3.02-2.98(m, 1H), 2.81-2.79(m, 2H), 2.62-2.59(m, 2H), 2.30-2.01(m, 6H), 1.82-1.80(m, 2H), 1.75-1.60(m, 4H). Chiral SFC A (40%MeOH): ee100%, Rt=1.92 min.

[0962] Compound 99-E2 LC / MS ESI 548(M+H) + . 1H NMR (400MHz, MeOD) δ7.62-7.60(m, 1H), 7.53-7.51(m, 1H), 7.28(d, J=7.6Hz, 1H), 7.17-7.14(m, 1H), 6.44(d, J=7.2Hz, 1H), 4.99-4.90(m, 1H), 4.79(s, 1H), 4.19-4. 17(m, 1H), 4.01-3.80(m, 2H), 3.60-3.35(m, 6H), 3.20-3.18(m, 2H), 2.81-2.79(m , 2H), 2.62-2.59(m, 2H), 2.30-2.01(m, 6H), 1.82-1.80(m, 2H), 1.75-1.60(m, 4H). Chiral SFC A (40%MeOH): ee98%, Rt=2.47 min.

[0963] [Example 30]: Preparation of 2-(2-(5,5-dimethyltetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (Compounds 100-E1 and 100-E2)

[0964] Step 1: Ethyl 3-(2-bromophenyl)acrylate

[0965] [ka]

[0966] To a solution of 2-bromobenzaldehyde (5.00 g, 27.0 mmol) in THF (30 mL) was added ethyl 2-(triphenyl-15-phosphaneilidene)acetate (9.89 g, 28.4 mmol), and the mixture was stirred at 60° C. overnight. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product as a yellow oil (6.51 g). Yield: 93%. 1 H NMR (400MHz, CDCl3) δ8.06(d, 1H), 7.61(m, 2H), 7.24-7.19(m, 2H), 6.40(d, 1H), 4.31-4.08(m, 2H), 1.36-1.15(m, 3H).

[0967] Step 2: 3-(2-bromophenyl)prop-2-en-1-ol

[0968] [ka]

[0969] To a solution of 3-(2-bromophenyl)acrylate (6.5 g, 30.7 mmol) in THF (anhydrous, 50 mL) at 0 °C, DIBAL-H (1 M, 61.3 mL, 61.3 mmol) was added dropwise. The mixture was stirred at 0 °C for 30 min, then warmed to room temperature and left for 1 h. The reaction mixture was poured into aqueous HCl (1 N, 200 mL) and stirred at room temperature overnight. The mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 10:3) to give the desired product (5.10 g) as a light yellow oil. Yield: 89%. 1 H NMR (400MHz, CDCl3) δ7.59-7.30(m, 3H), 7.18-7.08(m, 2H), 6.34-6.30(m, 1H), 4.37-4.27(m, 2H).

[0970] Step 3: 1-Bromo-2-(3-bromoprop-1-enyl)benzene

[0971] [ka]

[0972] To a solution of 3-(2-bromophenyl)prop-2-en-1-ol (4.80 g, 22.64 mmol) in diethyl ether (anhydrous, 50 mL) at 0 °C was added phosphorus tribromide (1.27 mL, 9.06 mmol). The reaction was stirred at 0 °C for 1 h, quenched with saturated NaHCO3, and extracted with diethyl ether (2 x 50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the desired product, 1-bromo-2-(3-bromoprop-1-enyl)benzene, as a yellow oil (5.20 g). Yield: 79%. 1 H NMR (400MHz, CDCl3) δ7.56-7.46(m, 2H), 7.34-7.26(m, 2H), 6.36-6.34(m, 1H), 4.18-4.03(m, 2H).

[0973] Step 4: Methyl 5-(2-bromophenyl)-2,2-dimethylpent-4-enoate

[0974] [ka]

[0975] To a solution of methyl isobutyrate (2.13 g, 20.88 mmol) in THF (anhydrous, 40 mL) at −78° C., LDA (1 M, 20.88 mL, 20.88 mmol) was added dropwise. The mixture was stirred at −78° C. for 30 min, and a solution of 1-bromo-2-(3-bromoprop-1-en-1-yl)benzene (5.20 g, 18.98 mmol) in THF (10 mL) was added dropwise. The reaction was stirred at −78° C. for 30 min, then warmed to room temperature and aged for an additional 1 h. The reaction was quenched with saturated NH4Cl and extracted with EtOAc (3×50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified using a silica gel column (petroleum ether:EtOAc 5:1) to give the desired product as a yellow oil (4.36 g, 78% yield). 1H NMR (400MHz, CDCl3) δ7.58-7.46(m, 2H), 7.23-7.09(m, 2H), 6.74-6.51(m, 1H) , 6.10-6.02(m, 1H), 3.69-3.64(m, 3H), 2.48-2.40(m, 2H), 1.24-1.15(m, 6H).

[0976] Step 5: 5-(2-bromophenyl)-2,2-dimethylpent-4-en-1-ol

[0977] [ka]

[0978] To a solution of methyl 5-(2-bromophenyl)-2,2-dimethylpent-4-enoate (4.36 g, 14.53 mmol) in THF (anhydrous, 20 mL) was added dropwise a solution of lithium aluminum hydride in tetrahydrofuran (2.4 M, 6.66 mL, 11.80 mmol) at -78 °C. The mixture was stirred at -78 °C for 3 h and then quenched with 1 M HCl (ca. 100 mL, dropwise addition started). The reaction was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 10:3) to give the desired product as a yellow oil (3.74 g, 93% yield). ESI: 267 (M+H). + .

[0979] Step 6: Ethyl 3-(2-bromophenyl)acrylate

[0980] [ka]

[0981] To a solution of 5-(2-bromophenyl)-2,2-dimethylpent-4-en-1-ol (3.74 g, 13.95 mmol) in dichloroethane (20 mL) was added tetrabutylammonium hexafluorophosphate (0.27 g, 0.70 mmol) and calcium(II) bis(trifluoromethanesulfonyl)imide (0.22 g, 0.70 mmol). The mixture was stirred at 90° C. for 20 hours, concentrated under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product, ethyl 3-(2-bromophenyl)acrylate, as a yellow oil (1.50 g, 40% yield). 1 H NMR (400MHz, CDCl3) δ7.54(d, J=6.8Hz,2H), 7.33(t, J=8.0Hz,1H), 7.10(t, J=7.2Hz, 1H), 4.56(d, J=9.6Hz, 1H) , 3.3(d, J=11.2Hz, 1H), 3.38(d, J=11.2Hz, 1H), 1.88-1.84(m, 1H), 1.59-1.53(m, 4H), 1.13(s, 3H), 0.88(s, 3H).

[0982] Step 7: Butyl 2-(2-(5,5-dimethyltetrahydro-2H-pyran-2-yl)phenyl)acetate

[0983] [ka]

[0984] To a mixture of ethyl 3-(2-bromophenyl)acrylate (1.50 g, 5.60 mmol), tris(dibenzylideneacetone)dipalladium (0.29 g, 0.28 mmol), and 1,2,3,4,5-pentaphenyl-1′-(di-tert-butylphosphino)ferrocene (0.20 g, 0.28 mmol) in THF (10 mL) was added (2-tert-butoxy-2-oxoethyl)zinc(II) bromide (1 M solution in THF, 28 mL, 28 mmol). The reaction was stirred at 60 °C for 2 h. The reaction mixture was poured into saturated NaHCO (100 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product as a red oil (1.21 g, 71% yield). ESI: 249 (M-C4H9+H). +

[0985] Step 8: tert-butyl 2-bromo-2-(2-(5,5-dimethyltetrahydro-2H-pyran-2-yl)phenyl)acetate

[0986] [ka]

[0987] To a solution of tert-butylbutyl 2-(2-(5,5-dimethyltetrahydro-2H-pyran-2-yl)phenyl)acetate (1.21 g, 3.17 mmol) in THF (10 mL) was added dropwise lithium diisopropylamide solution, 2.0 M in THF / hexane (4.0 mL, 8.0 mmol) at −78° C. The reaction was stirred at −78° C. for 30 minutes, and then chlorotrimethylsilane (864 mg, 8.0 mmol) was added and the reaction was stirred at −78° C. for an additional 30 minutes. Next, a solution of NBS (1.43 g, 8.0 mmol) in THF (10 mL) was added and the reaction was stirred at −78° C. for 1 hour. The reaction was quenched with MeOH (2 mL), the solvent was removed under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product tert-butyl 2-bromo-2-(2-(5,5-dimethyltetrahydro-2H-pyran-2-yl)phenyl)acetate as a yellow oil (1.31 g, 85% yield). ESI: 327 (M-C4H9+H) + .

[0988] Step 9: tert-butyl 2-(2-(5,5-dimethyltetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate

[0989] [ka]

[0990] A mixture of (S)-7-(4,4-difluoro-5-(pyrrolidin-3-yl)pentyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (200 mg, 0.65 mmol), 2-bromo-2-(2-(5,5-dimethyltetrahydro-2H-pyran-2-yl)phenyl)acetate (220 mg, 0.65 mmol), DIEA (252 mg, 1.95 mmol), and NaI (19.5 mg, 0.13 mmol) in acetonitrile (10 mL) was stirred at 50° C. for 6 h. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (DCM:MeOH 20:1) to give the desired product tert-butyl 2-(2-(5,5-dimethyltetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate as a yellow oil (150 mg, 45% yield). ESI: 578 (M+H) + .

[0991] Step 10: tert-Butyl 2-(2-(5,5-dimethyltetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (Compounds 100-E1 and 100-E2)

[0992] [ka]

[0993] tert-Butyl 2-(2-(5,5-dimethyltetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (150 mg, 0.26 mmol) was treated with a mixture of DCM (3 mL) and TFA (3 mL) at 25° C. overnight. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC A (30% to 65% MeCN) to give the desired product, tert-butyl 2-(2-(5,5-dimethyltetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (compound 100), as a white solid (96 mg, 70%). The racemic product was separated by preparative chiral SFC H to give diastereomeric products 100-E1 (29 mg) and 100-E2 (26 mg) as white solids.

[0994] Compound 100-E1 LC / MS ESI 522.7(M+H) + . 1 H NMR (400MHz, MeOD) δ7.68(d, J=8.0Hz, 1H), 7.59(d, J=8.0Hz, 1H), 7.45-7.38(m, 2 H), 7.15(d, J=8.0Hz, 1H), 6.37(d, J=7.2Hz, 1H), 4.93(s, 1H), 4.73(d, J=8.0Hz, 1H) ), 4.19(s, 1H), 3.56-3.36(m, 7H), 3.22-3.05(m, 3H), 2.70(t, J=6.0Hz, 2H), 2.57 (t, J=6.0Hz,2H), 2.14-1.92(m, 6H), 1.76-1.61(m, 6H), 1.15(s, 3H), 0.95(s, 3H). Chiral SFC H(45%MeOH): ee98%, Rt=1.54 min.

[0995] Compound 100-E2 LC / MS ESI 522.7(M+H) + . 1H NMR (400MHz, MeOD) δ7.68(d, J=8.0Hz, 1H), 7.59(d, J=8.0Hz, 1H), 7.45-7.38( m, 2H), 7.15(d, J=8.0Hz, 1H), 6.37(d, J=7.2Hz, 1H), 4.81-4.78(m, 2H), 4.17( s, 1H), 3.58-3.32(m, 8H), 3.22-3.15(m, 2H), 2.70(t, J=6.0Hz, 2H), 2.55(t, J =6.0Hz,2H), 2.18-1.92(m, 6H), 1.76-1.61(m, 6H), 1.12(s, 3H), 0.89(s, 3H). Chiral SFC H(45%MeOH): ee100%, Rt=2.35 min.

[0996] [Example 31]: Preparation of 2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(7-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid (diastereomeric compounds 101-A-E1, 101-A-E2, 101-B-E1, and 101-B-E2)

[0997] Step 1: 4-(2,6-dichloropyridin-3-yl)but-3-en-2-one

[0998] [ka]

[0999] A mixture of 2,6-dichloronicotinaldehyde (25 g, 143.5 mmol) and 1-(triphenylphosphoranylidene)-2-propanone (57.2 g, 179.6 mmol) in toluene (180 mL) was stirred at 110 °C for 16 h. The mixture was cooled to room temperature, H2O (40 mL) was added, and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over Na2SO4, filtered, and the solvent was removed under reduced pressure. The residue was purified by silica gel column (petroleum ether: EtOAc 1:1) to give the desired product as a yellow solid (13.3 g). Yield 43% (ESI 216.0 (M+H) + ).

[1000] Step 2: 4-(2,6-dichloropyridin-3-yl)butan-2-amine

[1001] [ka]

[1002] A mixture of 4-(2,6-dichloropyridin-3-yl)but-3-en-2-one (12 g, 55.8 mmol), NHOAc (21.5 g, 279.1 mmol), and NaBHCN (10.6 g, 167.4 mmol) in MeOH (100 mL) was stirred at 30 °C for 16 h. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column (DCM:MeOH 40:1) to give the desired product as a yellow oil (7.94 g). Yield 58% (ESI 219.0 (M+H) + ).

[1003] Step 3: (R)-7-chloro-2-methyl-1,2,3,4-tetrahydro-1,8-naphthyridine and (S)-7-chloro-2-methyl-1,2,3,4-tetrahydro-1,8-naphthyridine

[1004] [ka]

[1005] A mixture of 4-(2,6-dichloropyridin-3-yl)butan-2-amine (7 g, 32.1 mmol) and CsCO (52 g, 160.6 mmol) in DMF (120 mL) was stirred at 140 °C for 16 h. The mixture was cooled to room temperature, and EtOAc (100 mL) was added and washed with HO (3 x 100 mL). The organic layer was removed under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 1:1) to give the desired product as a yellow oil (1.9 g). Yield 32% (ESI 183.0 (M+H) +The racemic products were separated by preparative chiral SFC B to give Stereoisomer A (870 mg) and Stereoisomer B (890 mg) as yellow oils.

[1006] Step 4: (R)-tert-butyl 7-chloro-2-methyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate stereoisomer A

[1007] [ka]

[1008] A mixture of 7-chloro-2-methyl-1,2,3,4-tetrahydro-1,8-naphthyridine stereoisomer A (870 mg, 4.75 mmol), (Boc)2O (3.13 g, 14.35 mmol), and DMAP (1.75 g, 14.35 mmol) in THF (40 mL) was stirred at 60 °C for 2 h. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (petroleum ether: EtOAc 10:1) to give the desired product as a yellow solid (1.2 g). Yield 89% (ESI 283.0 (M+H) + ).

[1009] Step 5: tert-Butyl 7-(4-((R)-1-(tert-butoxycarbonyl)pyrrolidin-3-yloxy)butyl)-2-methyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate Stereoisomer A

[1010] [ka]

[1011] To a solution of (R)-tert-butyl 3-(but-3-enyloxy)pyrrolidine-1-carboxylate (512 mg, 2.13 mmol) in THF (anhydrous, 5 mL) under Ar, 9-BBN (0.5 M in THF, 8.5 mL, 4.25 mmol) was added. The reaction was stirred at 50 °C for 2 h, cooled to room temperature, and tert-butyl 7-chloro-2-methyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate Stereoisomer A (600 mg, 2.13 mmol), tricyclohexylphosphine (60 mg, 0.21 mmol), Pd(OAc) (47 mg, 0.21 mmol), and NaOH (127 mg, 3.19 mmol) were added. The mixture was stirred at 70 °C for 2 h. The solvent was removed under reduced pressure and the residue was purified by silica gel column (petroleum ether: EtOAc 8:1) to give the desired product as a yellow solid (988 mg). Yield 95% (ESI 490.0 (M+H) + ).

[1012] Step 6: 2-methyl-7-(4-((R)-pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine stereoisomer A

[1013] [ka]

[1014] tert-Butyl 7-(4-((R)-1-(tert-butoxycarbonyl)pyrrolidin-3-yloxy)butyl)-2-methyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate Stereoisomer A (1.2 g, 2.45 mmol) was treated with HCl / 1,4-dioxane (4 M, 8 mL) at 25° C. for 16 hours. The solvent was removed under reduced pressure to give the desired product (781.7 mg) as a white solid. Yield 88% (ESI 290.0 (M+H) + ).

[1015] Step 7: tert-butyl 2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(7-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate stereoisomer A

[1016] [ka]

[1017] A mixture of 2-methyl-7-(4-((R)-pyrrolidin-3-yloxy)butyl)-1,2,3,4-tetrahydro-1,8-naphthyridine stereoisomer A (200 mg, 0.55 mmol), tert-butyl 2-bromo-2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)acetate (206 mg, 0.55 mmol) and DIPEA (178 mg, 1.38 mmol) in acetonitrile (8 mL) was stirred at 50° C. for 4 hours. The solvent was removed under reduced pressure, and the residue was purified by silica gel column (DCM:MeOH 10:1) to give the desired product tert-butyl 2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(7-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate stereoisomer A as a yellow oil (120 mg). Yield 37% (ESI 582.3 (M+H) + ).

[1018] Step 8: 2-(5-Fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(7-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid stereoisomer A (compounds 101-A-E1 and 101-A-E2)

[1019] [ka]

[1020] To a solution of tert-butyl 2-(5-fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(7-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate stereoisomer A (120 mg, 0.21 mmol) in DCM (2.5 mL) was added TFA (2.5 mL), and the mixture was stirred at room temperature for 16 hours. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC A (30% to 65% MeCN) to give diastereomeric products Compound 101-A-E1 (40 mg) and Compound 101-A-E2 (1.5 mg) as white solids.

[1021] Compound 101-A-E1 LC / MS ESI 526.3(M+H) + . 1 H NMR (400MHz, MeOD) δ7.62-7.58(m, 1H), 7.46-7.43(m, 1H) 7.28-7.18(m, 2H), 6.45( d, J=7.2Hz, 1H), 5.02(s, 1H), 4.74(d, J=10.8Hz, 1H), 4.21(s, 1H), 4.01(d, J=7.2H) z, 1H), 3.71-3.69(m, 1H), 3.59-3.40(m, 5H), 3.15-3.10(m, 1H), 2.77-2.74(m, 2H) , 2.62-2.58(m, 2H), 2.05-1.89(m, 5H), 1.88-1.42(m, 10H), 1.22(d, J=10.8Hz, 3H).

[1022] Compound 101-A-E2 LC / MS ESI 526.3(M+H) + . 1H NMR (400MHz, MeOD) δ7.46-7.41(m, 2H), 7.31-7.29(m, 1H) 7.16-7.13(m, 1H), 6.47( d, J=7.2Hz, 1H), 5.32(s, 1H), 4.70(d, J=6.8Hz, 1H), 4.19(s, 1H), 4.10(d, J=10.0H) z, 1H), 3.71-3.40(m, 4H), 3.19-3.16(m, 3H), 2.78-2.76(m, 2H), 2.65-2.61(m, 2H) , 2.25-2.02(m, 2H), 2.00-1.96(m, 3H), 1.88-1.42(m, 10H), 1.22(d, J=10.8Hz, 3H).

[1023] Step 9: 2-(5-Fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(7-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid stereoisomer B (compounds 101-B-E1 and 101-B-E2)

[1024] [ka]

[1025] 2-(5-Fluoro-2-((S)-tetrahydro-2H-pyran-2-yl)phenyl)-2-((R)-3-(4-(7-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid stereoisomer B (compounds 101-B-E1 and 101-B-E2) was synthesized from tert-butyl 7-chloro-2-methyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate stereoisomer B by the same method as for stereoisomer A.

[1026] Compound 101-B-E1 LC / MS ESI 526.3(M+H) + . 1H NMR (400MHz, MeOD) δ7.62-7.58(m, 1H), 7.46-7.43(m, 1H) 7.26-7.18(m, 2H), 6.44 (d, J=7.2Hz, 1H), 4.99(s, 1H), 4.74(d, J=10.4Hz, 1H), 4.21(s, 1H), 4.03(d, J=10 .8Hz, 1H), 3.71-3.69(m, 1H), 3.59-3.40(m, 5H), 3.10(s, 1H), 2.76-2.73(m, 2H), 2.61-2.57(m, 2H), 2.20-1.89(m, 5H), 1.81-1.42(m, 10H), 1.22(d, J=10.8Hz, 3H).

[1027] Compound 101-B-E2 LC / MS ESI 526.3(M+H) + . 1 H NMR (400MHz, MeOD) δ7.47-7.37(m, 3H), 7.17-7.12(m, 1H), 6.49(d, J=7.2Hz, 1 H), 5.32(s, 1H), 4.69(d, J=9.2Hz, 1H), 4.19(s, 1H), 4.10(d, J=10.0Hz, 1H), 3. 71-3.40(m, 5H), 3.19-3.16(m, 2H), 2.79-2.76(m, 2H), 2.68-2.63(m, 2H), 2.3 5-2.22(m, 1H), 2.10-1.96(m, 4H), 1.86-1.44(m, 10H), 1.22(d, J=10.8Hz, 1H).

[1028] [Example 32]: Preparation of 2-(5-fluoro-2-(2,9-dioxaspiro[5.5]undecan-3-yl)phenyl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate (Compounds 102-A-E1, 102-A-E2, and 102-B)

[1029] Step 1: Ethyl 4-(but-3-en-1-yl)tetrahydro-2H-pyran-4-carboxylate

[1030] [ka]

[1031] To a solution of diisopropylamine (3.19 mL, 22.8 mmol) in anhydrous tetrahydrofuran (20 mL) was added n-butyllithium / hexane (2.5 M, 7.28 mL, 18.2 mmol) under a nitrogen atmosphere at −78°C. The mixture was stirred at −78°C for 45 minutes, and then ethyl tetrahydropyran-4-carboxylate (2.87 mL, 19.0 mmol) was added dropwise. The mixture was stirred at −78°C for 30 minutes. A mixture of 4-bromo-1-butene (2.5 mL, 24.6 mmol) and HMPA (1.85 mL, 10.6 mmol) in anhydrous tetrahydrofuran (5 mL) was added dropwise. The mixture was stirred at −78°C for 5 minutes, removed from the acetone / dry ice bath, stirred in an ice / water bath at 0°C for 20 minutes, and then stirred at room temperature for 25 minutes. The reaction mixture was quenched with saturated aqueous ammonium chloride and extracted three times with diethyl ether. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. Purification by column chromatography (silica, 3% to 15% diethyl ether / pentane) afforded the desired ethyl 4-(but-3-en-1-yl)tetrahydro-2H-pyran-4-carboxylate (3.19 g) in 79% yield. 1 H NMR (400MHz, chloroform-d) δ5.82-5.69(m, 1H), 5.04-4.91(m, 2H), 4.19(q, J=7.1Hz, 2H), 3.87-3.78(m, 2H), 3.53- 3.39(m, 2H), 2.14-2.05(m, 2H), 2.02-1.92(m, 2H), 1.66-1.59(m, 2H), 1.55-1.45(m, 2H), 1.28(t, J=7.1Hz, 3H).

[1032] Step 2: (4-(but-3-en-1-yl)tetrahydro-2H-pyran-4-yl)methanol

[1033] [ka]

[1034] To a solution of ethyl 4-(but-3-en-1-yl)tetrahydro-2H-pyran-4-carboxylate (3.17 g, 14.9 mmol) in anhydrous tetrahydrofuran (30 mL) was added lithium aluminum hydride / tetrahydrofuran (2.4 M, 6.22 mL, 14.9 mmol) under an argon atmosphere at 0 °C. The mixture was stirred at room temperature for 1 hour and quenched by the slow addition of ethyl acetate (20 mL). The mixture was washed with 1 M hydrochloric acid, the layers were separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with 1 M hydrochloric acid and brine, dried over sodium sulfate, and concentrated under reduced pressure. Purification by column chromatography (silica, 15% to 50% ethyl acetate / heptane) afforded the desired product (4-(but-3-en-1-yl)tetrahydro-2H-pyran-4-yl)methanol (2.21 g). Yield: 87%. 1 H NMR (400 MHz, chloroform-d) δ 5.91-5.78 (m, 1H), 5.10-4.92 (m, 2H), 3.76-3.60 (m, 4H), 3.53 (s, 2H), 2.09-1.98 (m, 2H), 1.59-1.48 (m, 4H), 1.48-1.40 (m, 2H), 1.36 (s, 1H).

[1035] Step 3: (4-(but-3-en-1-yl)tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate

[1036] [ka]

[1037] To a solution of (4-(but-3-en-1-yl)tetrahydro-2H-pyran-4-yl)methanol (1.75 g, 10.3 mmol) in dichloromethane (39 mL) at 0 °C, pyridine (2.5 mL, 30.9 mmol) and p-toluenesulfonyl chloride (3.14 g, 16.5 mmol) were added. The reaction mixture was stirred at room temperature for 4 days, concentrated under reduced pressure, diluted with saturated aqueous sodium bicarbonate, and extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. Purification by column chromatography (silica, 10% to 30% ethyl acetate / heptane) afforded the desired product, (4-(but-3-en-1-yl)tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate (3.15 g). Yield: 94%. 1 H NMR (400MHz, chloroform-d) δ7.84-7.75(m, 2H), 7.36(d, J=8.0Hz, 2H), 5.78-5.64(m, 1H), 5.00-4.89(m, 2H), 3.88(s, 2H), 3.67-3.47(m, 4H), 2.46(s, 3H), 1.90-1.79(m, 2H), 1.56-1.47(m, 2H), 1.44(t, J=5.6Hz, 4H).

[1038] Step 4: (4-(3-oxopropyl)tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate

[1039] [ka]

[1040] To a solution of (4-(but-3-en-1-yl)tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate (3.15 g, 9.70 mmol) in tetrahydrofuran (74 mL) and water (24 mL) was added sodium periodate (5.19 g, 24.3 mmol) and osmium tetroxide solution (4 wt% aqueous solution, 9.9 mg, 0.04 mmol). The mixture was stirred at room temperature for 1.5 hours, diluted with water, and extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressur...

Claims

1. A compound of formula (I) or a pharma- ceutically acceptable salt of said compound: 【Chemistry 1】 [In the formula, A is 【Chemistry 2】 and R 1 is H in each case; B is, 【Chemistry 3】 selected from the group consisting of: q is 0, 1, 2, or 3; p is 0, 1, or 2; C is, 【Chemistry 4】 and n is 0; R 2 teeth 【Chemistry 5】 and R 2 In the formula, n is 0 or 1; R 4 are independently alkyl, -C(F 2 ) CH 3 , cycloalkyl, heterocycloalkyl, -alkylene-cycloalkyl, -O-alkylene-cycloalkyl, -O-cycloalkyl, -O-alkyl, -alkylene-O-alkyl, -alkylene-O-cycloalkyl, and -alkylene-O-alkylene-cycloalkyl; R 5 is F; R a is H; The absolute configuration of any stereocenter is R, S or a mixture thereof.

2. B 【Chemistry 6】 2. The compound of claim 1 ,

3. The compound of claim 2 , wherein q is 2.

4. A 【Chemistry 7】 4. The compound of claim 3,

5. R 4 The compound of claim 4 , wherein is cycloalkyl.

6. R 4 The compound of claim 4 , wherein is heterocycloalkyl.

7. R 4 The compound of claim 4, wherein is -O-alkylene-cycloalkyl.

8. R 4 but 【Chemistry 8】 【change】 5. The compound of claim 4, selected from:

9. R 4 but 【Chemistry 9】 【change】 【change】 5. The compound of claim 4, selected from:

10. R 2 but 【Chemistry 10】 and R 2 The compound according to claim 4, wherein n is 1.

11. R 4 but 【Chemistry 11】 11. The compound of claim 10,

12. R 4 but 【Chemistry 12】 11. The compound of claim 10,

13. R 4 but 【Chemistry 13】 11. The compound of claim 10,

14. R 4 but 【Chemistry 14】 11. The compound of claim 10,

15. The following formula: 【Chemistry 15】 2. The compound of claim 1, having the formula:

16. The following formula: 【Chemistry 16】 2. The compound of claim 1, having the formula:

17. The following formula: 【Chemistry 17】 2. The compound of claim 1, having the formula:

18. The following formula: 【Chemistry 18】 2. The compound of claim 1, having the formula:

19. The following formula: 【Chemistry 19】 2. The compound of claim 1, having the formula:

20. A pharmaceutical composition formulated for oral delivery of an αvβ6 integrin inhibitor, comprising as an active compound an αvβ6 integrin inhibitor compound described in claim 1 or a pharma- ceutically acceptable salt of said compound, and a pharma- ceutically acceptable carrier formulated for oral therapeutic administration of the αvβ6 integrin inhibitor compound.

21. A compound of formula (I) or a pharma- ceutically acceptable salt of said compound: 【Chemistry 20】 [In the formula, A is, 【Chemistry 21】 and R 1 is H in each case; B is, 【Chemical 22】 selected from the group consisting of: q is 0, 1, 2, or 3; p is 0, 1, or 2; C is, 【Chemistry 23】 and n is 0; R 2 teeth, 【Chemistry 24】 and R 2 In the formula (I), n is 0; R 4 are independently alkyl, -C(F 2 ) CH 3 , cycloalkyl, heterocycloalkyl, -alkylene-cycloalkyl, -O-alkylene-cycloalkyl, -O-cycloalkyl, -O-alkyl, -alkylene-O-alkyl, -alkylene-O-cycloalkyl, and -alkylene-O-alkylene-cycloalkyl; R a is H; The absolute configuration of any stereocenter is R, S or a mixture thereof.

22. A 【Chemistry 25】 and B 【Chemistry 26】 and q is 2; C 【Chemical 27】 and n is 0; R 4 is heterocycloalkyl; R a is H; 22. The compound of claim 21, or a pharma- ceutically acceptable salt thereof, wherein the absolute configuration of any stereocenter is R, S or a mixture thereof.

23. The following formula: 【Chemistry 28】 23. The compound of claim 22, having the formula:

24. A pharmaceutical composition formulated for oral delivery of an αvβ6 integrin inhibitor, comprising an αvβ6 integrin inhibitor compound described in claim 21 as an active compound, and a pharma- ceutical acceptable carrier formulated for oral therapeutic administration of the αvβ6 integrin inhibitor compound.

25. A compound of formula (I) or a pharma- ceutically acceptable salt of said compound: 【Chemical 29】 [In the formula, A is, 【Chemistry 30】 and R 1 is H in each case; B is, 【Chemistry 31】 selected from the group consisting of: q is 0, 1, 2, or 3; p is 0, 1, or 2; C is 【Chemistry 32】 and n is 0; R 2 teeth 【Chemical 33】 and R 2 In the formula, m is 0 or 1; R 4 are independently alkyl, -C(F 2 ) CH 3 , cycloalkyl, heterocycloalkyl, -alkylene-cycloalkyl, -O-alkylene-cycloalkyl, -O-cycloalkyl, -O-alkyl, -alkylene-O-alkyl, -alkylene-O-cycloalkyl, and -alkylene-O-alkylene-cycloalkyl; R 5 is F; R a is H; The absolute configuration of any stereocenter is R, S or a mixture thereof.

26. B 【Chemical 34】 and q is 2; C 【Chemistry 35】 where n is 0, R 4 is cycloalkyl; R a is H; 26. The compound of claim 25, or a pharma- ceutically acceptable salt thereof, wherein the absolute configuration of any stereocenter is R, S or a mixture thereof.

27. The following formula: 【Chemical 36】 26. The compound of claim 25, having the formula:

28. The following formula: 【Chemical 37】 26. The compound of claim 25, having the formula:

29. A pharmaceutical composition formulated for oral delivery of an αvβ6 integrin inhibitor, comprising an αvβ6 integrin inhibitor compound described in claim 25 as an active compound, and a pharma- ceutical acceptable carrier formulated for oral therapeutic administration of the αvβ6 integrin inhibitor compound.

30. The compound is 【Chemical 38】 【change】 【change】 2. The compound of claim 1 selected from the group consisting of:

Citation Information

Patent Citations

  • Inhibition of αvβ6 integrin

    JP7540998B2

  • Inhibitors of (alpha-v)(beta-6) integrin

    WO2018160521A2